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1CHAPTER 1: INTRODUCTION
Complex phenotypes, including complex diseases, are the results of genetic and environmen-
tal factors. When a mismatch exists between genotype and environment, this mismatch can lead
to an increased disease risk. However, this mismatch cannot always be broken down neatly into
genetic effect (effect of the genotype) and environmental effect. Instead, different genotypes can
respond differently to environmental variation, known as gene-environment interaction (genotype-
environment interaction, GxE). Understanding these interactions is important, as it can both pro-
vide insight behind molecular mechanisms of diseases as well as identify relevant environmental
contexts for increased disease risk.
To study the association between genotype and phenotype, several methods exist including
genome-wide association studies (GWAS).Through these methods, many genetic variants have
been identified whose genotypes are associated with complex phenotypes. A large fraction of
these variants are outside gene bodies, suggesting that much of the association with phenotype is
a result of changes in gene regulation, rather than changes in protein coding regions. However,
understanding the impact of such variation on gene regulation (and therefore expression) remains
a challenge. Furthermore, even when a specific variant is shown to be associated with a phenotype,
it remains a challenge to identify the relevant environmental contexts under which its influence is
exerted.
COMPLEX PHENOTYPES AND REGULATORY GENETIC VARIATION
To connect genetic variants to measurable complex phenotypes, one common approach is to
perform a genome-wide association study (GWAS). GWAS involve a large cohort, usually thou-
sands of individuals, who are categorized based on a phenotype of interest. This phenotype can
be qualitative (disease/non-disease, e.g., (1)) or quantitative (height (2), low-density lipoprotein
levels (3), etc). Each participant is genotyped across an array of single nucleotide polymorphisms
(SNPs), and the genotype of each SNP is tested for association with the phenotype of interest. For
binary qualitative traits, an odds ratio is calculated between the odds of having the phenotype for
2individuals with a specific genotype, and the odds of having the phenotype for individuals without
the genotype, and significance (i.e., genotypes significantly more frequent in individuals with the
phenotype) can be assessed using a Chi-squared test. For quantitative traits, quantitative trait loci
(QTL) mapping is performed, using a generalized linear model to test the association between the
continuous phenotype values and the genotype classes (used as a categorical predictor variable).
However, there are several limitations to using GWAS to identify genetic variants with an im-
pact on phenotype. Firstly, the genotyping arrays typically used in GWAS do not cover every
variant, instead covering a subset of variants and relying on linkage disequilibrium (LD) between
the targeted variant and the causal variant in the region. Because of this limitation, variants iden-
tified through GWAS are unlikely to be causally related to the phenotype themselves, and instead
are linked to the causal variant. In order to identify exactly which variant is driving the association,
one would need to fine-map the region. This would require all the variants in an associated region
to be genotyped, or to have their genotypes imputed using a reference panel of densely genotyped
haplotypes, such as those from the 1000 Genomes Project (4). Secondly, even when a variant is
causally associated to a phenotype, this does not explain the mechanism driving the association,
especially if that variant is in a non-coding region. In order to understand mechanistically how
these variants influence phenotype, it is necessary to have an accurate functional characterization
of the region containing the association signal.
Recent efforts to characterize non-coding regions of the genome have generated large annota-
tions of regulatory regions, and these annotations have been used to attempt to functionally charac-
terize GWAS hits (5–12). However, many of these studies use a simple positional overlap between
a genetic variant and a regulatory region, which is not necessarily proof that the variant has an
effect on gene regulation, for example through altered transcription factor (TF) binding. To effec-
tively dissect regulatory elements, high-resolution (single nucleotide resolution) functional assays
like DNase-seq and ATAC-seq can be combined with computational methods that integrate se-
quence motif models (7, 9, 13, 14). However, these methods rely on accurate motif models, and
current motif models for TF binding are not sufficiently calibrated to predict the binding impact
3of a sequence change. Without such calibrated models and the methods to use them to accurately
predict the effect of a sequence change on a regulatory region, we cannot assess which non-coding
genetic variants are more likely to alter gene regulation, and ultimately, complex phenotypes.
IDENTIFYING GENETIC VARIANTS WITH GXE INTERACTIONS
In order to study the consequence of a mismatch between genotype and environment, it is
necessary to first determine the relevant environmental context. When studying phenotypes at
the organismal level, such as through GWAS, environmental covariates are complex and difficult
to measure and control. Alternatively, the cellular environment can be studied as a proxy for
the organismal environment. For example, in vitro treatments in cell culture can be studied as a
simplified version of an organismal environment, and the resulting sub-cellular phenotypes such
as gene expression can be measured.
One method to measure the association between genotype and gene expression is expression
quantitative trait loci (eQTL) mapping. eQTLs are genetic loci that associate with expression
of a gene, and their genotype-dependent association with gene expression suggests they contain
potentially functional variants, responsible for the observed changes in gene expression. With
eQTL mapping, gene expression is measured in vitro for a panel of individuals (usually tens to
hundreds), and correlated with genotypes over an array of SNPs. Similar to GWAS, these geno-
typing arrays do not cover every variant, instead relying on LD between the targeted variant and
the causal variant in the region. To date, a few studies have successfully identified GxE through
the use of response eQTL (reQTL) mapping, which compares eQTL signals found at baseline to
eQTL signals found in response to environmental perturbations such as drug treatment (15–17) and
pathogen exposure (18, 19). For example, (15) found that the genetic variant rs9806688 displayed
a genotype-dependent association with expression levels of the glycine amidinotransferase gene,
GATM. This association appeared following exposure to simvastatin, a medication typically used
to lower blood cholesterol levels, but not at baseline. Furthermore, they found that the minor allele
at this GATM differential eQTL locus, which was associated with reduced GATM expression, was
associated with reduced risk of statin-induced myopathy.
4The in vitro nature of eQTL mapping allows for the tight control of the cellular environment,
and for the accurate measurements of molecular phenotypes such as gene expression, which serve
as a proxy for the organismal phenotype. However, while this method is powerful for identifying
genetic variants with GxE, one major drawback is that it does not scale well to a large number of
environments. In order to assay 50 environments for a panel of 100 individuals, one has to perform
5,000 experiments. So a different approach is needed in order to do high-throughput identification
of GxE signals.
An alternative to eQTL mapping is to use an allele-specific approach. While eQTL mapping
compares genotypic effects across individuals that have different genotypes at other sites in their
genome, allele specific expression (ASE) approaches compare allelic effects within individuals,
therefore within the same genetic background and cellular environment. By comparing the expres-
sion of two alleles at heterozygous loci within a transcript, ASE can identify genes with eQTLs in
individual samples: a departure from the expected 1:1 ratio of the two alleles indicates a genotype-
dependent effect on the expression of that gene. ASE approaches naturally control for both the
genetic background and the cellular environment, which limits the influence of confounding fac-
tors such as trans-acting modifiers of gene expression, like the genotype at other loci (20–28).
Because of this, allele specific approaches have greater statistical power to detect genetic effects in
cis than a traditional QTL mapping approach, especially when using a small sample size.
OVERVIEW OF CHAPTERS
This dissertation integrates my research into three chapters that address two central questions.
Chapter 2 addresses the question, “Can we determine which genetic variants are more likely to
have a functional impact on gene regulation?”. In Chapter 2, I discuss an approach for predicting
which genetic variants are more likely to affect transcription factor binding, and how follow-up
studies use this information to inform the inference of causal variants from GWAS data. Chapters
3 and 4 address the question, “Can we use genetic variants that show environment-specific effects
to understand the link between genotype and complex phenotypes?”. In Chapter 3, I describe a
cost efficient and high-throughput method for studying gene expression changes in response to
5environmental perturbations, such as drug treatments. This method, broken up into two steps,
allows for the screening of many sample conditions before selecting which conditions elicit a
response, and therefore merit further in depth analysis. In Chapter 4, I apply the strategy from
Chapter 3 to 250 cellular environments (5 cell types and 50 treatment conditions) and use ASE
analysis to identify GxE in response to environmental perturbations. Finally, in Chapter 5 I discuss
the results of the above research chapters and their impacts.
Environment	X
R
AA
R
Environment	Y
R
AA
R
Gene	regulation
GxE ASB
(GxE-eQTN)
Gene	expression
GxE ASE
(gene	with	aGxE-eQTN)
Phenotype
GWAS	for
trait	or	disease
Chapter	2
Chapter	4
Chapter	3
Chapter	3
Figure 1.1: Hypothetical model detailing the use of GxE interactions to characterize putative molecular mech-
anisms behind complex phenotypes. Gene regulation is depicted as a transcription factor (green triangle) binding
to a regulatory region (yellow boxes, left side) or not. Determining which genetic variants (indicated as R [refer-
ence allele] or A [alternate allele]) are more likely to disrupt this process is the focus of chapter 2. Gene expression
is depicted as genes (yellow boxes, right side) being transcribed into RNA (red and blue wavy lines, depending on
genotype). Chapter 3 addresses the measurement of gene expression changes between two environments, shown here
as environments X and Y. Finally, comparing allele-specific expression measurements between two environments to
identify GxE is the focus of chapter 4.
6CHAPTER 2: WHICH GENETIC VARIANTS IN
DNASE-SEQ FOOTPRINTS ARE MORE LIKELY TO
ALTER BINDING?*
INTRODUCTION
Despite large ongoing efforts to characterize regulatory regions in the human genome (e.g.,
ENCODE (8), Roadmap Epigenomics (29)), the lack of a regulatory genetic code to discrimi-
nate functional from silent non-coding variants in regulatory sequences poses severe limitations
in interpreting the results of many human and population genetic analyses. For example, large
numbers of genetic variants associated with disease and normal trait variation have been identi-
fied through genome-wide association studies (GWAS) (30); yet a formidable challenge remains
in determining the specific molecular mechanisms underlying association signals in non-coding
regions. Similar challenges also arise when exploring the evolutionary functional significance of
non-coding variants, for example through analysis of differences in genotype distribution across
populations (31, 32). This is also complicated by the fact that GWAS hits and signals of selection
are usually found in large regions of association and do not directly pinpoint the true causative vari-
ants. In general, we do not know in which cell types/tissues these variants may have a functional
impact.
Computationally and experimentally derived annotations for regulatory regions have been used
to functionally characterize GWAS hits (5–12). However, a simple positional overlap between a
genetic variant and regulatory regions is a necessary but not a sufficient condition to demonstrate
an impact on transcription factor (TF) binding. Many experimentally derived annotations are very
useful to identify broad genomic regions across many cell-types, but lack the resolution necessary
to pinpoint the regulatory sequences. High resolution functional assays like DNase-seq and ATAC-
seq combined with computational methods that integrate sequence motif models (7, 9, 13, 14) can
effectively dissect the regulatory elements; yet the motif models for TF binding are generally not
*This chapter originally appeared as: Moyerbrailean GA, Harvey CT, Kalita CA, Wen X, Luca F, Pique-Regi
R. 2016. Which Genetics Variants in DNase-Seq Footprints Are More Likely to Alter Binding? PLoS Genetics,
12(2):e1005875.
7sufficiently well calibrated to predict the binding impact of a sequence change. Alternative ChIP
based approaches (such as ChIP-seq and ChIP-exo), may provide increased TF and regulatory
element specificity, but rely upon the availability of antibodies to target specific TFs or tagged
TFs (33, 34). The consequence is that we cannot provide a satisfactory answer to the following
questions: Which genetic variants are more likely to impact binding of specific TFs? What is the
fraction of genetic variants in regulatory regions that are not neutral? If we can adequately answer
these questions, we may further ask: Did polygenic adaptation occur at binding sites for the same
TF? Do variants in certain types of TF footprints and tissues contribute to variation in specific
complex traits?
To help answer these questions, we have extended the CENTIPEDE approach to generate a cat-
alog of regulatory sites and binding variants encompassing more than 600 experimental samples
from the ENCODE and Roadmap Epigenomics projects with DNase-seq data, and recalibrated se-
quence motif models for more than 800 TFs. We then incorporated allele-specific hypersensitivity
(ASH) information to provide additional empirical evidence, to validate the accuracy of the com-
putational predictions and to estimate the fraction of genetic variants in regulatory regions that are
not neutral. Importantly, our annotation is specific at the motif level (i.e., TF-specific) and at the
sample level (i.e., tissue-specific). We then compare our results with the only alternative TF-centric
annotation that has been recently published (35), but we also compare with non TF-centric sup-
port vector machine (SVM) derived annotations (36). Using our new catalog, we then examined
genomic properties of the annotations, identifying characteristics that predict variants that disrupt
binding, and demonstrated the action of natural selection on TF binding sites.
MATERIALS AND METHODS
Identification of active regulatory sites and motif recalibration
We used 1,949 position weight matrix (PWM) sequence models (motifs) from the TRANSFAC
(37) and JASPAR (38) databases to scan the genome for a set of representative motif matches
(Appendix A.3.1). For each motif, we used the matching sequences to calculate a new PWM
model which we then used to scan the genome and identify all genome-wide motif matches using
8a two step approach:
Step 1: Initial CENTIPEDE scan and motif recalibration. For each motif, we extracted DNase-
seq data at sequence matches across 653 samples (corresponding to 153 unique tissues) publicly
available from the ENCODE and Roadmap Epigenomics projects (Appendix A.1 and A.2.1). The
motifs and samples used are summarized in A.1 and A.2. For each motif and only for this initial
step, we used a reduced subset of motif matches that include the top 5,000 best sequence matches,
and up to 10,000 additional low-scoring sequences (Appendix A.3.1, note that for Step 2 we will
use all motif matches in the genome). To avoid overfitting and to heuristically reduce the search
space, these low scoring motif instances are human sequences that have orthologous very high
scoring motif instances in the chimp or rhesus genome. We then applied the CENTIPEDE model
to survey TF activity for each 1,272,697 tissue-TF pair. For each pair we then determined that the
TF is active if the sequence matches that exhibit a CENTIPEDE footprint can be predicted from
the PWM score (Z-score > 5, A.4 and A.5). Using this criterion, we determined that 1,891 TF
motifs are active in at least one tissue. The full list of motifs active in each tissue can be found in
A.3. We then recalibrated the PWM model for each active motif using the sequences of all motif
matches that have a DNase-seq footprint (CENTIPEDE posterior > 0.99).
Step 2: Full genome CENTIPEDE scan and genetic variant analysis. Using the recalibrated
sequence models we scanned the human genome again for all possible sequence matches. We used
the CENTIPEDE algorithm to assess the probability that each motif instance is bound by a TF, both
to the reference and to alternate alleles when the match contained a genetic variant catalogued in
the 1KG Project (4). In this second step, we included all high and low scoring PWM matches down
to the threshold corresponding to a CENTIPEDE prior probability of binding of 10% (Equation
A.2 and Appendix A.3.2).
ChIP-seq validation of the revised sequence motif models
To evaluate whether the updated sequence models derived from DNase-seq data are better at
predicting TF binding than the original seed motifs, we compared to ChIP-seq data available for
a small set of TFs from the ENCODE project (as these data are generated in independent exper-
9imental assays that should be highly TF-specific). Using precision recall operating characteristic
(P-ROC) curve analysis (see Appendix A.6.1), we determined that for a given precision (precision
= 1 - FDR, false discovery rate), the updated sequence models have higher recall (sensitivity) than
the original PWM in detecting ChIP-seq peaks (A.7). Additionally, we compared the correlation
between the prior probability of binding (calculated by CENTIPEDE based on the PWMs) and the
number of ChIP-seq reads overlapping motif matches (A.8, Appendix A.6.2).
Categorization of footprint-SNPs based on predicted functional impact
We classified a SNP in a CENTIPEDE footprint (footprint-SNP) as having a predicted effect on
binding (effect-SNP) if the difference in the prior log odds ratio (from the logistic sequence model
in CENTIPEDE, Equation A.2) between the two alleles was ≥3, indicating a ≥20-fold change in
the prior odds of TF binding. We further classified an effect-SNP as switching the likelihood of
binding (switch-SNP) if the prior log odds ratio flips; i.e, if it is≥ 0 for one allele and ≤ 0 for the
other. To generate a final set of annotated SNPs, we aggregated the data from each sample and
motif into one table. For cases where a SNP is within multiple predicted binding sites, we selected
the factor whose CENTIPEDE likelihood ratio was the greatest, i.e., the factor most likely to be
binding at that location.
Identification of allele-specific hypersensitivity (ASH)
Starting from raw sequencing reads, we used a custom mapper (39) to align the reads to the
hg19 reference genome. As allele-specific analysis is extremely sensitive to mapping errors and
PCR duplicates, we employed several methods to reduce these sources of potential bias (Appendix
A.2.2 -A.2.4). To detect allele-specific hypersensitivity, we applied QuASAR (40) to the processed
read data to infer genotypes for all 1KG SNPs and determine the likelihood of allelic imbalance at
heterozygous sites. Note that we only test a SNP with QuASAR if it is covered by ≥10 reads. To
adjust for multiple testing, we used the q-value method (41) on the p-values produced by QuASAR.
Validation of predicted effect-SNPs using ASH-hSNP integrated analysis
We overlapped heterozygous SNPs (DHS-hSNPs) identified by QuASAR with CENTIPEDE
footprints-SNPs and effect-SNPs catalogued for each sample. SNPs were then partitioned based
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on their predicted effect on binding into three non-overlapping categories: 1) hSNPs in predicted
footprints whose binding effect is in the direction predicted, 2) all other hSNPs in footprints, 3) all
other DHS-hSNPs. Because each annotation has a different prior expectation of being functional,
we re-adjusted for multiple testing within each annotation separately using the q-value method (41)
on p-values produced by the QuASAR model. We denote as ASH-hSNPs those hSNPs with a q-
value< 20% in any of the partitions.
Regression model for binding effect
To determine which features of a SNP are predictors of functional effect, we performed multi-
ple regression analysis using a logistic model considering the dependent binary variable El, indi-
cating whether the footprint-SNP, l, is also an effect-SNP.
logit(El) ∼ Cl + Fl + Tl +Nl + Pl
We considered the following variables related to the probability of a footprint-SNP being an effect-
SNP: the footprint likelihood ratio (without the sequence model) (Cl); the minor allele frequency
(Fl); the absolute distance to the nearest transcription start site (Tl); the number of tissues for which
the motif containing the footprint-SNP was predicted to be bound (Nl); the phyloP conservation
scores calculated from primates (Pl).
This model does not evaluate the sequence, rather it combines the results shown separately in
Fig 2 into a single model to characterize the predictions made by CENTIPDE. The model was fit
using the GLM function in R. The result of this regression analysis can be seen in A.8.
Identification of selection signals on TF motifs
To identify divergent TF binding sites, we used the UCSC liftOver tool on binding sites with-
out a known polymorphism to obtain orthologous regions in the chimpanzee genome. Using the
PWM model, we calculated PWM scores and CENTIPEDE prior probabilities of binding on the
chimpanzee sequences. Sites with a sequence change in the motif instance (prior probability of
binding differs from the humans sites) were classified as divergent, and were further categorized
11
by the difference in binding affinity: “functional” for sites that change ≥20-fold between species
(analogous to effect-SNPs), and “silent” for those that do not. For the binding sites containing a
polymorphism, we used the definition of effect-SNPs to identify functional for silent sites and foot-
print -SNPs for silent sites. For each factor motif, we then calculated the number of binding sites
belonging to each of the four categories (divergent functional, divergent silent, polymorphic func-
tional, and polymorphic silent) and calculated a selection score similar to the McDonald-Kreitman
test (Appendix A.8.4).
Integrating high-resolution functional annotations with GWAS and fine-mapping
To integrate functional annotations and GWAS results, we used the fgwas command line tool
(42). fgwas computes association statistics genome wide using all common SNPs from Euro-
pean populations in the 1KG Project, splitting the genome into blocks larger than LD. Summary
statistics were imputed with ImpG using Z-scores from meta-analysis data. Using an empirical
Bayesian framework implemented in the fgwas software, GWAS data were then combined with
functional annotations. We then compared the informativeness of these annotations from each of
the 1891 motifs with CENTIPEDE predicted regulatory sites to a baseline model (see Appendix
A.9.2) consisting of previously used genomic annotations identified as relevant (42). For each lo-
cus that contains at least one SNP with a PPA > 0.2, we only consider the SNP with the highest
p-value or PPA from fgwas. Rather than look at a credible set, we pick a single SNP most likely to
be causal and see if that SNP has a higher PPA with the annotation than without it. While reduc-
tion in size of the credible set is very important for assessing fine-mapping methodologies, here
our focus is on combining annotations to identify the single most likely causal SNP per GWAS
locus.
Enrichment Analyses
Unless otherwise noted, tests for enrichment on two-way categorical variables are based on
Fisher’s exact test. Tests involving multiple categorical, discrete or continuous variables use a
logistic regression model and Wald’s test on each enrichment parameter, and are identified as such.
12
RESULTS
Computational prediction of functional variants in regulatory sequences
The CENTIPEDE approach allows to predict TF activity by integrating sequence motif mod-
els together with functional genomics data, and gains the most information from high-resolution
data such as DNase-seq or ATAC-seq (43). The spatial pattern in which reads are distributed, or
footprint, is specific for each TF and can be very useful for discriminating between classes of TFs
with distinct profiles (13). In the original CENTIPEDE approach, the sequence models are pre-
determined; e.g, k-mers or previously defined position weight matrix (PWM) models. However,
many sequence models in existing databases were created with very few instances of known TF
binding sites and do not represent the full spectrum of sequence variation that can be tolerated
without affecting binding. Here, we have extended CENTIPEDE to readjust the sequence models
for TF binding (Fig 2.1 and A.1) using DNase-seq data and sequence orthologs (Methods). Com-
pared to the original motif models the consensus sequence is largely maintained in the recalibrated
motifs (2.4). However, when we consider ChIP-seq peaks as validation we obtain superior pre-
cision recall characteristics (A.7, Appendix A.6.1) and a much higher correlation with the prior
probability of binding calculated by CENTIPEDE (A.8, Appendix A.6.2).
Across all 653 DNase-seq samples, we identified a total of 6,993,953 non-overlapping foot-
prints corresponding to 1,372 motifs active in at least one tissue and collectively spanning 4.15%
of the genome. Each individual sample contained, on average, 280,000 non-overlapping footprints
for 600 motifs and spanning 0.162% of the genome, indicating that footprints are highly tissue
specific. Considering all SNPs from 1000 Genomes Project (1KG) at any allele frequency (even
singletons), we found 5,810,227 (0.19% of the genome) unique genetic variants in active footprints
(footprint-SNPs), 3,831,862 (66%) of which are predicted to alter the prior odds of binding ≥20-
fold (effect-SNPs) based on the logistic sequence model hyperprior in the CENTIPEDE model (Fig
2.1C-D, Equation A.2). Effect-SNPs are further classified as switch-SNPs (264,965) if the allele
flips the prior odds of binding. Importantly, in any of these categories we retain for each prediction
the motif identity (TF-specific) and the underlying sample (cell-type specific) information.
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Figure 2.1: A visual description of the methods. (A) Data sources (B) Iterative process of using CENTIPEDE and
seed sequence models (bottom left) to call footprints (top), then to revise the sequence models (bottom right), and call
footprints again. (C) Computational predictions of genetic variant impact on factor binding. Conditional on a motif
sequence match and observing a DNase-seq footprint a prediction is made using CENTIPEDE’s logistic model for the
the prior probability of binding for each allele: pH for the high binding allele (upward triangle), and pL for the lower
binding allele (downward triangle). (D) SNPs in non-coding regions are successively classified into nested categories
base on being in a DHS, CENTIPEDE footprints and having a predicted functional impact on binding (based on the
difference between pH and pL.)
Allele-specific analysis confirms need for accurate prediction of function
These functional categories we computationally defined provide an answer to the question of
which genetic variants in DNaseI sensitive regions are more likely to affect binding. To exper-
imentally assess the accuracy of our answer, we used Quantitative Allele-Specific Analysis of
Reads (QuASAR) (40) to perform joint genotyping and ASH analysis within DNase I hypersensi-
tivity (DHS) regions (A.2). While the initial quality filtering is the same as for the CENTIPEDE
analysis, the parameters of the QuASAR model also allowed us to detect tissues with chromoso-
mal abnormalities or samples from pooled individuals (Appendix A.4.2). These DNase-I samples
were therefore excluded from ASH analysis (A.9, A.10, A.6). Across the remaining 316 sam-
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ples suitable for ASH analysis, we identified 204,757 heterozygous SNPs (hSNPs) in DHS sites
(DHS-hSNPs) with coverage >10x and with MAF> 0.05.
Overlapping our predictions with the DHS-hSNPs, 55,044 are footprint-hSNPs, 26,773 of these
are effect-hSNPs, and 5,991 of these are switch-hSNPs. Overall, our computational predictions are
highly concordant with the direction of ASH; 75% of the sequence models show positive cor-
relation between the predicted and observed ASH (A.11, A.7, Appendix A.5.4). Each of the
nested SNP functional categories have marked differences in p-value distribution (Fig 2.2A) for
the QuASAR test of ASH. Compared to what would be expected from the null uniform distribu-
tion, effect-hSNPs and switch-hSNPs have 8x and 14x times more SNPs with p < 0.001 respec-
tively, showing that our functional annotations can predict ASH. Furthermore, these enrichments
for lower p-values are much higher than those of DHS-hSNPs (4x) and footprint-hSNPs (6x), in-
dicating that identifying SNPs in DHS regions and/or footprints alone is not enough to predict
functional effects on binding. A similar observation can be made using the observed allelic ratios
across CENTIPEDE annotations (A.12). The result that SNPs that are just located in footprints
or DHS regions tend to be silent is also true for other existing annotations (A.13) or if we change
the threshold for discriminating between footprints-SNPs and effect-SNP (A.14). We also see that
conservation score alone is not accurate enough to predict which SNPs have a functional impact
on binding (A.16).
To quantify the fraction of genetic variants that in each annotation will truly affect TF binding,
we used ASH p-values as input evidence and followed the strategy of Benjamini et al. (44) to per-
form multiple testing correction in each category separately using Storey’s q-value procedure (41).
At an FDR threshold of 20%, we detected 3,217 unique hSNPs displaying significant ASH (Table
2.1), hereafter referred to as ASH-hSNPs. Taking into account LD (R2 < 0.8) these ASH-hSNPs
constitute at least 3,158 independent loci. Several of the ASH-hSNPs were significant in more
than one cell-type, giving a total of 4,940 observations of ASH-hSNPs across all samples. The
20% FDR threshold was chosen because this data was not originally sequenced to the depth that is
generally required to call ASH at a single site with high confidence. In this reanalysis, we instead
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Figure 2.2: Determining which genetic variants affect TF binding. (A) ASH p-value densities for heterozygous
SNPs in different categories (the dotted blue line represents the null distribution). Numbers shown are the estimated
proportion of true signal, i.e., 1−pˆi0. (B & C) Precision versus Recall operating curve (PROC) comparing CENTIPEDE
predictions to (B) dsQTLs (Degner et al., 2012) and (C) CTCF binding QTLs (Ding et al., 2014). For our annotation
(in purple), the line is drawn for different threshold on what is considered an effect-SNP, with the (x) indicating all
footprint-SNPs and the (+) indicating the default threshold of 20x difference between alleles. (B) Except for CATO
(Maurano et al., 2015; dark blue) and our annotation, the other prediction methods were already included in Lee et
al. (2015). Note, the curve of some methods do not end at the lower-right corner because not all the dsQTLs have an
annotation (e.g., if they are not in footprints). (C) For both CATO and effect-SNPs we only considered CTCF motifs,
while for the methods that are not TF-centric all the scores are used. (D) Comparison of predicted binding effect for
CTCF footprint-SNPs to CTCF-QTLs. Each dot represents a SNP within a CTCF binding region (ChIP-seq peak) and
in a CENTIPEDE footprint with the same color annotation as in (A), the x-axis shows the predicted change in binding
and the y-axis the QTL effect size for the alternate allele.
focus on the aggregate distribution of p-values to estimate the proportion of true null hypotheses
(Storey’s procedure pˆi0 estimate). We estimate that 56% of the effect-SNPs show evidence of ASH.
While this conservative estimate can be considered a lower bound, it is still much higher than the
estimates for DHS-SNPs (2.1%) and footprint-SNPs (3.1%), indicating that most SNPs in DHS
16
regions and even in the putative binding sites do not affect binding.
Table 2.1: Summary of allele-specific hypersensitivity SNPs. Each row represents a category that is a subset of the
category in the previous row. Each column reports the number of heterozygous SNPs, SNPs displaying significant ASH
(20% FDR), and the estimated proportion of non-null hypotheses using Storey’s q-value approach. In parentheses are
reported the numbers for SNPs that are not present in any of the subsequent subsets and are the basis for our partitioned
q-value approach to detect ASH-hSNPs.
# hSNPs # ASH-hSNPs (20% FDR) 1− pˆi0
All DHS-hSNPs 204,757 (179,137) 0 (0) 2.1 (1.7)%
Footprint-hSNPs 55,044 (42,098) 0 (0) 3.1 (0.3)%
Effect-hSNPs 26,773 (26,773) 3,217 (3,217) 56.5 (56.5)%
In addition to the DNase-seq ASH validation, we compared our annotations to the results of
QTL analyses targeting DNase-seq sensitivity sites (dsQTLs, (39)), and CTCF binding sites from
ChIP-seq (45). For dsQTLs, using the same PROC analysis (see Fig 2.2B) as in (36) demonstrates
that effect-SNPs have a good performance compared to SNPs identified using a SVM approach or
CATO (35). Note that we have not repeated the PROC analysis for the methods studied by (36), but
we used directly the results provided by them, as PROC analysis could be sensitive to a redefinition
of the underlying true labels of the set used to evaluate performance (see discussion in Appendix
A.7). If we constrain the gk-SVM model to those predictions that overlap with our CENTIPEDE
footprints, the precision (at 10% recall) improves to 80%. This indicates that SVMs are better
sequence models than PWMs, but are not as specific without footprint information. To further
investigate the TF-specificity accuracy of our annotations we used CTCF QTLs. CTCF is a very
special type of TF with insulation (46), DNA loop organization (47), and barrier functions (48).
Compared to training an SVM on the DNase-seq data-set (non TF-centric), models that are TF-
centric such as CATO and our effect-SNPs (integrating the footprint and sequence preferences)
demonstrate a superior accuracy in discriminating dsQTLs that are also CTCF QTLs from those
that may affect other factors (see Fig 2.2C). Among all CTCF footprint-SNP instances, all those
that are also effect-SNPs are enriched for low CTCF QTL p-values and we predicted the correct
direction (the allele with higher binding) in 100% of the cases (Fig 2.2D, Appendix A.3.3).
Some of the alternative methods include information such as conservation, distance to the TSS
17
and allele frequency, however we have not included them in our annotation as we wanted to use
those measures for analyzing the potential impact on organismal function and study differences
among distinct TF motifs.
Characterization of functional regulatory variants
Regions of the genome with demonstrated molecular function (e.g. genic regions) generally
show reduced diversity (49) and a site frequency spectrum skewed towards rare variants. This
is due to negative (purifying) selection, which prevents alleles from reaching high frequencies in
the population if the molecular trait translates to a negative impact on organismal function. We
investigated whether a similar skew in the site frequency spectrum exists at functional non-coding
variants (effect-SNPs). We observed that effect-SNPs display an enrichment for rare variants (<
0.5%) comparable to what it is observed in coding regions (Fig 2.3A), where rare variants are 1 to
2 times more likely to be non-synonymous changes than synonymous (4).
eQTL studies have found that variants associated with gene expression tend to occur close to
the transcription start site (TSS) (27, 50–52). We detect a similar trend among our annotations,
with 83% of footprint-SNPs occurring within 100kb of the TSS. However, we find a 1.12-fold
depletion of effect-SNPs within 300 bases of a TSS (Fig 2.3B), which represents the core promoter
region (53). Effect-SNPs in this region are also enriched among rare variants (MAF<0.001, 1.15-
fold enrichment, Fisher’s test p-value =6.027×10−13). This is likely because effect-SNPs in these
regions have a major impact on regulatory processes that are shared across tissues. Accordingly, we
also discovered a 1.18-fold enrichment for effect-SNPs in footprints active in 5 or fewer samples
and a 1.38-fold depletion for effect-SNPs in footprints active in 50 or more samples (Fig 2.3C).
Since allele frequency can be correlated with distance to the TSS or sequence conservation,
and shared footprints may also be more common at the promoter region, we tested several features
(individually explored in Fig 2.3) in a joint model (Methods). All tested factors are significant
predictors when considered together in a multiple regression logistic model, and the direction of
the effect is the same as when they are considered separately (A.8). These results support the
hypothesis that factors binding closer to the TSS and/or active in many tissues are housekeeping
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Figure 2.3: Characterization of SNPs in DNase I footprints. (A) Comparison of the minor allele frequency of
SNPs predicted to affect binding or to be silent, showing both counts (bars) and proportions within SNP category
(lines). Minor allele frequency at coding SNPs (from 1KG), separated into non-synonymous and synonymous, is
shown for comparison. MAF is in bins of 10%, with the exception of rare (MAF < 1%) SNPs. (B) Proportion of
SNPs at increasing distance from the nearest transcription start site (TSS) up to 50Kb. Distance is absolute distance,
regardless of direction (up- or downstream) from TSS. (C) Stratification of footprint-SNPs by the number of tissues
for which the footprint was predicted active, showing both counts (bars) and proportions within SNP category (lines).
Number of tissues is binned by 5 or 10 until 50, where the remainder is binned.
factors and those that recruit the transcriptional machinery and as a consequence are less likely to
harbor common regulatory variants.
Motif-wise characteristics of functional regulatory variants
To examine the distribution of ASH-hSNPs across the different regulatory factors, we calcu-
lated the ASH enrichment ratio for each TF defined as the fraction of ASH-hSNPs over hSNPs
relative to the average fraction across all TF (A.17, Appendix A.8.3). At a nominal p-value cutoff
19
of p < 0.01 (Binomial test), we detected 32 motifs enriched for ASH and 56 depleted for ASH
(Fig 2.4A; A.9). In cases where multiple motifs correspond to the same factor, we observe sim-
ilar enrichment for ASH-hSNPs (A.10), most notably for the factor AP-1, showing a >2.5-fold
enrichment for ASH SNPs in all but one of the seven motif models. We see the same pattern for
motifs significantly depleted of ASH-hSNPs, such as CTCF (1.5-fold median depletion) and E2F
(1.8-fold median depletion). ASH enrichment ratios are also consistent across factors with sim-
ilar functions. For example, three factors in addition to AP1 with roles in the immune response,
CREB (54), c/EBP (55), and NF-κB (56) are over 2-fold enriched for ASH-hSNPs within their
binding sites (A.11).
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Figure 2.4: Motif-wise characteristics of functional regulatory variants. (A) Plot showing factors whose binding
sites are significantly enriched (positive log2(fold change)) or depleted (negative log2(fold change)) for ASH-hSNPs,
relative to the average number of ASH-hSNPs for a TF (p-value <0.01), with indication of the number of tissues
affected (color) and the median distance to the TSS (shape). Horizontal lines represent the 95% confidence interval
of the ASH enrichment ratio. An asterisk denotes a possible human analog for the specified factor. Redundant motifs
were excluded from the plot. (B & C) Boxplots showing the distance to the nearest TSS (B) and the number of tissues
in which a motif was predicted to be active (C) for motifs either enriched or depleted for ASH-hSNPs. Notches on the
boxplots are a non-parametric 95% CI interval on the median based on the inter-quartile range (IQR).
We then examined the genomic characteristics at TF binding sites to identify features that
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distinguish motifs enriched for ASH versus those that are not. We found that motifs enriched for
ASH are significantly farther from the TSS, having an average median distance to the TSS of 23kb
compared to 17kb for those depleted (Mann-Whitney p = 3.2 × 10−8; Fig 2.4B). Furthermore,
motifs enriched for ASH are active in significantly fewer samples, on average active in 20% vs
40% for those depleted (Mann-Whitney p = 1.9× 10−7; Fig 2.4C), indicating that TFs with a high
degree of ASH across their binding sites tend to be active in fewer tissues. This further confirms
that changes in footprints active in a large number of tissues (constitutionally active) are more
likely to have pleiotropic effects and therefore impact negatively the fitness of the organism and
suggests polygenic mechanisms of evolution on motifs categories (i.e. groups of binding sites for
a given TF or for TFs regulating genes with similar functions).
Evidence for motif-wise selection in TF binding sites
An important question in evolutionary biology is the extent to which selection has acted on
cis-regulatory elements in humans (57–60). While methods are being developed to address this
question (61,62), such methods have only been applied to a narrow subset of TFs, and, in the case
of (62), rely on RNA expression data to classify mutations as up- or downregulating transcription
relative to the reference enhancer sequence. Given our categorization of footprint-SNPs relative to
their effect on factor binding, we performed an initial survey of selection across TF binding sites
using a test similar to the McDonald-Kreitman (MK) test (63) (A.3, Appendix A.8.4). Applying
our modified motif-wise MK test, we obtained a selection score for TF motifs with a sufficient
number of binding sites (Fig 2.5A, A.12). At an FDR of 1%, we observe 84 factors whose binding
sites are enriched for fixed functional differences (higher selection scores), suggestive of positive
selection acting on those sites. Among the top scoring motifs are several factors that regulate
neural and neuro-developmental processes, including POU1F1, PHOX2B, DBX2, UNCX, and
YY1 which were not previously seen (61). Among the factors with the lowest selection scores,
we find ARNT, RBPJ, CREB1, POU2F2, and MYC which match with what has previously been
observed (61). While the interpretation of a positive selection score is generally that of positive
selection, interpreting negative scores is more challenging. Generally, deleterious alleles are much
21
less likely to reach fixation in populations than neutral alleles, however a negative selection score
could also be explained by relaxation of selection or balancing selection. To identify the most likely
evolutionary scenario for variation in binding motifs with negative selection scores, we calculated
the derived allele frequency (DAF) for SNPs in binding sites. We observed an excess of rare
alleles for SNPs in binding sites with a negative selection score (Fig 2.5B, A.19, Appendix A.8.5),
suggestive of weak purifying selection, rather than relaxation of selection (similar DAF spectrum
across categories) or balancing selection (excess of intermediate frequency alleles).
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Figure 2.5: Examining selection on TF binding sites. (A) Comparison of fixed functional (Df ) to fixed silent
(Ds) (y-axis) versus polymorphic functional (Pf ) to polymorphic silent (Ps) (x-axis) variants across all of the binding
sites for each TF examined. Scores towards the top left are suggestive of positive selection (excess of fixed functional
changes) while scores towards the bottom right are suggestive of weak negative (purifying) selection. Several of the
highest- and lowest-scoring factors are shown labeled with the corresponding TF. (B) Derived allele frequency for
SNPs within TF binding sites. For each pairwise bin of of DAF (rows) and selection score (columns), the enrichment
is defined as the ratio between the observed proportion of SNPs in that bin and the expected (i.e., the product of the
two marginal probabilities).
We next asked whether the excess of functional polymorphism relative to functional diver-
gence were influenced by background selection from nearby genes (A.18), as functional regula-
tory variants may occur closer to the TSS, compared to silent variants. We find a mild but signif-
icant positive correlation between selection score and median TSS distance (Spearman ρ = 0.16,
22
p =5.6×10−9). Additionally, there is a negative correlation between tissue specificity and selection
score (Spearman ρ = -0.20, p =1.2×10−13). While some of the selection signal may come from
nearby genes, there does appear to be a pattern of selective constraint on broadly active factors
binding in promoter regions.
Functional regulatory variants are enriched for GWAS hits
Given that our annotations comprise predicted functional effects across multiple cell-types/tissues
and are anchored at footprints for known TF motifs, we asked if they could help interpret genomic
hits reported in the GWAS catalog. We first considered a gross overlapping approach that con-
siders each variant in a GWAS hit region equally likely to be causal (using an r2 cutoff of 0.8
from 1KG Project data, as in Ward et al. (10)). In GWAS hit regions, we compared the proportion
of effect-SNPs over footprint-SNPs and found a moderate 1.11-fold enrichment for effect-SNPs
(p < 2.2 × 10−16, 95% CI: 1.10 - 1.14). These moderate but statistically significant enrichments
are typical of other annotations as well and are likely due to the fact that: i) we only consider
the strongest GWAS hits (missing variants with moderate and small effects), ii) not all the factors
and tissues may have the same enrichment, and iii) lack of resolution, as expanding the GWAS
hit region makes the enrichment effects more moderate. Nevertheless, if we add our annotation to
category 2 SNPs from the RegulomeDB (7) (SNPs with multiple regulatory annotations, but not
yet shown to be functional), we detect a 1.6-fold enrichment for GWAS hits compared to category
2 SNPs alone (p = 6.11×10−5, 95% CI: 1.27 - 1.99). This result demonstrates that our annotation
adds relevant information as it filters genetic variants not likely to be functional, but the overlap ap-
proach employed cannot take full advantage of the resolution and contextual information provided
by our CENTIPEDE predictions.
Follow-up results
To test if the annotated effect-SNPs can help fine-mapping and give a mechanistic support for
variants associated with complex traits, a follow-up analysis integrated them into GWAS meta
analyses for 18 traits (see A.13) using the recently developed hierarchical model fgwas (42). Im-
portantly, this analysis used as input the association p-values measured or imputed to all known
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common variants in the genome. Furthermore, each trait was compared to a baseline model (42)
that considers previously defined annotations (11,64) and confounders (e.g., distance to TSS, cod-
ing region, and others). For each trait, factors were identified whose binding sites were enriched
for associated SNPs (Fig 2.6A & B, A.20 and A.14) over the baseline model (the enrichments
reported by fgwas are log-odds ratios from the model parameters).
Overall, the results showed high enrichments for biologically relevant factors. For example, the
enrichment for effect-SNPs in OCT-4 (POU5F1, a TF with a key role in embryonic development
and stem cell pluripotency (65)) regulatory sequences when considering genetic variants associ-
ated with human height is 6.6-fold higher (95%CI: 3.7-8.2) than in the baseline model. This is
consistent with previous observations of genetic variants associated with height being enriched in
embryonic stem cell DHS sites (66). In addition, there was an enrichment for the developmental
regulators TBX15 (3.9x), FOXD3 (3.9x), and NKX2-5 (4.7x) for genetic variants associated with
height. From a study of low-density lipoprotein (LDL) levels in the blood, enriched factors include
the liver-specific factor HNF4A (9.1x), as well as several regulators of immune function, including
CREB1 (3.7x), IRF1 (6.2x), and IRF2 (7.1x).
Our high resolution annotations allowed the dissection of the most likely functional variant
(posterior probability of association, PPA> 0.2) in 88 previously identified GWAS regions (A.15).
All but two of these 88 SNPs have at least a 2-fold increase on the posterior odds of picking the
potentially causal genetic variant according to fgwas (8.5x median fold increase) when compared
to the comprehensive baseline annotation used by (42).
As an example, rs4519508, associated with a 2.1cm decrease in height (2), is in a binding
site for the cell-cycle regulator family E2F (Fig 2.6D). Our annotation increased the PPA from a
baseline of 10.5% to 44.4%, and it is the highest associated SNP in the association block (A.21A).
This E2F footprint is active in >300 tissues (most of them fetal) and has ASH at this SNP in
lung fibroblasts, validating that the reference allele at rs4519508 confers stronger binding than the
alternate. Finally, this SNP is located within the promoter of PPP3R1, a regulatory subunit of
calcineurin important for cardiac and skeletal muscle phenotypes; and a SNP in the same region
24
A C
E2F (M01114)
RFX1 (M01641)
Foxd3 (MA0041.1)
TBX15 (M01264)
CDP CR1 (M00104)
SMAD (M00792)
Nkx2−5 (M00241)
Oct−4 (POU5F1) (M01124)
SREBP (M00776)
Oct−4 (POU5F1) (M01125)
Pou5f1 (MA0142.1)
0 5 10
Enrichment
Height
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●●
●
●
●
●●
●●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
68 68.5 69 69.5 70
−4
−2
0
2
4
6
Position on chromosome 2 (Mb)
−l
og
10
( B
F 
)
rs4519508)(T/C))
E2F)
lo
g(
 B
F 
) 
B D
ATF (M00017)
CREB/ATF (M00981)
ATF (M00338)
ATF−2 (M01862)
CREB1 (MA0018.2)
ATF2:c−Jun (M00041)
CG1 (M00440)
TGA2 (M01586)
bZIP911 (M00359)
Cell09/HLH−29_RC (PBM0191)
Cell09/HLH−29 (PBM0176)
USF (M00187)
CPRF−1 (M00942)
ATF−3 (M00513)
ATF−3 (M01863)
TGA2 (M01812)
AP−1 (M00517)
NF−E2 (M00037)
IRF−1 (M00062)
HNF1 (M00206)
HSF (M00169)
Pax6 (MA0069.1)
RCS1 (M00753)
IRF−2 (M00063)
HNF4a (M00638)
Zfp206 (M01742)
0 5 10 15
Enrichment
LDL
●
●
●
●
●●
●
●
●
●
●
●
●●●
●●
●●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●●●●●●
●●●
●
●
●
●●●●●
●●
●●●●●●●●●●●
●
●
●●●●●●
●
●
●●●●●●●●
●
●●
●
●●●●
●●●●
●●
●
●
●
●●●
●
●●●
●
●●
●
●●●
●●
●
●●
●
●
●●
●●
●●●●
●●●
●
●
●
●
●
●●
●
●●
●
●
●●
●
●
●●
●
●
●
●
●●
●●
●●●
●●
●
●
●●
●
●●●●●
●
●●
●●
●●●●
●
●●
●
●●
●●
●
●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●
●●
●●
●
●
●
●●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●●●●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●
●●
●
●●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●●●
●●●
●
●
●
●●
●●
●●●
●
●
●●●●●●●●●●
●●
●
●
●●
●
●
●●●
●●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●●
●
●●
●●
●
●●●
●
●●
●
●●
●
●
●●
●●●
●●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●
●●
●
●
●●
●●
●
●
●
●
●●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●●
●●
●
●
●
●
●●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●●
●
●●
●
●
●
●●●
●
●
●
●●
●●
●
●
●
●
●●
●
●
●●
●
●●
●
●●
●●●●
●
●●
●
●
●
●●●●●
●
●●
●
●●●●
●●●
●
●
●
●●●●
●●●
●●●●●●●●
●●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●●
●
●
●●●
●
●
●
●●●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●●
●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●
●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●
●
●●
●
●
●
●●
●
●
●●●
●
●●●
●
●
●
●●
●
●
●
●●●
●
●●
●
●
●
●●●●●
●
●●●●●
●●
●●
●
●●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●●●
●
●
●
●
●
●●●●
●
●
●●●●●● ●●
●
●●●
●●
135 135.5 136 136.5 137
0
10
20
30
40
50
60
Position on chromosome 9 (Mb)
−l
og
10
( B
F 
)
rs532436((T/C)(
USF/E2box(l
og
( B
F 
) 
Figure 2.6: Integration of annotations into GWAS results. (A & B) Enrichment (log2(change in prior odds w.r.t
the baseline model)) of factors for association with (A) height and (B) low-density lipoprotein levels. Error bars are
drawn for 95% confidence intervals. (C & D) Association plots showing the Bayes factor of each SNP in the displayed
region for (C) height and (D) low-density lipoprotein levels. Shown in red are SNPs with a posterior probability of
association >0.4.
has been shown to be associated with endurance (67) in humans. The p-value of association for
this GWAS locus (p = 8.1 × 10−6) does not reach genome-wide significance in the height meta-
analysis data we used (2); however, in a recent more extensive meta-analysis for height (68) this
locus achieves genome-wide significance p = 8.4× 10−10, demonstrating that our annotation can
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be useful to rescue relevant loci.
Finally, a SNP associated with LDL levels, rs532436, is within a footprint for USF, an E-box
motif (Fig 2.6C). Adding our annotation increased the PPA of the SNP from 39.7% to 94.7%
(A.21B). The alternate allele, associated with a 0.0785 mg/dL increase of LDL in the blood, is
predicted to have a lower binding probability and results in 1.8-fold lower expression, compared
to the reference allele. This SNP is identified by GTEx (69) as an eQTL for two proximal genes
in whole blood: ABO (p = 5× 10−5) and SLC2A6 (GLUT6, a class III glucose transport protein;
p = 8× 10−5). The SNP has an opposite effect on expression of the two genes, with the alternate
allele showing lower expression for ABO and higher expression for SLC2A6.
These follow-up results show that our integrated analysis provides support for likely mecha-
nisms linking regulatory sequence changes to complex organismal phenotypes. Furthermore, these
mechanisms can be directly investigated through molecular studies, providing additional support
that these sequence changes are truly functional.
DISCUSSION
We have developed an approach for assessing functional significance of non-coding genetic
variants in DNase-seq footprints. Our strategy integrates sequence information with functional
genomics data to predict the impact of single nucleotide changes on tissue-specific TF binding.
This is achieved while integrating footprint information that preserves the identity of the underlying
factor with high specificity. By borrowing data from ENCODE and Roadmap Epigenomics, we
generated one of the most comprehensive catalogs available to date annotating regulatory regions
and functional genetic variants across the genome.
Thus far, most common approaches for identifying regulatory variants from functional ge-
nomics data assume that each SNP in a regulatory region is equally likely to be functional. A key
finding in this study is that genetic variants in active regulatory sequences, as defined by DNase
I sensitivity and footprinting, are mostly silent; only 2.1% of SNPs in DHS regions and 3.1% of
SNPs in CENTIPEDE footprints are estimated to have ASH. This is analogous to SNPs in coding
regions, where most genetic changes are synonymous and do not result in an amino acid change (4).
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The sequence model developed in this study provides a very useful filter for non-coding genetic
variants that are not functional, resulting in a tissue-specific and motif-specific annotation of effect-
SNPs (56.5% of which are estimated to have an impact on ASH). This is crucial information to
take into account when we attempt to understand the molecular mechanism behind GWAS hits
and evolutionary signals of selection. As additional functional genomics studies are performed,
across larger sample sizes, tissue types and cellular conditions, it will be important to further de-
termine the functional subset of regulatory variants within binding sites to achieve greater power
in functionally annotating genetic variants associated with complex traits.
We find that genetic variants that are predicted to impact TF binding are depleted in the core
promoter regions, exhibit higher sequence conservation in closely related species, tend to have low
allele frequency and are enriched in tissue-specific footprints. These properties largely reflect the
family-wise characteristics of motifs, which are further reflected in signals of selection. Future
studies could incorporate tissue breath, conservation and distance to TSS as features to further
filter effect-SNPs that may not show ASH. It should also be noted that our definition of functional
regulatory variants is connected to the predicted effect on binding in the specific subset of cell-
types/conditions that were available. Analyzing the allelic effects of non-coding variants in the
context of other tissue types, conditions and functional genomic assays may potentially identify
a functional role for some of the sites here defined as silent. In this study, we treated each TF
separately, but future work should further explore the combinatorial grammar that different groups
of motifs may define by cooperative binding to determine tissue specific binding sites. This will
probably require more complex sequence models (e.g., SVMs (36, 70) or deep neural networks
(71,72)) than the PWMs used here. Here we show that the footprint information helps in predicting
functional variants by further identifying the underlying TF compared to a sequence-fits-all model.
More sophisticated footprint models (73) may also offer additional improvements to dissect the
complexity of the regulatory grammar.
As not all genetic variants that have an impact on binding may lead to changes in gene expres-
sion and ultimately an organismal phenotype, combining these predictions with eQTL data across
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several tissues or environmental conditions would be important to further refine this annotation. As
an example, Wen et al. (52), using an early release of this annotation in lymphoblastoid cell-lines
demonstrates that effect-SNPs are 1.49 fold (with 95%CI [1.38, 1.63]) more likely than baseline
SNPs (SNPs that are not located in a footprint) to be eQTLs (p = 4.93× 10−22); in contrast, silent
footprint-SNPs are 1.15 fold (with 95%CI [1.04, 1.27]) enriched in eQTLs, comparing to baseline
SNPs (p = 0.0035).
A key feature of our annotation is that it spans a large collection of tissues and transcription
factor motifs. This allowed us to trace some of the evolutionary history of TF binding and iden-
tify evolutionary constraints on specific molecular functions, which may reflect selective pressures
during human history. For example, we observed that immune TFs are enriched for ASH sites,
which supports the hypothesis that this may be a consequence of human adaptations to pathogen
exposures (74). On the other hand, we identified neural development TFs that may have under-
gone positive selection in humans. The large number of regulatory variants predicted in our study,
together with previously reported eQTL signals (75–77), and the overall relevance that they have
in explaining complex traits provide further support for polygenic models of complex traits in hu-
mans. By taking advantage of the factor-specific annotations in our study, a follow-up study motifs
that are enriched for regulatory variants associated with relevant GWAS traits and we provide ex-
amples of molecular mechanisms behind the association signals; e.g., immune TFs in the lipids
study, and developmental TFs for height. The study also showedFinally, we show how regula-
tory annotations improve the identification of potential causal SNPs in GWAS. Overall, the GWAS
meta-analysis and selection signals in our study support the concept that polygenic variation in
binding sites has been a major target of evolutionary forces and a key contributor to disease risk
and complex phenotypes in human populations.
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CHAPTER 3: A HIGH-THROUGHPUT RNA-SEQ
APPROACH TO PROFILE TRANSCRIPTIONAL
RESPONSES*
INTRODUCTION
In the field of transcriptomics, a variety of study designs could take advantage of a strategy
that tests a large number of conditions prior to further analysis of relevant ones. Examples of
such applications include time-course experiments (e.g., Amit et al. (78)), with an initial screen
over a large number of timepoints; population-specific response profiling (e.g., Maranville et al.
(79)), with a large number of treatments performed in a few individuals; and large scale sh-RNA
studies (e.g., Cusanovich et al. (80)). In each of these cases, deep sequencing can then be used to
characterize the transcriptome only in the most relevant conditions (i.e. timepoint, treatment, tissue
type). When interested in understanding the regulatory mechanisms underlying a cell’s response
to environmental perturbations, current experimental setups are costly and laborious and focus
only on the analysis of one particular cellular environment. One of the few examples of studies
considering more than one cellular environment is the Connectivity Map initiative (81), which
characterized the transcriptional response to 164 small-molecule perturbagens in four cancer cell
lines using microarray technology. Similar projects could now instead use RNA-seq technology for
the initial screening step with many practical advantages when transitioning to a focused analysis
of the most relevant conditions (e.g., isoform quantification, identifications of new transcripts,
allele-specific expression, and changes in lowly expressed genes or long non-coding RNAs).
Since the development of RNA-seq (82–84), a variety of protocols have been introduced to
measure transcript expression and investigate specific biological problems. For example, direct
RNA sequencing (85) allows sequencing of RNA molecules skipping cDNA synthesis and can
thus analyze short, degraded and/or small quantity RNA samples. Another example of fast and
automatized RNA-seq protocols is the Tn-RNA-seq (86) approach, which uses transposase-based
*This chapter previously appeared as: Moyerbrailean GA, Davis GO, Harvey CT, Watza D, Wen X, Pique-Regi R,
Luca F. 2015. A highthroughput RNA-seq approach to profile transcriptional responses. Scientific Reports, 5:14976.
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incorporation of sequencing adapters in cDNA libraries. Most RNA-sequencing studies that only
require gene expression quantification are currently collecting tens of millions of reads per sam-
ple. A recent report by Hou et al. (87), however, shows that gene expression for highly abundant
transcripts can be reliably quantified with less than five million reads per library. Similarly, recent
theoretical predictions and empirical findings demonstrated that shallow mRNA sequencing at ex-
tremely low depths may be useful for other applications (e.g., Kliebenstein et al. (88)). Pollen and
colleagues (89), for example, have shown that tissue identity from single cells transcriptome analy-
sis can be detected with a shallow sequencing depth of 10,000 reads/single cell, while specific gene
expression signatures require at least 50,000 reads/cell. Here we investigated whether a shallow
sequencing approach can be used as an initial screening step of differential gene expression, to be
followed up with deep sequencing of the most informative libraries.
To this end we have developed a cost-effective two-step strategy that uses the ability to index
and pool many (96 or more) RNA-seq libraries in parallel, and it can be used in combination with
any RNA-seq technique as long as it allows for multiplexing. This strategy allows the researcher
to rapidly screen a large number of sample conditions and strategically allocate sequencing re-
sources for in depth analysis only of the relevant cases. We demonstrate this approach by explor-
ing the transcriptional response to a wide panel of environmental perturbations (26 treatments) in
three lymphoblastoid cell lines (LCLs) samples. The results show that our approach should also
be applicable to similar scenarios requiring high throughput screening across multiple cell lines,
treatments, time points and/or patient samples in a variety of contexts, such as: population genetic
studies, parallel shRNA knockdowns, mutagenesis screens, pharmacological drug testing, stem
cell differentiation monitoring and cancer transcriptome profiling.
MATERIALS AND METHODS
Cell culture and treatments
Lymphoblastoid cell lines (LCLs) were purchased from Coriell Cell Repositories. Prior to the
experiment, cells were cultured, at 37◦ and 5% CO2, in RPMI 1640 (Gibco), supplemented with
15% heat-inactivated fetal bovine serum and 0.1% Gentamycin. The following LCLs were used:
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GM19239, GM18507, and GM18508. LCLs were cultured in “starvation medium” composed of
RPMI 1640, supplemented with 15% charcoal-stripped fetal bovine serum (CS-FBS) and 0.1%
Gentamycin for four days. Cells were then treated, while in mid-log phase exponential growth,
with the treatment panel (Sigma Aldrich) in Table 3.1 for 6 hours.f
Sample Collection and mRNA isolation
Treated cells were collected by centrifugation at 2000 rpm and washed 2X using ice cold PBS.
Collected pellets were lysed on the plate, using Lysis/Binding Buffer (Ambion), and frozen at -80◦.
Poly-adenylated mRNAs were subsequently isolated from thawed lysates using the Dynabeads
mRNA Direct Kit (Ambion) and following the manufacturer instructions.
A modified RNA-seq library preparation protocol
We modified the NEBNext Ultradirectional (NEB) library preparation protocol to use 96 Bar-
codes from BIOOScientific added by ligation, this allowed us to reduce the overall library prepara-
tion cost to $47/sample. Specifically, RNA-seq libraries were prepared using the NEBNext ultra-
directional library preparation protocol, with the following changes. RNA was fragmented at 94◦
for 5 minutes to obtain fragments 200-1500bp in size. SPRI Select beads (Beckman Coulter) were
used in all purification steps and size selection was performed to obtain 300-450bp fragments . Af-
ter the cDNA synthesis, to the 65 µL of dA-Tailed cDNA were added the following components:
15µL of Blunt/TA Ligase Master Mix, 2.39µL of BIOO Scientific Barcode Adaptors (1-96), 1.11
µL of Nuclease-free water. The samples were incubated for 15 minutes at 20◦ in a thermal cycler.
USER Excision and PCR Library Enrichment were performed according to the following proto-
col. To the size selected cDNA (20µL) were added the following components: 3µL of NEBNext
USER Enzyme, 25µL of NEBNext High-Fidelity PCR Master Mix, 2X, 2µL of BIOO Scientific
Universal Primer (12.5µM). The individual libraries were quantified using the KAPA real-time
PCR system, following the manufacturer instructions and using a custom-made series of standards
obtained from serial dilutions of the phi-X DNA (Illumina). Pools of 96 samples from the first
step were sequenced on two lanes of an Illumina HiSeq2500 in fast mode to obtain 50bp PE reads,
at the University of Chicago Genomics core. Alternatively, this could be run on one lane of the
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Illumina Next-Seq 500 (75 cycles, PE). Re-pooled libraries for step two were sequenced on the
Illumina HiSeq2500 in Rapid Run mode to obtain 50bp and 140bp PE reads.
Calculating optimal re-pooling proportions
To calculate optimal re-pooling proportions after shallow sequencing, we first calculated the
digital concentration of reads/µL (R). For each sample i sequenced in step one, Ri is defined as
the number of raw sequencing reads per µL of pooled library. The re-pooling proportion for each
sample i is then calculated using the following formula:
T −Di
Ri
(3.1)
where T represents the total number of reads desired for each sample i (here 75M) and Di repre-
sents the number of reads collected for sample i in previous runs. Changing the value for Di and
Ri also allows for iterative adjustments of pooling proportions in order to reach the desired total
number of reads through multiple re-pooling and sequencing runs.
RNA-seq data processing and differential gene expression analysis
Sequencing reads were aligned to the reference human genome hg19 using bwa mem (90)
(http://bio-bwa.sourceforge.net). Reads with quality <10 and duplicate reads were
removed using samtools rmdup (http://github.com/samtools/). We also removed
two samples (barcodes) because the sequencing failed (extremely low number of reads, <1M).
Read counts covering each transcript were calculated using samtools and the Ensembl gene anno-
tations for 57605 genes. Counts data for transcripts with >20 reads were used to run DESeq2 (91).
To best account for overdispersion, the DESeq2 model was fit on all sequencing data simultane-
ously, rather than pairwise matching of treatments and controls. Each control-treatment pair was
then matched from an experimental design matrix, and differentially expressed (DE) genes were
determined as those with at least one transcript with a Benjamini-Hochberg controlled FDR (92)
(BH-FDR) of 10%. For step two, reads from multiple runs were merged after alignment (at the
bam stage) and prior to applying any filter. Reads obtained in step one were not pooled with reads
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obtained in step two.
To perform hierarchical clustering of the expression levels across treatments, for each tran-
script in the Ensembl annotations, we calculated FPKMs from the number of reads covering the
transcript. To control for potential confounders of expression data, a linear model was used to
regress out effects from GC content, transcript length, and an interaction term between GC content
and transcript length. These residuals were quantile normalized within each sample, and normal-
ized within each individual by subtracting that individual’s average value per transcript across all
treatments. This was calculated after removing the top and bottom 10%-iles of data, usually re-
ferred to as 10% trimmed mean or Tukey’s mean. The procedure is implemented in R “mean”
function using the “trim=0.1” option.
The downsampling of reads from shallow sequencing to test the limits of highly multiplexing
approaches was performed using the samtools command “view” with the “sub-sampling” option.
RESULTS
The two-step approach
Figure 3.1 presents an outline of the new high-throughput two-step RNA-seq approach we have
developed. In step one we characterize global changes in gene expression. Here we used a modified
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Figure 3.1: Workflow of the two-step approach.
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RNA-seq protocol (see Methods) better suited for our specific application, but similar results can
be achieved with popular commercial RNA-seq kits that allow for high multiplexing (96-well plate
format) such as the Illumina TruSeq Stranded mRNA HT Sample preparation kit or the NEBNext
Ultradirectional (NEB) library preparation kit. Many of these commercially available kits can work
with liquid handling robots that automatize the majority of the experimental steps (e.g., Beckman
Coulter Biomek FXp, Eppendorf epMotion 5075, and others).
In the first step, all samples are experimentally processed in parallel, from tissue culture and
treatments to library preparation, thus minimizing experimental variation from testing hundreds
of conditions at the same time. Additionally, high multiplexing allows reducing the number of
controls that would need to be repeated across different treatment batches in a less multiplexed
experimental setup (e.g., 93 treatments plus 3 controls). A 96-libraries pooling and shallow se-
quencing strategy is then used to minimize the amount of resources used in the screening step.
Here we demonstrate that shallow sequencing depth (<10M reads) allows detecting global and
biologically relevant gene expression changes and can be used to identify relevant conditions to
follow up in step two. Even for study designs that require deep sequencing of large number of
samples (e.g., 96), our two-step approach allows using the first step to QC the libraries, before
investing in deep sequencing efforts.
For the second step, we do not need to prepare new libraries, and we can simply repool a selec-
tion of the initial libraries, without additional experimental costs. Furthermore, we can optimize
library concentrations to pool in order to achieve even representation of individual libraries. This
is done by calculating a digital library concentration from the sequencing run performed in step
one. Note that this digital library concentration is the fraction of reads from the total sequenced in
the pool, and it naturally takes into account potential differences across the libraries in sequencing
output (e.g., due to flow cell cluster formation in Illumina sequencing machines) (see Methods,
Equation 3.1). Even in situations where deep sequencing data are to be collected for all samples,
using a two-step approach makes possible to repool the samples to achieve a more uniform alloca-
tion of sequencing reads across samples. As a result, in many applications, using the same budget,
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greater sequencing depth can be allocated to step two instead of step one. Below we present an
application of the two-step approach to analyze the response to 26 environmental perturbations in
LCLs.
Step one: Identifying global changes in gene expression from low-coverage data
To characterize the response to treatments, cells were treated with the panel of treatments listed
in Table 3.1 for 6 hours. Cells from all treatment conditions, including the vehicle controls, were
Table 3.1: Treatments used in step one. The control for each treatment is the vehicle that was used to dilute
it. For example, dexamethasone was prepared from a powder diluted in EtOH, so we used EtOH as control for the
dexamethasone treatment. Note that we also matched the concentration of the vehicle used. In the case of all the
treatments with EtOH as control, both the treatment and the control wells received 1ul of EtOH per 10,000 ul of
culturing media.
Treatment Common Name Control Concentration†
Ascorbic acid Vitamin C Media 1.00× 10−5
Biotin Biotin Media 4.75× 10−10
Nicotinic Acid Vitamin B3 Media 1.50× 10−5
Pantothenic Acid Vitamin B5 Media 1.00× 10−7
Pyridoxine Vitamin B6 Media 1.00× 10−5
Retinoic Acid Vitamin A Ethanol 1.00× 10−8
Tocopherol Vitamin E Ethanol 5.00× 10−5
Plumbagin Vitamin K3 Ethanol 1.00× 10−6
Aldosterone Aldosterone Ethanol 1.00× 10−5
Progesterone Progesterone (C1) DMSO 1.00× 10−6
Progesterone Progesterone (C2) Ethanol 1.00× 10−5
Beta-Estradiol Estrogen Ethanol 1.00× 10−5
Dexamethasone Dexamethasone Ethanol 1.00× 10−5
Caffeine Caffeine Media 1.16× 10−3
Nicotine Nicotine Media 6.16× 10−4
Copper (II) Chloride Copper Media 6.00× 10−5
Iron (III) Chloride Iron Media 5.00× 10−3
Manganese (II) Chloride Manganese Media 3.00× 10−3
Molybdenum (V) Chloride Molybdenum Media 5.00× 10−4
Sodium Selenite Selenium Media 1.00× 10−5
Zinc Chloride Zinc Media 8.00× 10−5
Tunicamycin Tunicamycin DMSO 2 µg/mL
PM 2.5 (Detroit) PM 2.5 Media 5 µg/mL
† All concentrations are in molarity (M) unless otherwise specified.
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cultured and harvested in parallel at the same time point, thus allowing for a better control of
technical noise, or biological variation that is independent of the treatment. For example, this
design controls for temporal changes in gene regulation that are independent of the treatment (e.g.,
changes in cell cycle phase over time, reagent batch effect) but otherwise could be confounded or
add noise to the measurements. To achieve greater confidence and accuracy to measure baseline
gene expression, for each LCL sample, the control treatments were performed in triplicates. For
all stages of sample preparation we have used a 96-well plate study design (3 samples and 32
treatment conditions, Figure B.1) from cell culturing to RNA extraction and library preparation,
thus facilitating increased sample processing throughput. To identify differentially expressed (DE)
genes we used the method implemented in the software DEseq2 (91), which estimates variance-
mean dependence in the read counts for each gene and tests for differential expression based on
a model using the negative binomial distribution. Each treatment was matched to the appropriate
vehicle control (Table 3.1) for this analysis. However, when comparing pairs of controls to each
other we did not detect any DE genes (10% Benjamini-Hochberg controlled FDR (92)[BH-FDR],
Figure B.2). To assess the calibration of the tests for differential expression on low coverage data,
we used QQ-plots and compared the p-value distribution from DESeq2 to the expected uniform
distribution. We observed that in most cases the tests are well calibrated (Figure 3.2 and Figure
B.3).
We next asked whether our ability to identify the conditions with strongest differential expres-
sion may depend on sequencing depth. Figure 3.3 shows that in the context of the expected varia-
tions in sequencing depth from multiplexing of samples, the strongest conditions stand out even if
they were sequenced at relatively lower depths than other conditions. For example, we identified
thousands of DE genes for iron and tunicamycin, which are among the treatments with less cov-
erage. On the other hand, we detected <100 DE genes in response to vitamin B6 and vitamin E,
even though these are the treatments for which we collected the largest number of reads. Prior ex-
periments performed by our group (see Luca et al., 2013 (93), Maranville et al., 2011 (17)) showed
that dexamethasone induces a strong transcriptional response in LCLs, while estrogen doesn’t have
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Figure 3.2: QQ-plot of the p-value distribution for DE genes in response to dexamethasone (black) and estrogen
(green), compared to the expectation under a uniform distribution (red). Additional QQ plots from step one and
step two are available in the supplements.
a strong impact on gene regulation in this cell type. After running DESeq2, we identified 1,919 DE
genes in response to dexamethasone, while only 26 DE genes were detected in cells treated with
estrogen, thus confirming previous results (Figure 3.2).
To identify major similarities and differences in the transcriptional response to our panel of
treatments, we performed hierarchical clustering on the transcript expression data for each treat-
ment (expressed in FPKMs). Figure 3.4 shows a heatmap of the correlation matrix across all
treatment conditions and samples. Some key features appear evident even with low sequencing
depth: control samples cluster together; treatments that induce a strong response are distinct from
all other treatments and controls, and show a clear pattern where the three samples for each treat-
ment condition cluster very tightly.
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Figure 3.3: DE genes and sequencing depth. Scatterplot of DE genes (10% BH-FDR) versus the sequencing depth
for each shallow sequencing treatment. The reported sequencing depth is the total number of reads across the three
individuals.
Overall the results from step one show that even from low sequencing depth data it is possible
to identify biologically meaningful global changes in gene expression that are relevant to assess
the cellular response to environmental perturbations.
Step two: Following up the most relevant conditions
The information collected in step one of our approach can be most effectively used to re-
pool individual libraries by selecting the treatment conditions biologically relevant for the system
under-study. As a proof of principle, we selected four treatment conditions, vitamin A, copper,
iron, and selenium, for deeper sequencing (75M reads/sample) in all three cell lines to investigate
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Figure 3.4: Heatmap and hierarchical clustering of gene expression levels across all shallow sequenced sam-
ples. Gene expression levels (FPKMs) were obtained for each sample (individual X treatment combination) as a vector
indexed by gene. Those vectors were clustered using hierarchical clustering and the dendrogram is displayed at the top
of a heatmap visualizing the Pearson correlation between each sample. The sample identity is detailed by a two-way
coloring indexing the individual and treatment (see legend).
the transcriptional response to these environmental perturbations with greater resolution.
One of the challenges when sequencing highly multiplexed pools of libraries is achieving sim-
ilar depth of coverage across samples. Figure 3.5 shows density plots of sequencing depth across
shallow and deep sequencing samples. The distribution of sequencing depth is a function of factors
related to the sequencing technique and instrument (for example, efficiency in cluster generation on
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Figure 3.5: Density plot of raw (unfiltered) sequencing depth across individual barcoded samples for the
shallow sequencing (blue) and for the deep sequencing (red) runs. Note that in step two, we aimed to collect
approx 75M reads for each treatment sample, while for the control samples (e.g., EtOH) we aimed to collect 75M
reads across the three technical replicates (approx 25M reads per replicate), in order to achieve even representation of
sequencing depth across treatment conditions. In this plot reads for each control sample were pooled across technical
replicates. Only for the iron samples we did not aim for 75M reads as we noticed the cytotoxic effect and decided not
to pursue much further. Dotted lines indicate the average sequencing depth in each step.
an Illumina sequencer). For this reason, it is possible to account for these factors when determining
pooling concentrations for the deep sequencing pool. We developed a formula (Equation 3.1) that
uses information from the low coverage data to learn about “read” concentration per library and
also accounts for the sequencing output of each individual sequencing run (see Methods). This is
much better than any standard library quantification approach, because we have a “digital” count
of the actual reads that contribute to generate clusters on the flow-cell per unit of volume of the
library. As expected, in step two, we observe a much tighter distribution of sequencing depths
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across samples.
We then used DEseq2 to identify DE genes in the deep sequenced libraries. Table 3.2 shows
the number of DE genes, and their direction of expression change. We found that expression
Table 3.2: Differentially expressed genes identified in step two.
# DEG† (% total)
Shallow Deep
Copper Up 758 (6.73%) 1806 (11.43%)
Down 769 (6.82%) 2167 (13.71%)
Iron Up 7754 (27.56%) 12465 (41.48%)
Down 3133 (11.13%) 6134 (20.41%)
Selenium Up 3198 (21.24%) 5937 (24.01%)
Down 2535 (16.83%) 5266 (21.29%)
VitaminA Up 2156 (11.15%) 3337 (14.82%)
Down 1239 (6.41%) 2553 (11.34%)
†10% BH-FDR
fold change is highly correlated between the shallow and deep sequencing experiments for the
same treatment (Spearman ρ > 0.7, Figure 3.6, Figure B.4, Figure B.5), which confirms that
gene expression changes detected from shallow sequencing can be used to identify biologically
relevant treatments for follow up studies. The small subset of DE genes identified only in the
shallow sequencing data are most likely false positives due to larger uncertainties in the fold change
estimates. Accordingly, we find larger standard errors (0.006 - 0.02 higher) for the log fold changes
in the shallow data, compared to the deep sequencing data, for all treatment conditions except
iron (0.003 lower) (Figure B.6). We found minimal changes in transcript length (100bp - 350bp
difference) and average GC content (0.04% - 0.6% difference) between DE genes identified from
shallow or deep sequencing. No major differences are detected in gene expression levels derived
from shallow and deep sequencing (Figure B.5) due to a run effect as samples cluster by individual
rather than sequencing run. As expected, with deep sequencing data we can identify transcriptional
changes with greater sensitivity at the same FDR level. Figure 3.7 shows the increase in number
of DE genes as a function of sequencing depth in step one and step two.
To investigate to which extent we can decrease the amount of sequencing performed in step
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Figure 3.6: Correlation in the transcriptional response between shallow and deep sequencing. Plotted is the
log2(fold change) for each gene calculated from shallow and deep sequencing data for the four treatments analyzed
in step two. Colored points represent genes differentially expressed at 1% BH-FDR. Vitamin A (A), copper (B), iron
(C), selenium (D). Spearman’s ρ (legend) is calculated using all genes.
one, we downsampled reads from shallow sequencing runs to simulate the effects of using a lower
coverage for the first step (from the proposed 96 up to 1152 multiplexed samples). Figure 3.8 and
Figure B.7 show the correlation between fold changes at downsampled depths with fold changes
from step two. Although the number of significantly DE genes may decay more rapidly as we
multiplex more samples, the correlation with deep sequencing is>0.5 when we subsample down to
1/8, corresponding to multiplexing 768 samples. The observed correlations support the possibility
of using higher multiplexed study designs.
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between shallow and deep sequencing runs. The reported sequencing depth is the total number of reads across the
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In depth analysis of gene regulation in response to environmental perturbations from step
two
To investigate similarities in the transcriptional response to the four treatments that were deep
sequenced, we calculated pairwise Spearman rank correlations on the transcript fold change. We
observed that responses to metal ions (copper, iron, selenium) tend to be more highly correlated
with each other than to vitamin A. The highest correlation was observed between copper and iron
(0.43, p = 0). This suggests that LCLs respond to these treatments through similar gene regulatory
pathways.
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Figure 3.8: Correlation of downsampled shallow sequencing runs (step one) to deep sequencing data (step two).
The DEseq2 log fold-change obtained after step two are correlated (Spearman correlation) with the fold changes
obtained at step one for different downsampling ratios (1,1/2,1/4,1/6,1/8, 1/10 and 1/12), that would correspond to
multiplexing higher number of samples (96, 192, 384, 576, 768, 960 and 1152).
To further investigate the regulatory pathways altered during the response to these treatments,
we performed GO (Gene Ontology) enrichment analysis using the DAVID online tool (94) and
focusing on biological processes (5% BH-FDR, Supplementary Tables B.1-B.8). We observed
that upregulated genes in response to vitamin A are enriched for the immune response and re-
lated processes (e.g., leukocytes and lymphocytes activation), which is in line with the known role
of vitamin A as an activator of immune function (95). Upregulated genes in response to copper
are enriched for genes involved in the protein ubiquitination biological processes, and the same
result is observed for upregulated genes in response to selenium. This supports the observation
44
that these two metal ions elicit very similar transcriptional responses, which are clearly distinct
from the response induced by treatment with vitamin A. However GO enrichment analysis also
points to an anti-inflammatory role for selenium, as down-regulated genes in response to this metal
ion are enriched for leukocytes activation. Finally, genes upregulated in response to iron are en-
riched for metal ion transport and cell-cell adhesion among the top biological processes, while
down-regulated genes are enriched for RNA and DNA metabolic processes as well as key cellu-
lar processes such as mitosis. These last enrichments reflect the observed cytotoxicity of the iron
treatment we performed on the cells.
DISCUSSION
We have developed a novel high-throughput and cost-effective approach to screen and analyze
the transcriptional response to a large number of environmental perturbations through RNA-seq.
This approach consists of two steps, where only the first step requires cell culture experiments and
library preparation and allows for a fast and economical screen of a large number of environmental
conditions that are followed up in the second step through deep sequencing of re-pooled libraries.
We have shown that shallow sequencing of 96 pooled libraries allows identifying, with minimal
costs (approximately $60/sample, including library preparation and sequencing), the most interest-
ing conditions while capturing biologically relevant and informative gene expression changes. This
removes the burden of deep sequencing uninformative libraries in pilot studies. We have presented
an application of this approach to analyzing 23 environmental perturbations and appropriate con-
trols in three LCL samples. However, this approach can be successfully applied to other study
designs where it is most economical to test a large number of conditions prior to further analysis
of relevant ones. Examples of such applications include analysis of environmental perturbations,
genotypic differences, disease states, and time course experiments.
The second step of our approach can be designed to achieve varying levels of sequencing depth
and read length, depending on the question being asked. Here we have used step two to validate
the shallow sequencing step and learn about transcriptional changes in response to three metal ions
and a vitamin/nuclear receptor ligand treatments.
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Given the significant savings allowed by step one, it is possible to invest in deep sequencing of
step two pools to the degree necessary to answer specific biological questions. For example, using
more cycles to get longer reads may facilitate transcript isoforms detection and quantification (96).
A sequencing depth of 80M reads or above combined with longer reads also helps in identifying
allele specific expression (ASE) even in the absence of genotype information, as our group has
recently shown (40).
With the availability of desktop sequencer instruments (such as the Illumina NextSeq500), this
two-step protocol will allow for fast screening and in-depth analysis of relevant conditions in less
than 1 week-time. Compared to microarray-based pilot studies with 96 samples, our approach
allows for 40% savings (e.g., $9,600 with the least expensive microarray option vs $5,800), with
subsequent optimal allocation of resources to meaningful biological conditions (in step two), thus
reducing the amount of time and funds spent on unsuccessful pilot/exploratory studies. In our
example application, for the same treatments we would consistently detect more than 50% of the
originally differentially expressed genes (on average) even if we had multiplexed 2 times more
samples (192 total) in step one. Thus this approach could be even more effective when a project
requires a higher number of samples.
46
CHAPTER 4: HIGH-THROUGHPUT ALLELE-SPECIFIC
EXPRESSION ACROSS 250 ENVRIONMENTAL
CONDITIONS*
INTRODUCTION
For complex traits, a mismatch between genotype and environment can cause a higher disease
risk. However, it is generally difficult to determine the relevant environmental factors to measure
in order to study gene-by-environment interactions (GxE). Consequently, some of the genetic ef-
fect sizes measured in GWAS may be underestimated, when the relevant environmental factors are
not controlled. Molecular phenotypes measured in tightly controlled cellular environments pro-
vide a more tractable setting in which we can study GxE interactions simplifying both complex
phenotypes and environments (Fig 4.1A).
The cellular environment is determined by the complex of stimuli (e.g. hormonal and metabolic)
to which a cell is exposed and can be defined as an agent that can potentially change the state of
the cell, and is measurable at the molecular level. Examples include, agents secreted by nearby
cells, hormones and metabolites secreted by other organs, pollutants, drugs or micronutrients ab-
sorbed by the organisms. For example, physical or emotional environmental stressors alter blood
glucocorticoid levels, which induce significant cellular changes in global gene expression patterns
mediated through glucocorticoid receptor (GR) activation (93,97). Response eQTL mapping stud-
ies (reQTLs) found that SNPs associated with specific immune traits are enriched for infection
reQTLs and for eQTLs identified only in infected cells (19, 98, 99). However, eQTL mapping re-
quires a large number of samples, thus limiting the number of cellular environments that can be
analyzed in parallel. While association mapping compares genotypic effects across individuals that
have different genetic backgrounds, Allele Specific Expression (ASE) approaches compare allelic
effects within individuals, thereby controlling for genetic background and cellular environment.
Currently, ASE approaches represent the most effective assay to quantify cis-regulatory variants
within a defined cellular environment and to regulate trans-acting modifiers of gene expression,
*This chapter is currently in review.
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such as genotype at other loci (20–28, 100–102).
Building on the results from chapter 3, we used ASE analysis to identify GxE in individual
samples at heterozygous sites. We focused on 50 treatments (Supplemental Table C.1) in 5 cell
types (250 conditions) across 15 individuals (3 samples per cell type), including paired vehicle-
controls. These treatments represent the cellular counterparts of a range of organismal exposures
(Supplemental Table C.1). We broadly grouped the treatments into six categories: steroid hor-
mones, peptide hormones, metal ions, dietary components, common drugs, and environmental
contaminants. For each treatment we used the metabolically active form detected in the blood-
stream at the highest physiological concentration reported by the Mayo Clinic (http://www.
mayomedicallaboratories.com) or the CDC (http://www.cdc.gov/biomonitoring/),
as available. Our goal is to identify GxE across these conditions and characterize their role in com-
plex traits.
MATERIALS AND METHODS
Cell culture and Treatments
Experiments were conducted using the following cell types: lymphoblastoid cell lines (LCLs),
peripheral blood mononuclear cells (PBMCs), human umbilical vein endothelial cells (HUVECs),
human smooth muscle cells (SMCs) and melanocytes. LCLs (GM18507, GM18508, and GM19239)
were purchased from Coriell Cell Repository, cultured and treated according to (103). PBMCs
were derived from whole human blood purchased from Research Blood Components. Blood spec-
imens were obtained from 3 individual donors. Primary HUVECs and SMC were isolated from hu-
man umbilical cord tissue collected shortly following birth. Additionally, cryopreserved HUVECs
(CC-2517-0000315288) and SMCs (CC-2579-7F3794) were purchased from Lonza. See Supple-
mental Methods C.1 for additional details on HUVEC and SMC preparation. Primary melanocytes
(NHEM) isolated from neonatal foreskin were purchased from Lonza (CC-2504 lot # 252410 and
5F0885J) and from Promocell (C-12400 lot # 3052103.1). Details on cell culturing are provided
in the Supplemental Methods C.2. Supplemental Table C.1 shows the concentrations used for
the each treatment. For each treatment panel and cell type, cells derived from three individuals
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were treated at the same time on a 96-well plate. A schematic of the study design is provided in
Supplemental Fig C.1.
RNA-seq library preparation and sequencing
We used a two step approach to gene expression analysis that we recently developed (103). A
96-library pooling and shallow sequencing strategy (<10M reads per library, Supplemental Table
C.2) was used to minimize the amount of resources used in the first step. For the second step, we
repooled a selection of the initial libraries (Supplemental Methods C.8.1, Figure 1B), to achieve
a more uniform allocation of sequencing reads across samples (130M reads/sample on average,
Supplemental Table C.4). Pools of 96 samples from Step 1 were sequenced on two lanes of an
Illumina HiSeq2500 in fast mode to obtain 50bp PE reads, at the University of Chicago and at
the Michigan State University Genomics Cores; or on one lane of the Illumina NextSeq500 for
75 cycles PE in HO mode in the Luca/Pique-Regi laboratory. Step 2 resequencing was performed
on the NextSeq500 in the Luca/Pique-Regi laboratory. The number of reads collected for each
sample in step 1 and step 2 is reported in Supplemental Table C.2 and Supplemental Table C.4,
respectively.
Sequence alignment and post-processing
RNA-seq data for step 1 was processed as described in (103). For step 2, reads were aligned to
the hg19 human reference genome using STAR (104)(https://github.com/alexdobin/
STAR/releases, version STAR_2.4.0h1), and the Ensembl reference transcriptome (version
75). Details are provided in Supplemental Methods C.7.1. To correct for potential alignment bi-
ases, we used the WASP suite of tools for allele-specific read mapping (105)(https://github.
com/bmvdgeijn/WASP, downloaded 09/15/15). Note that we do not use the WASP combined
haplotype test (CHT) as we tested each SNP separately using QuASAR (40). Retained read counts
per sample after filtering can be found in Supplemental Table C.4.
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Differential gene expression
To identify differentially expressed (DE) genes, we used the method implemented in the soft-
ware DESeq2 (91) (R version 3.2.1, DESeq2 version 1.8.1). DE genes were determined as genes
with at least one transcript having a Benjamini-Hochberg controlled FDR (92) (BH-FDR) of 10%
and an absolute log2 (fold-change) > 0.25. The same procedure was used for step 1 and step 2. A
summary of differential expression for both steps can be found in Supplemental Tables C.3, and
C.5, and a full set of differential expression results from step 2 can be found in Supplemental Table
C.6.
Joint genotyping and ASE inference
To create a core set of SNPs for ASE analysis, we started with all 1KG SNPs from the phase
3 release (v5b.20130502, downloaded on 08/24/15), and first removed SNPs with low minor al-
lele frequency (MAF < 5%). We also removed SNPs within regions of annotated copy number
variation and ENCODE blacklisted regions (39), leaving a total of 7,340,521 SNPs in the core set.
Counts of reads covering each allele at selected SNPs (Supplemental Methods C.9.1) were ob-
tained by “piling up” aligned reads for each sample over SNPs using samtools mpileup and
the hg19 human reference genome. All sample pileups for a given individual across all treatment
conditions and the two treatment plates were processed together (not merged) using the QuASAR
package (40) for joint genotyping. ASE inference was performed for each sample separately. Het-
erozygous SNPs with a read coverage >40 were tested for ASE using QuASAR (40). A summary
of the amount of ASE detected in each sample is in Supplemental Fig C.10 and Table C.9. A full
list of SNPs tested can be found in Supplemental Table C.10.
Identification of induced ASE
To identify genes with iASE, we selected SNPs that were well covered in the treatment (i.e.,
>40 reads) and had ASE (10% FDR) but had little to no expression in the matched control. We
used a coverage threshold in the control of 10 × (DC/DT ), where DC and DT represent the se-
quencing depth of the control and treatment libraries, respectively, in TPM (see Supplemental
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Methods C.10.5). This equates to a ratio of 40 reads to 10 (expression in the control is 4-fold lower
than the minimum required for a gene to be considered expressed in the ASE analysis), while ac-
counting for sequencing depth differences. Finally, we required the SNP-based log2( fold change)
(Supplemental Methods C.9.3) to be greater than log2(5).
Meta-analysis of subgroup heterogeneity (MeSH)
We used MeSH to model potentially heterogeneous cASE effects across multiple subgroups
contained within the data. The input to MeSH is a pair of ASE observations derived from QuASAR
summarized by the parameter β measuring the allelic imbalance and a standard error of the parame-
ter. To look specifically at conditional ASE, a Bayes factor for cASE is calculated asBFtreatment−
BFshared (treatment-only cASE) and BFcontrol − BFshared (control-only cASE). All the cASE
Bayes factors are then used to rank and select the observations with strongest evidence for cASE.
∆AST: A novel method to measure cASE
Differential Z-scores (Z∆) were calculated from QuASAR β parameters using the following
formula. For each SNP,
Z∆ =
βT − βC√
se2T + se
2
C
where βT and seT represent the estimates for the ASE parameter and its standard error for the treat-
ment condition, and βC and seC represent the corresponding estimates for the control condition.
The Z∆ scores were then normalized by the standard deviation across Z∆ scores corresponding
to control vs control (CO1 vs. CO2). Finally p-values (p∆) are calculated from the Z∆ scores as
p∆ = 2× pnorm(−|z|). Under the null, Z∆ are asymptotically normally distributed and Fig 4.3C
shows that when contrasting the two sets of controls the p∆-values are almost uniformly distributed
as expected. To further correct for this small deviation we used the control vs. control p-values
to empirically estimate the FDR (see Supplemental Methods C.10.3). The list of significant cASE
SNPs is in Supplemental Table C.11.
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Analysis of environmental displacement of genetic effects (EDGE)
Within each treatment and cell line subgroup, we examined the Pearson’s correlation of the
treatment standardized effect size (ASEZT=βT/seT ) to the matched control one (ASEZC=βC/seC)
across all SNPs tested (see Supplemental Fig C.15). This correlation measures the consistency of
the genetic effect between the treatment and control, and therefore a lower correlation indicates
a higher perturbation or displacement of the genetic effects. We define this as the environmental
displacement of genetic effect (EDGE) index, and is formally defined as::
EDGEs,t =
Pearson(Zs,CO1, Zs,CO2)
Pearson(Zs,t, Zs,c)
(4.2)
where Pearson(Zs,t, Zs,c) is the sample Pearson correlation coefficient between treatment t and con-
trol cASE Z-scores across all observed SNPs in cell type s . Equivalently, Pearson(Zs,CO1, Zs,CO2)
is the Pearson correlation coefficient between the two control sets ASE Z-scores across all ob-
served SNPs in cell type s. The EDGE index values for each cell type and condition can be found
in Supplemental Fig C.16 and Supplemental Table C.14.
RESULTS
High-throughput characterization of transcriptional responses
Literature reports on transcriptional responses for many treatments across cell types are often
contradictory or non-existent. To characterize transcriptional responses to 50 environmental per-
turbations (Supplemental Table C.1) in 5 cell types (250 conditions), we utilized a high-throughput
two-step RNA-seq approach (Supplemental Fig C.2) (103). In step one, we used shallow RNA-
seq (8.2 million reads/sample on average, Supplemental Table C.2) and DEseq2 (91) to coarsely
characterize global changes in gene expression (Supplemental Fig C.3, Supplemental Table C.3).
We considered only treatment-by-cell-type combinations with >80 differentially expressed genes
detected at 10% FDR and corresponding to |logFC| >0.25. We found 8 treatments that induced
gene expression changes across all cell types , such as dexamethasone and vitamin A, while other
treatments had a cell type specific effect, such as vitamin B6 in PBMCs (Fig 4.1B). Of the 50 treat-
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ments, 16 did not induce significant changes in gene expression in any cell type. We excluded a
few outlier response conditions (see Supplemental Methods C.8.2). Using this criteria, we selected
89 conditions (35 treatments across 5 cell types and 3 individuals) corresponding to 297 RNA-seq
libraries and re-sequenced them to 130M reads/sample on average (Supplemental Table C.4) in
step two.
Analysis of Allele Specific Expression
We used QuASAR (Quantitative Allele Specific Analysis of Reads) to identify genes with evi-
dence of ASE. QuASAR (40) identifies heterozygous genotypes and uses a beta binomial distribu-
tion to infer ASE in RNA-seq data. In the 89 treatment conditions, we identified 11,305 instances
of ASE (10% FDR, Fig 4.2), corresponding to 1,455 unique ASE genes out of 11,990 genes with
heterozygous sites. In an individual sample, 0.92% of expressed genes with heterozygous SNPs
are ASE genes, on average.
The ASE analysis was performed on all expressed genes and was not limited to differentially
expressed genes as some genes may not change total expression level. When we consider all ASE
genes in our dataset, 92% were also identified with eQTLs in the Genotype-Tissue Expression
(GTEx) project. Thus, similar to other ASE studies (101), we were able to capture genes with
regulatory variants that were previously identified at baseline. Additionally, many of the genes
identified in GTEx with eQTLs may have unknown latent environmental components modulating
their expression.
Analysis of Gene-by-Environment Interactions (GxE)
Next, we characterized GxE on gene expression by analyzing ASE differences between treat-
ment and control. Reliably estimating ASE effect sizes required a significant amount of reads for
detecting condition-specific ASE (cASE, see Fig 4.3A and Supplemental Fig C.11). However,
some genes had very low expression levels in the control condition and high expression with ASE
following treatment, suggesting that expression of these genes would be induced by a specific
treatment. For these cases, ASE in the control condition cannot be defined accurately. We denoted
this phenomenon as induced ASE (iASE, see Fig 4.3B), which indicated cases when the ASE was
53
 
HU
VE
C
LC
L
M
el
PB
M
C
SM
C
              Progesterone (C2)
              Progesterone (C1)
              Estrogen
              Dexamethasone
              Aldosterone
              Vasopressin
              Oxytocin
              Insulin
              Glucagon
              Acetyl Choline
              Zinc
              Selenium
              Molybdenum
              Manganese (C1)
              Manganese (C1)
              Iron (C2)
              Iron (C1)
              Copper
              Cadmium
              Triclosan
              PM 2.5
              Phthalate
              PFOA
              Nicotine
              CCl3
              BPA
              BP−3
              BHA
              Acrylamide
              Vitamin K3
              Vitamin H
              Vitamin E
              Vitamin D
              Vitamin C
              Vitamin B9
              Vitamin B6
              Vitamin B5
              Vitamin B3
              Vitamin A
              MSG
              Glucose
              Cholesterol
              Caffeine
              Tunicamycin
              Loratadine
              Ibuprofen
              Dextromethorphan
              Cetirizine
              Aspirin
              Acetaminophen
2331 3111 1022 9480 6680
2762
249 3193 189
2027
1604
8470 14057 2506 3657
817 5202 1277
16525
7869 268
1582 1926
1254 869 120
1350 846 1901 1952
1571 248
3261
909 82
792 185
369 1165 1039
771 1515 192
86*
4737 3643
1332 3616 25803 1726
61* 714
83* 632
113*
2512 7679 2298 2701 1377
2823 6909 2683 12777 5151
12308
1891 7561
1312
1689
214 84 36 1385 58
1892 1589 547
 
HU
VE
C
LC
L
Me
l
PB
MC SM
C
                    Progesterone
                    Progesterone
                    Estrogen
                    Dexamethasone
                    Aldosterone
                    Vasopressin
                    Oxytocin
                    Insulin
                    Glucagon
                    Acetyl Choline
                    Zinc
                    Selenium
                    Molybdenum
                    Manganese
                    Manganese
                    Iron
                    Iron
                    Copper
                    Cadmium
                    Triclosan
                    PM 2.5
                    Phthalate
                    PFOA
                    Nicotine
                    CCl3
                    BPA
                    BP−3
                    BHA
                    Acrylamide
                    Vitamin K3
                    Vitamin H
                    Vitamin E
                    Vitamin D
                    Vitamin C
                    Vitamin B9
                    Vitamin B6
                    Vitamin B5
                    Vitamin B3
                    Vitamin A
                    MSG
                    Glucose
                    Cholesterol
                    Caffeine
                    Tunicamycin
                    Loratadine
                    Ibuprofen
                    Dextromethorphan
                    Cetirizine
                    Aspirin
                    Acetaminophen
3625 3439 1252 10775 8786
3963
1184 4156 1845
3833
1802
10782 14661 3805 4915
1274 6258 1932
17617
8805 273
5659 3200
4928 1090 1187
5714 4094 2177 3554
5336 1549
3995
3913 1554
4224 1585
1702 1316 1246
5504 7175 1805
86*
6560 3951
2944 5048 26707 2872
61* 1608
84* 1470
123*
3738 8550 3578 2992 2549
4080 7656 3887 13945 7712
13904
7403 9165
1773
5691
634 808 36 1816 1439
2216 2245 3371
0 5 10
# Shallow DEG
Color Key
 
HU
VE
C
LC
L
Me
l
PB
MC SM
C
                    Progesterone
                    Progesterone
                    Estrogen
                    Dexamethasone
                    Aldosterone
                    Vasopressin
                    Oxytocin
                    Insulin
                    Glucagon
                    Acetyl Choline
                    Zinc
                    Selenium
                    Molybdenum
                    Manganese
                    Manganese
                    Iron
                    Iron
                    Copper
                    Cadmium
                    Triclosan
                    PM 2.5
                    Phthalate
                    PFOA
                    Nicotine
                    CCl3
                    BPA
                    BP−3
                    BHA
                    Acrylamide
                    Vitamin K3
                    Vitamin H
                    Vitamin E
                    Vitamin D
                    Vitamin C
                    Vitamin B9
                    Vitamin B6
                    Vitamin B5
                    Vitamin B3
                    Vitamin A
                    MSG
                    Glucose
                    Cholesterol
                    Caffeine
                    Tunicamycin
                    Loratadine
                    Ibuprofen
                    Dextromethorphan
                    Cetirizine
                    Aspirin
                    Acetaminophen
3625 3439 1252 10775 8786
3963
1184 4156 1845
3833
1802
10782 14661 3805 4915
1274 6258 1932
17617
8805 273
5659 3200
4928 1090 1187
5714 4094 2177 3554
5336 1549
3995
3913 1554
4224 1585
1702 1316 1246
5504 7175 1805
86*
6560 3951
2944 5048 26707 2872
61* 1608
84* 1470
123*
3738 8550 3578 2992 2549
4080 7656 3887 13945 7712
13904
7403 9165
1773
5691
634 808 36 1816 1439
2216 2245 3371
0 5 10
# Shallow DEG
Color Key
0 100 1,00010 10,000
# Shallow DEG
 
HU
VE
C
LC
L
M
el
PB
M
C
SM
C
choline
2331 3111 1022 9480 6680
2762
249 3193 189
2027
1604
8470 14057 2506 3657
817 5202 1277
16525
7869 268
1582 1926
1254 869 120
1350 846 1901 1952
1571 248
3261
909 82
792 185
369 1165 1039
771 15 5 192
86*
4 37 3643
1332 3 16 25803 1726
61* 714
83* 632
13*
512 7679 298 2701 1377
2823 6909 2683 12 7 5151
12308
1891 7561
312
1689
214 84 36 1385 58
1892 1589 547
A B
Cadmium
BHA
Vitamin A
Selenium
Vitamin B6
Loratadine
Tunicamycin
Iron
Zinc
C
Caffeine
Cetirizine
Figure 4.1: Overview of gene expression response. (A) Schematic of experimental design and rationale. Our
approach uses specific cellular environments as a tightly controlled proxy for the organism environment and measures
molecular phenotypes, such as gene expression, to infer genetic and molecular mechanisms for complex traits. (B)
Heatmap of differential gene expression. Shown for each cell type (columns) and treatment (rows) combination
are the number of differentially expressed genes (10% FDR and |logFC| > 0.25). The shade of red indicates the
number of differentially expressed genes from an initial screening step (see Supplemental Text C.5 and C.8.1). Cellular
environments with a strong response were further sequenced to a higher depth (>58M reads, 113M on average), and
the number of differentially expressed genes is indicated by the text. Environments marked with a “*” were chosen to
confirm that treatments with a small response from the shallow sequencing data, similarly have a small response when
deep sequenced. Colors next to treatment names represent treatments chosen for deep sequencing. Grey indicates
treatments that were not deep sequenced. (C) Global co-expression network inferred using WGCNA on 14,535 genes.
Each dot represents a gene. Each module is assigned a color based on the treatment with the highest eigengene t-value.
Note that colors representing treatments are consistently used across all the figures.
only observed in genes induced by the treatment. Studies that only consider baseline eQTLs or
ASE may fail to characterize or may mischaracterize genes with iASE if the relevant environmen-
tal stimulus is present as latent exposure. We identified 75 iASE SNPs (10% FDR) corresponding
to 60 unique genes (Fig 4.3C). The genetic effect in these iASE SNPs is slightly stronger than that
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Figure 4.2: Heatmap of Allele specifi expression. For each individual (row) and treatment (column), listed is the
number of SNPs displaying ASE (as determined in QuASAR at 10% FDR). The shade of red represents the fraction
of ASE SNPs to the number of heterozygous SNPs tested (% ASE SNPs) in a given sample and condition. The dotted
line on the density plot indicates the average % ASE across all individual samples and conditions.
of baseline ASE (Supplemental Fig C.13).
When we can reliably measure ASE in both treatment and control conditions for the same SNP
and individual, we can contrast the amount of ASE between conditions to determine cASE. ASE
across cell types was never contrasted because the samples correspond to different individuals.
Here we used two approaches to identify cASE (see Fig 4.3D): a qualitative “on/off” approach
using a meta-analysis framework, and a new quantitative approach to detect ASE changes even
when ASE is present in both conditions.
For the qualitative analysis of cASE we used MeSH (106), a Bayesian meta-analysis approach
that has been previously used in eQTL studies to contrast effect sizes across conditions (17) and
tissues (107). Here, for each SNP, individual and treatment/control experiment pair, we assume
four different mutually exclusive models: 1) No ASE in either condition, 2) ASE in both condi-
tions, 3) ASE in treatment only, or 4) ASE in control only. Configurations 3 and 4 represent cASE,
while configuration 2 represents shared ASE accommodating for random effects in the genetic
effect size. This results in a stringent test for cASE.
For each of the QuASAR treatment/control measurement pairs, MeSH calculated a Bayes fac-
tor (BF) for each configuration. We observed that the majority of genes had ASE shared between
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Figure 4.3: Gene-environment interactions. (A & B) Two types of gene-environment interactions: conditional ASE
(A) and induced ASE (B). Treatment condition (red), control condition (blue) with shade (dark/light) representing the
allele (reference/alternate). In this example of cASE, there is an imbalance of expression between the two alleles in
the treatment condition, while the control shows balanced expression. iASE, is defined by an imbalance of expression
between the two alleles in the treatment condition, and expression below detectable levels (dotted line) in the control
condition. (C) Plot of all iASE SNPs detected. Each iASE SNP is represented as two points (representing treatment
and control expression) connected by a line (representing the fold-change between conditions). SNPs are plotted based
on the expression (TPM, tags per million) of each allele, with the higher expressed allele in the treatment on the y-axis,
and the lower allele on the x-axis. Points are colored by treatment (controls are black and grey), and the dotted lines
represent constant expression levels 0.1, 1, and 10. For ease of display, expression of SNPs <0.01 have been set to
0.01. (D) Scatter plot of the Z-scores in the paired treatment and control samples for all tested SNPs. Colored points
indicate those displaying cASE: red are SNPs identified by MeSH as having cASE in the treatment, blue are SNPs
identified by MeSH as having cASE in the control, and green are SNPs identified by ∆AST that were not identified by
MeSH. (E) QQ-plot of p-values for cASE identified with the ∆AST method for treatment vs control (green line) and
Control1 vs Control 2 (grey line). (F) Venn diagrams showing the number of cASE SNPs identified by two methods:
MeSH, and ∆AST at different empirically estimated FDR thresholds.
treatment and control conditions (Fig 4.3D). We identified 75 SNPs with cASE (difference in the
BFtreatment or BFcontrol and the BFshared > 30) corresponding to 71 unique genes. We observed
a larger proportion of treatment-only cASE compared to control-only cASE (59 vs 16, Fig 4.3D
and Fig 4.4). These proportions are consistent with observations from eQTL studies contrasting
individual treatments and tissues (15, 17, 107, 108).
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Figure 4.4: Forest plot of all cASE SNPs. Each
row shows the ASE βˆ for paired treatment (red) and
control (blue) conditions. Defined as in Figure 4.2,
colored squares indicate the treatment (left) and cell
type (right) in which cASE was identified, along with
the gene name and SNP rsID.
MeSH detects qualitative interactions and
strictly requires ASE only in one condition ana-
lyzed, either treatment or control, while showing no
ASE in the alternate condition. However, these ex-
treme on/off ASE cases are rare. Other cASE mod-
els may exist. For example, a prior report identified
eQTLs with genetic effects in opposite directions in
the treatment and control conditions in stimulated
monocytes (98). Additionally, the majority of GxE
can arise in cases where the genetic effects differ
significantly between treatment and control condi-
tions, but they are non-zero in both conditions.
To capture cASE genes that may have ASE
in both conditions but of a significantly different
magnitude, we developed an alternate approach
named ∆AST (Differential Allele-Specific Test).
The goal was to detect quantitative GxE interac-
tions. For each heterozygous site, we compared the
QuASAR-derived ASE estimates following treat-
ment to those observed in the matched control
within each individual. We calculated a p-value for
the difference in ASE between the two conditions
(Fig 4.3E).
A key component of our experimental approach
is the inclusion of two sets of vehicle controls
in each experimental batch, which empirically es-
timates the true underlying FDR for identifying
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cASE, equivalent to permutation-based approaches used in eQTL studies (see Supplemental Meth-
ods C.10.3). Using ∆AST we identified 67 cASE SNPs corresponding to an FDR of 10%, 38 of
these cASE SNPs were also identified by MeSH. When we relaxed the FDR threshold (25%), we
found a total of 178 cASE SNPs corresponding to 160 genes. Of these genes, 65 were identified
with both methods (Fig 4.3D-F, Fig 4.4).
Features of Gene-by-Environment interactions
When we considered all cASE SNPs, we observed a significant positive correlation between the
gene expression log2(fold change) after treatment and differences in the genetic effect in treatment
and control samples (Fig 4.5A). This result could be a consequence of increased power to detect
ASE with more highly-expressed genes. However, we observed a negative correlation between
gene expression levels and the difference in the genetic effect in the treatment and the control
samples (Fig 4.5B). This finding suggests that stronger cASE occurs at genes with stronger positive
responses to treatment with little impact from the overall expression levels.
To determine if we can validate some of the few previously known reQTLs with cASE, we
compiled a list of 106 genes reported to have GxE effects from prior reQTLs and ASE studies. Of
these genes, 83 were heterozygous and could be tested for cASE in our data (16–18,102,109,110).
63 out of 83 genes were identified as cASE genes in our analysis (p<0.05) (Supplemental Table
C.13). For example, gene IRF5 has a rhinovirus-reQTL (111) and showed cASE in response to
two treatments, phthalate (p = 0.04) and vitamin B5 (p = 0.04). Additionally, IRF5 is also linked
to autoimmune responsivity through its association to lupus (112–114). Interestingly, phthalates
may play a role in lupus etiology, since they induce anti-DNA antibodies (115) while vitamin B5
deficiency is found in lupus patients (116).
We next wanted to determine the difference in the number of cASE across cellular environ-
ments (Fig 4.5C-D, Supplemental Fig C.14). We found that acetylcholine, selenium and caffeine
had significantly higher numbers of cASE compared to the mean number of cASE per treatment,
while acrylamide and BP-3 had significantly fewer (binomial, p-value < 0.05). In addition, we
found that environmental contaminants and common chemicals have a significantly lower propor-
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Figure 4.5: Features of cASE SNPs. (A & B) Scatter plot comparing the absolute difference in ASE βˆ between
treatment and control (y-axis) and (A) the average log2(expression) or (B) log2(fold change) between treatment and
control samples for cASE SNPs. The green line indicates the trendline from a linear model fit on the points. (C & D)
Percent of cASE SNPs identified in each treatment category (C) or treatment (D). For each group, plotted is the percent
of cASE SNPs identified, relative to the number of SNPs tested for that group. The dotted black line represents the
average percent of cASE SNPs across all groups. Groups with a "*” are significantly enriched or depleted (Binomial
p-value < 0.05) relative to the average. The colors in (C) represent the relative proportion of cASE SNPs for each
treatment in a treatment category.
tion of cASE (p < 0.003).
To assess the extent of GxE on gene regulation in different cellular environments we developed
an index that aggregates all cASE tests for each condition and cell type and determines how much
the environment can globally perturb ASE. To achieve this, we can compare the correlation of the
standardized effect size between treatment and control (as shown in Fig 4.3D) across all SNPs
tested for a given cell type and condition. We denote this genome-wide measurement as environ-
mental displacement of genetic effect (EDGE) index (see Methods for more details). Specifically,
the EDGE index is the ratio between the pair-wise correlation observed between the two control
sets and the correlation observed between the treatment and control conditions (EDGE is 1 for the
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control conditions (Supplemental Fig. C.15A) and will have higher values for treatments that can
affect ASE for a large number of genes (Supplemental Fig. C.15B). We find significant differences
in the EDGE index across many treatments (Supplemental Fig C.16). As expected, we found a
high correlation between the proportion of cASE and the EDGE index (Spearman ρ = 0.717, p =
3.8× 10−6, Supplemental Fig C.15C).
Gene-by-Environment interactions and Complex Traits
We then used the GxE interactions we identified in vitro to characterize putative molecular
mechanisms for risk or protective environmental factors for complex traits (Fig. 4.6A). We found
that 22% of differentially expressed genes overlap with those identified in GWAS analyses (117)
compared to 4% of non-differentially expressed genes expressed in our samples (Fig 4.6B). This
overlap corresponds to a 7-fold enrichment (p < 2.2 × 10−16). These results suggest that genes
responsive to our treatments are more likely involved in organismal traits.
To investigate the role of GxE in complex traits directly, we analyzed genes containing iASE or
cASE. 49% of genes (105 out of 215) that contain either iASE or cASE were identified by GWAS
as associated with various complex traits, this corresponds to 3.5-fold enrichment (p < 2.2 ×
10−16), when comparing to differentially expressed genes without iASE or cASE. Importantly,
genes with iASE or cASE also have a 1.4-fold increased relevance for complex traits (p = 0.025)
when compared to ASE genes and a 3.2 fold enrichment (p = 4.3 × 10−15) when compared
to genes with eQTLs identified at baseline (eGenes from GTEx). Note that by design much of
our detected ASE may have an environmental component, but we may lack the power to claim
cASE/iASE. These results suggest that GxE represent an important mechanism for inter-individual
variation in complex traits.
We find similar results when we analyze per SNP heritability for 18 complex traits using
Genome-wide Efficient Mixed Model Association (GEMMA) (118, 119). Similar to the LD-score
regression method that partitions heritability estimates across SNPs functional categories (120), we
contrasted SNPs in genes with cASE/iASE, genes with ASE, genes without ASE, and inter-genic
regions. The per SNP heritability for each of these categories is then compared to the genome
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average. A higher value of per SNP heritability for one of these categories indicates a higher
number of causal SNPs, higher effect sizes or both in that category. We found that the per SNP
heritability estimate for SNPs in genes with ASE is 11.1 times higher than the genome average for
high-density lipoprotein (HDL). For 13 of the 18 traits analyzed, per SNP heritability estimates for
SNPs in genes with cASE, iASE, or ASE were significantly higher than the genome average. For
7 of these, the cASE and iASE category estimates were even higher than any other partition (Fig
4.6C), thus indicating that GxE for these traits are particularly relevant. The highest values for
cASE and iASE were observed for blood total cholesterol level (TC) (9.7-fold), triglicerides (TG)
(7.9-fold), and for mean corpuscolar hemoglobin levels (MCH) (8.6-fold). Overall, these results
suggest an important role for GxE in these traits.
When we isolated genes with iASE, we found 28 genes associated with a phenotype in the
GWAS catalog (Supplemental Table C.16). Additional investigation into these genes may yield in-
sights not only on the GxE role in specific traits, but also on the underlying molecular mechanisms.
For example, previous reports show that caffeine prevents and treats obesity presumably through
mitotic clonal expansion effects (121–123). Our work suggests that caffeine activates the GIPR
pathway, which regulates insulin production. GIPR is linked to obesity and several obesity-related
traits, including body mass index and type 2 diabetes (124–131). We identified a SNP, rs5390, in
GIPR that demonstrates iASE following caffeine treatment. Specifically, we found higher GIPR
expression and ASE favoring the rs5390 reference allele following caffeine treatment and low ex-
pression in controls. The rs5390 reference allele is located on the same haplotype as the non-risk
allele for body mass index in the individual sample used here (124,128,132). These results suggest
that caffeine may reduce obesity through its effect on gene expression and ASE in GIPR.
Among the genes with cASE, 79 are associated with complex traits in the GWAS catalog
(Supplemental Table C.16). Fig 4.6D shows four examples of cASE genes associated with complex
traits. These include cASE in SAMM50 in response to copper, in ERAP1 in response to selenium
treatment, in GOSR2, following treatment with mono-n-butyl phthalate and in LAMP3 in response
to selenium. This last example may explain the influence of selenium on Parkinson’s disease (PD).
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Previous studies found reduced selenium levels in PD patients (133). In addition, selenium reduces
bradykinesia, a well-described symptom of PD, in rats (134), suggesting that higher selenium
levels would be beneficial for Parkinson’s patients. A GWAS hit for PD (135, 136) was an eQTL
for LAMP3, where the reference/PD-risk allele led to increased expression of LAMP3 (137). In
our data, cASE at rs16833703 in LAMP3 preferentially expressed the alternative allele at this
SNP, located on the same haplotype as the non-risk allele at the GWAS SNP. These data suggest
that selenium is beneficial for PD patients through its influence on allelic expression in LAMP3.
Overall, these cASE examples illustrate genes associated with complex traits, with a plausible
biological association with the treatment (see supplements for details on the other three genes).
DISCUSSION
We presented a scalable high-throughput approach to characterize the effect of environmental
and genetic perturbation on gene expression levels. In this study, we tightly controlled environ-
mental exposure using in vitro treatments in different cell types and analyzed the transcriptional
response for hundreds of conditions that was previously uncharacterized. These results will be
invaluable to many researchers interested in changes to specific genes or pathways following vari-
ous treatments and cell types. Among the genes differentially expressed, we found that 22% have
been associated with complex traits in GWAS. These data confirm the environmental component
of complex traits and will assist the design of future experiments by highlighting environmental
variables that should be considered in animal models for human complex traits, in patient studies
and in re-analyzing GWAS data when the relevant exposure variable was collected as part of the
study.
One of the main advantages of our approach is that it can be used to detect GxE in a single in-
dividual for many treatments and cell types using allele specific expression analysis. In this study
we have analyzed three individuals per cell type, in order to explore a large number of environ-
mental conditions that would not be practical for a reQTL study design. While some GxE may
be detected in a conventional baseline eQTL study, this would only occur if all or a subset of the
samples were exposed to a relevant environment. However, in eQTL studies, the specific exposure
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would likely remain uncharacterized as a latent variable that may be unknown or difficult to model.
Though we do not require many individuals, our approach is limited by the requirement of having
two heterozygous variants: at the causal regulatory variant and at the variant for which ASE is
measured. A small fraction of the ASE we detected may actually correspond to low frequency
variants that are sampled in three individuals, but the majority will correspond to common vari-
ants. The requirement that at least one of the three individuals is a double heterozygote means that
we are missing instances of GxE, especially those at low allele frequencies. Nonetheless, the 215
instances of GxE described here represent a lower bound to the amount of GxE signal that can be
identified by applying our approach to additional treatment panels, cell types and/or larger sample
sizes.
Our catalog of GxE interactions, and future ones expanding on the one generated here, will be
a necessary resource to thoroughly annotate genes and create a bridge between epidemiological
and genome-wide association studies. Here we showed that 49% of genes with GxE are GWAS
genes. Although limited by our false negative rate, we compiled the most comprehensive list to
date of GxE and relevant environmental conditions that can aide in the interpretation of specific
GWAS findings. Follow-up analyses provided some examples of candidate GxE mechanisms for
complex traits and released our results as a browsable web-resource.
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Figure 4.6: Integration with GWAS. (A) Hypothetical model detailing the use of GxE interactions to characterize
putative molecular mechanisms for risk or protective environmental factors for complex traits. In the treatment en-
vironment a regulatory region is either active or inactive depending on the haplotype, therefore resulting in different
levels of gene expression. In the control environment the regulatory region is inactive regardless of haplotype. Risk
and protective haplotypes are identified in GWAS. (B) Enrichment analysis of GWAS genes. Reported genes from
the GWAS catalog (version 1.0.1) were compared to different gene sets analyzed in this study: 1) genes that were
not differentially expressed in any condition, 2) genes that were differentially expressed in any condition, 3) genes
previously associated with an eQTL in GTEx (eGenes (The GTEx Consortium, 2015)), 4) genes containing ASE in
any condition, and 5) genes containing either iASE or cASE. The percentage of genes in these datasets that were
found in the GWAS catalog is indicated by a darker shade. Genes that can be perturbed by our environments are
highlighted in purple, and indicate a GxE mechanism for the GWAS association. Odds ratios and enrichment p-values
were calculated using Fisher’s exact test and are shown on the right for each pair of gene categories contrasted. (C)
GEMMA per SNP heritability estimates relative to the genomic average for cASE (SNPs in genic regions with cASE
or iASE), ASE (SNPs in genic regions with allele specific expression), Other Genic (SNPs in genic regions) and In-
tergenic (SNPs farther than 100kb from any gene). Only significant enrichment values are reported, with darker tone
of purple indicating higher enrichment odds ratio relative to the genome average. (D) Forest plots of four cASE SNPs
in genes associated with a GWAS trait. For each SNP, shown is the ASE βˆ for each treatment in which the SNP was
tested. 95% CI bar is colored for each treatment as in Figure 4.2.
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CHAPTER 5: CONCLUSION
Somewhere in the relatively minor differences between individuals lie factors that contribute
to why some are more likely to develop a disease, why some might not respond to a treatment that
works for others. However, genetics are not the only differences between individuals. Throughout
history, we have adapted to live all over the world, and in a variety of environments. Understanding
how these genetic and environmental components interact is a critical area of research, but also a
very difficult one to study. First, because the impact of a genetic variant might not be readily
obvious, especially when it lies outside of a coding region, and second, because studying the effect
of one environmental exposure while controlling for the rest–at the organismal level–is extremely
difficult. Throughout my research and this dissertation, I sought to address these issues and to
develop methods to better study GxE interactions and their link to complex phenotypes.
In Chapter 2, I developed and tested an approach for predicting which genetic variants have a
functional impact on transcription factor binding. One important aspect of the approach is that it
allows for the recalibration of the sequence models used to find candidate TF binding sites. These
recalibrated sequence models are not only better at predicting TF binding than the original seed
motifs, they also better capture the full range of binding events, including weak binding sites.
Because of its ability to fine-tune existing sequence models, this recalibration method is a useful
resource for researchers who use these sequence models. Applying this approach and the recal-
ibrated sequence models to a large set of DNase I footprinting data, I generated one of the most
comprehensive annotations of regulatory regions and genetic variants within them. Importantly,
these annotations highlight which variants are more likely to affect TF binding, which is crucial
information for researchers interested in characterizing non-coding variation, such as those iden-
tified through GWAS. For example, follow-up studies showed how useful these predictions were
in identifying putative molecular mechanisms behind signals from GWAS, and how the TF- and
tissue-specific information provides support to identify the potential causal SNP in an association
window. This approach will continue to be useful as more in-depth functional genomics data is
produced, such as the recently published deep sequenced DNase I footprinting data from Maurano
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et al. (35).
Chapter 3 describes my work on a high-throughput approach to assess transcriptional responses
using RNA-seq data. The major motivation here was to develop a high-throughput and cost-
effective approach to characterizing gene expression changes in response to environmental per-
turbations. The advantage to this approach is that its 2-step design allows researchers to first
screen a large number of conditions by first sequencing the sequencing libraries at a low depth
(e.g., 5M reads / condition), then assessing gene expression response. Conditions that elicit a re-
sponse can be quickly resequenced after re-pooling the original libraries, this time at the desired
sequencing depth and read length depending on the questions being asked. I showed the merit
of this approach by analyzing 23 environmental perturbations in lymphoblastoid cell-lines from
three individuals. However, researchers could easily adapt the approach to studies whose goal is
to examine genotypic differences, or to differentiate disease states, or to examine changes over a
time course study.
In Chapter 4, I use the approach from Chapter 3 to identify genetic variants that show environment-
specific effects. Compared to model organisms and transgenic models, studying GxE in humans
poses significant challenges. In clinical trials a limited number of exposures can be tested, while, in
large scale epidemiological studies many exposures convolve together. One of the main advantages
of this approach is that it can be used to detect GxE in a single individual for many treatments and
cell types using allele specific expression analysis. Comprehensive catalogs of GxE interactions
such as the one generated here, as well as the methods to identify them, are indispensable to thor-
oughly annotate genes and create a bridge between epidemiological and genome-wide association
studies. Similar to Chapter 2, following up on these GxE annotations shows that almost half of
the GxE genes discovered in my work were associated with at least one trait through GWAS. This
represents an increased relevance for complex traits compared to ASE genes alone, confirming
both the significance of GxE in inter-individual variations in complex traits and the importance of
catalogs of GxE interactions such as the one generated here. In the future, mining of our results by
other researchers has the potential to inform new GWAS findings and identify latent variables in
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GWAS that are important risk/protective factors for human complex traits and diseases.
Future work can be done to further dissect the regulatory regions derived in Chapter 2 under
different environmental contexts (such as those described in Chapter 4) as to better understand
the role of these regions in GxE. Approaches such as these present a promising solution to study-
ing rare disease variants and individualized outcomes of combinatorial interactions of common
genetic variants, through clinical analysis of in vitro DNase I hypersensitivity and/or ASE for a
large panel of cell types extracted and derived from single patient stem cells. Ultimately, I antic-
ipate that the approaches described in this dissertation will aid precision medicine by identifying
molecular mechanisms and environmental exposures relevant for complex diseases, allowing for
the development of tailored medication and resulting in improved patient outcomes.
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APPENDIX A: SUPPLEMENTAL MATERIAL FOR
“WHICH GENETIC VARIANTS IN DNASE-SEQ
FOOTPRINTS ARE MORE LIKELY TO ALTER BINDING?”
A.1 DATA SOURCES
A summary of the data used in this paper can be found in Tables A.1 and A.2. Chromatin
accessibility data used for the analysis presented in this study was obtained from the ENCODE
Project and the Roadmap Epigenomics Project. The ENCODE Project data was downloaded from
the main ENCODE data distribution center (EncodeDCC) at the University of California Santa
Cruz (UCSC), publicly available at ftp://hgdownload.cse.ucsc.edu/goldenPath/
hg19/encodeDCC/ (downloaded 07/2013). The Roadmap Epigenomics Project data was down-
loaded in the form of sequence read archives (SRAs) from the NCBI GEO repository, http:
//www.ncbi.nlm.nih.gov/geo/roadmap/epigenomics/ (downloaded 07/2013).
Positional Weight Matrices (PWMs) for 1,949 transcription factors were obtained from the on-
line databases TRANSFAC (37) (http://www.gene-regulation.com/pub/databases.
html, downloaded11/01/11) and JASPAR (38) (http://jaspar.genereg.net/, down-
loaded 09/23/11).
Known genetic variants from the 1000 Genomes (1KG) Project Phase 1 data were downloaded
from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/.
Note that except for ASH analysis (Section A.2.4), we did not restrict variants used for the analy-
sis on any criteria, including allele frequency. Linkage disequilibrium (LD) data between variants
was also obtained from the 1KG Project. The LD data used in this analysis comes from European
individuals.
Ensembl transcript positions used to annotate transcription start sites were obtained via the
UCSC table browser (http://genome.ucsc.edu/cgi-bin/hgTables, downloaded 10/21/12).
Conservation (46-way primate phyloP) data was obtained via the UCSC table browser (http:
//genome.ucsc.edu/cgi-bin/hgTables, downloaded 12/17/13).
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Genetic variants identified via genome-wide association studies (GWAS) were extracted from
the GWAS catalog (https://www.genome.gov/26525384, downloaded 7/16/13).
GWAS meta-analysis data and imputed statistics used to run fgwas via (42) were obtained
through personal communication. Annotations used in the model were downloaded from https:
//github.com/joepickrell/1000-genomes (downloaded 03/2014).
A.2 DATA PREPROCESSING
A.2.1 Preprocessing for CENTIPEDE analysis
Pre-aligned DNase-seq reads from the Roadmap Epigenomics Project were not directly avail-
able, so raw reads were obtained in the form of Sequence Read Archives (SRA) files. We then con-
verted the SRA files to FastQ format using the fastq-dump program from the NCBI SRA toolkit.
Reads were then aligned using a custom mapper previously described in (39). To identify tech-
nical replicates, we extracted sample annotations from the SRA metadata database (downloaded
6/20/13) using the SRAdb R package from Bioconductor (138). Aligned reads from samples iden-
tified as technical replicates were then merged using samtools (139).
Aligned DNase-seq data for ENCODE samples was obtained directly from the EncodeDCC as
described in Section A.1. As the choice of aligner should have little impact on the ability to run the
CENTIPEDE algorithm, we did not remap the reads as for the Roadmap Epigenomics samples.
A.2.2 Preprocessing for allele-specific analysis
Reads for allele specific analysis have to be carefully processed, as allele specific analysis is es-
pecially sensitive to biases in read data. To account for this, we aligned DNase-seq read data using
a custom mapper with mappability filters (see Section A.2.3). The Roadmap Epigenomics samples
were previously aligned using our mapper (Section A.2.1). To process the ENCODE samples in
the same manner, we obtained raw sequence reads (FastQ format) directly from the EncodeDCC
and reads were realigned with our custom mapper. Reads sequenced on old Solexa machines were
removed, as these reads were often of lower quality and more prone to base calling errors. Samples
with fewer than 25 million reads were removed from analysis, as these typically displayed too low
a coverage to be informative. We want to note that the same quality filter thresholds are applied
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for both footprinting and allele-specific mapping. However, to further minimize mapping errors
and reference biases, we also had to apply additional mappability filters (see Section A.2.3) for
allele-specific analysis.
A.2.3 Mappability filtering
We created an array of hash tables containing all possible 20-mer reads, where a 4-mer prefix
indexes an array of 256 hash tables and the 16-mer suffix is used as hash key. The values of the hash
tables record the locations a read can align to (up to a maximum of 128 locations). These arrays
are then used for aligning the reads in our custom mapper (39). We can also use the hash tables
to identify which locations of the genome can generate reads that can align to multiple locations.
Two of these arrays have been created and are denoted as M0 and M1:
* M0 Hash Table - The 20-mers starting at each bp position of the genome are added into this
table, as well as all 20-mers with alternate alleles (i.e., overlapping SNPs and InDels).
* M1 Hash Table - The same 20-mers as in M0 are generated, but for each genomic 20-mer
(reference or variant) we consider all the possible single base pair errors that could have occurred.
Each 20-mer has 3x20=60 other 20-mers at Hamming distance of 1.
The M0 hash table is used to align reads with our mapper; which means that only reads that map
without mismatches are used. Both hash tables are used to create the two following mappability
tracks to assess alignment quality:
* M0 mappability track - For each base of the genome we record the number of locations that
match the same exact 20-mer (considering all 1KG genetic variants). When aligning for allele
specific analyses, we only consider reads that originate at locations with mappability M0 value
exactly equal to one (i.e., reads with unique mappability when there are no base-calling errors).
* M1 mappability track - For each base of the genome we record the number of locations
that match the same exact 20-mer (considering all 1KG genetic variants) or any one base pair
mismatch. For allele specific analyses we only consider reads that originate at locations with
mappability M1 value ≤ 70. Using this value, a location can have up to 69 other loci with only
one nucleotide different, reads from which could potentially map to the location of interest if a
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sequencing error occurs. Using this threshold and considering a base-calling error rate of 0.01 and
an average background coverage of ∼ 1X , we expect << 0.5 reads from other loci to incorrectly
map at locations of interest. This is an upper bound calculated from what would be expected when
there is at most 70 locations that are one base-pair different when compared to the query sequence.
We further considered that the errors that change a 20-mer so it aligns to the other location occur
randomly with a probability at most 0.01. It naturally follows that the number of errors follow a
binomial distribution with parameter N = 70, and p = 0.01/20, and thus has an expected value
E = 0.01/20 ∗ 70 = 0.035 << 0.5. This upper bound will also hold until the base-calling
probability is as high as 5%.
The motivation behind the M1 mappability filter is that very repetitive regions of the genome
can generate reads that are very similar to other regions. Even when the base calling error is small,
20-mers with high similarity may generate reference calling biases when doing allele specific anal-
yses. We do not consider a more complex filter as the probability of a read with two base-calling
errors at 20bp read-length is very small.
A.2.4 Selection of genetic variants for ASH analysis
To create a core set of SNPs for ASH analysis, we started with bi-allelic 1KG SNPs (38,248,779)
and first removed rare (MAF < 5%) SNPs. To avoid the possibility of multiple SNPs in the same
motif, we next removed SNPs within 25 bases up- or downstream of another SNP. Next we re-
moved SNPs in regions prone to mapping biases, masking approximately 1% of the genome (39).
Ultimately, these filters left (4,828,763) SNPs for analysis.
Aligned reads were then piled up on this set of 1KG SNPs using samtools mpileup and the
hg19 reference genome. Reads were discarded if the SNP was either at the first or last base of
the read to avoid the possibility of an experimental bias at these positions caused by the DNaseI
cleavage preference (39). Finally, the following filters were applied to SNPs:
1. The SNP must be covered by ≥10 reads
2. 50% or more of the reads covering the SNP cannot start at the same position (i.e., PCR
duplicates)
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3. The coverage on the SNP cannot be in the top 0.01% sample-wise, as such exaggerated
coverage usually indicates an unannotated copy number.
A.3 IDENTIFICATION AND MAPPING OF ACTIVE
TRANSCRIPTION FACTORS
A.3.1 Recalibration of position weight matrices
To recalibrate the PWMs in our two step approach we first created a reduced subset of motif
matches. We obtained 1,949 seed PWMs from online databases as described in Section A.1. Using
these, we scanned the genome for candidate motifs and calculated the PWM score according to the
following formula (140):
PWM score (Sl) =
∑W
w=1
log2
(
Pr (seeing Sl+won position w|PWM)
Pr (seeing Sl+w| background)
)
=
=
∑W
w=1
log2 (p [Sl+w, w])−
∑W
w=1
log2 (0.25) = (A.1)
=
∑W
w=1
log2 (p [Sl+w, w])− log2 (0.25)W
where Sl indicates the observed nucleotide at position l of sequence S, the PWM model is given
by the probability p[Sl+w, w] of observing the nucleotide Sl+w(A,C,G,T) at position w, and W is
the motif length. Here we use a background that assigns the same probability for each base. While
this assumption is not true for the entire genome and may also depend on the sequence content
of the open chromatin and binding site neighboring regions, when we were developing this study
(results not shown) changing this background did not seem to have any major impact on the results
(i.e., the average ASH validation rates essentially remained the same). Alternative approaches to
PWMs, like using support vector machines (SVM) (141), may provide a better way to incorporate
the impact of the background sequence and more flexibility that the PWM model but were not
considered in this study.
Using these PWM derived scores, we created for each motif a reduced set of locations (con-
taining between 5,000 and 15,000 sites) that include both high and low scoring sequence matches
to the original seed PWM. Note that we use this reduced set of motif instances to discover which
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TF are active for each tissue and for recalibrating the PWM model which will then be used to scan
the full genome (Section A.3.2). In order to construct this reduced sets, we first selected the top
5,000 best scoring sites in the human genome. Then, to expand the sequences included for a motif,
we considered using two different strategies. The first strategy was to randomly select additional
sequences in which one randomly chosen base w of the PWM was not considered in the PWM
score calculation. For the second strategy, which is the one we used for this paper, the additional
sequences are selected using a heuristic that relies on sequence conservation due to evolutionary
constraints across closely related species. In short, we conducted the following steps:
1. Scan the top 5,000 motif sequence matches in the chimp and macaque genomes
2. Lift over the coordinates to the human genome using the UCSC liftOver tool (excluding
chains that are <10,000 bases or on very repetitive regions)
3. Calculate the PWM score again using the human sequence
Using this approach we add up to 10,000 new sites from the human genome that have lower
PWM scores but are more likely to retain relevant sequence information as they were highly scoring
in two of the other primate genome orthologous sequences. Compared to the sequences obtained
using the first approach, these sequences are more likely to maintain the TF identity of the original
PWM and to harbor true binding sites that will show a footprint. This implicitly assumes that a
fraction of these new instances would be functionally conserved (a footprint is observed in humans)
and hence the sequence change in the human sequence is more likely to be in the set of sequences
that are bound by the TF. This strategy is not expected to perform worse than random nucleotide
changes (i.e., first strategy), even in the case that TF binding domain or binding sites are not
conserved across the species.
Using these locations and the DNase-seq data listed in Table A.1, we applied the CENTIPEDE
model for each sample/motif combination. Then, we estimated the overall activity of each fac-
tor/sample combination by calculating a Z-score for the following logistic model that is used to
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calculate the prior probability of binding in CENTIPEDE:
log
(
pil
(1− pil)
)
= β0 + β1 × PWM Scorel (A.2)
where l represents each of the positions in our set of candidate sites, and pil represents the prob-
ability of that position having a footprint. For most factors and experimental samples, a Z-score
of at least 5 was the minimum for which a modest footprint was clearly evident (Figure A.4). Us-
ing this Z-score value as a threshold, we detect 1,891 factors active (Z-score > 5) in at least one
cell-type/tissue.
Finally, we used the CENTIPEDE binding predictions of this initial set to generate recalibrated
sequence models. For each factor, we selected the best representative tissue (i.e., the one with
highest Z-score) and extracted the sequences predicted to have a factor bound (posterior prob-
ability > 0.99). The best representative tissue usually includes more bound regions, perhaps
due to a higher transcription concentration factor in the nucleus. In essence, the other tissues
only represent a subset of the regions of the so-called best representative tissue. Using these
sequences, we calculated a new PWM from the base frequencies of each position in the motif
including 20 additional nucleotides on each side to allow for a longer revised motif. We kept
this extra bases if the information content at those position for the new motif were high enough,
ICw = 2−
∑
b p[b, w]× log2(p[b, w]) > 0.25bits. In general none of these additional bases seem
to be very informative, and those with higher IC were already part of the core motif.
In our experience, the recalibrated PWMs are almost always essentially identical independent
of the tissue of choice. This is probably because our approach is not capable of completely chang-
ing the PWM, a side-by-side comparison for several recalibrated PWMs to the original PWM can
be seen in Figure A.6. It may be interesting in future research to use or calibrate multiple sequence
models that can distinguish different sequence context across tissues for each TF or build models
that capable of accommodating multiple modes of binding across tissues or within the same tissue
(e.g., considering different cis-regulatory module contexts beyond the scope of this work). Even
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with this simplifications that only consider one mode of binding (i.e., one PWM model) per TF, an
evaluation with ChIP-seq data and ASH in Section A.6.3 shows an improvement in the recalibrated
model over the old one.
A.3.2 Generation of CENTIPEDE binding predictions
Using the recalibrated PWM sequence models (see Section A.3.1), we scanned the reference
genome to identify all motif matches genome-wide. As a threshold on the scan, we calculated
an automatic threshold score separately for each sequence model designed to retain all sequences
with at least a 10% prior probability of binding as in Equation A.2. Scanning was done in two
stages. First, we identified every match above the threshold using eq. (A.1) as before. Next, we
scanned the genome, this time only considering motifs that overlapped 1KG variants. For each of
these matches we calculated two PWM scores, one for each allele.
To generate the binding predictions, we first trained the CENTIPEDE model on motif locations
that do not overlap a SNP for each sample/motif pair using the updated sequence models. As a
check for how well calibrated the sequence models are for the data, we examined the correlation
between the PWM scores and the CENTIPEDE log ratio. Using a Spearman correlation test and
a nominal threshold of p < 10−7, we discarded 519 sequence models, leaving us with data for
1,372 sequence models. At the end of this process (Fig. A.1) we generated an annotation of
footprints with a CENTIPEDE posterior probability > 0.99 divided in two major sets depending
on whether they overlap with 1KG sequence variants. Genetic variants in footprints (footprint-
SNPs), are further classified based on CENTIPEDE’s prior probability of binding (eq. (A.2)) for
each allele into “effect-SNPs” and “switch-SNPs”. Effect-SNPs are footprint-SNPs predicted to
alter the prior odds of binding ≥20-fold based on the logistic sequence model hyperprior in the
CENTIPEDE model, while switch-SNPs are effect-SNPs where the allele changes the direction
on the prior odds (i.e., one allele has CENTIPEDE prior probability of being bound > 0.5 and
the other one < 0.5). We find that our results are robust to the values chosen for these thresholds
(Figure A.14). For many TFs, we start from different seed motifs, and the thresholds are slightly
different resulting in small differences in numbers of motif instances, but overall the downstream
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analysis of different motif models that correspond to the same TF are highly consistent.
A.3.3 Comparison of binding predictions to binding QTLs
To check the accuracy of the predictions, we compared them to a recent binding QTL analysis
for CTCF ChIP-seq (45). Of the 23,028 unique SNPs that are significant QTLs (1% FDR) in the
study, 1,209 of them were contained within the measured CTCF binding regions (i.e., ChIP-seq
peak) as defined by (45). For each of these QTLs within binding regions, we selected those within
CENTIPEDE-predicted CTCF footprints, leaving 151 SNPs shared between the two analyses. For
these shared SNPs, we compared the change in probability of binding (alternate prior log ratio
- reference prior log ratio) to the binding QTL effect size (β-value, reference allele vs alternate
allele).
The two values are well correlated (Spearman ρ=0.82, p < 2−16), and only 16 SNPs are pre-
dicted to have the opposite effect as the QTL, none of those are predicted to have a functional
effect by our model (i.e., are not effect-SNPs). These may be cases where the QTL signal is mod-
ulated by a SNP affecting another factor nearby and not the CTCF binding site being interrogated
directly. All CTCF QTLs considered here that are also effect-SNPs (46) and switch-SNPs (39), are
predicted to affect binding in the same allelic direction as the QTL effect.
A.4 ANALYSIS OF ALLELE-SPECIFIC HYPERSENSITIVITY
A.4.1 Validation of genotype predictions
To verify the genotyping accuracy, we compared the genotype calls from QuASAR for an indi-
vidual fully resequenced by the 1KG Project (1KG individual NA12878). Of the 1,400 QuASAR-
predicted heterozygous loci, all of them were confirmed to be true heterozygotes. Of the 11,278
QuASAR-predicted homozygous loci, only seven of them were actually heterozygotes. Addition-
ally, all of the true homozygous calls were correct for the predicted allele. The seven miscalled
heterozygotes are likely cases of extreme allelic imbalance, as QuASAR was designed to be conser-
vative to avoid miscalling homozygous genotypes as heterozygotes with extreme allelic imbalance.
The results of our comparisons are summarized in Table A.5.
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A.4.2 Postprocessing of allele-specific data
To further filter out samples not well-suited for allele specific analysis, including cancer tissues
and samples from pooled individuals (e.g., Figure A.9), we examined two parameters estimated
by QuASAR, ρ and M , as well as the non-reference allele frequency φ obtained from 1KG. The ρ
parameter represents the proportion of reads overlapping a SNP that match the reference allele. For
heterozygous SNPs under the null model (no allelic imbalance) we would expect that the average
ρˆ should be centered at or near 0.5. Deviation from 0.5 in a sample can be an indication of genetic
aberrations, such as in a cancer sample, where copy number variation can be extensive, or very
high base-calling error rates. We also examined the correlation (Pearson correlation coefficient)
between the ρ estimates and φ for each heterozygous locus, as the two should be independent of
each other. Otherwise, this is a strong indication of sample mix-up or cross-sample contamination
as new modes appear at ρ = 0.25, 0.75 or other intermediate frequencies with probabilities that
are correlated with the reference allele frequency φ. The M parameter in QuASAR controls the
degree of overdispersion of the beta-binomial distribution in the QuASAR model. A very high
value of M indicates that the beta-binomial is almost a binomial distribution. On the other hand, a
low value of M indicates more and more dispersion and a very high uncertainty in the underlying
ρ being centered around 0.5, as is the case of samples with chromosomal aberrations and copy
number alterations, for example in cancer cell lines (see Figure A.9B). After applying all filters,
316 samples remained for ASH analysis. A summary of the post-processing results can be found
in Table A.6 and Figure A.10.
A.5 ANNOTATION OF ASH WITH BINDING PREDICTIONS
A.5.1 Combining predictions and ASH data
To determine which positions displaying ASH fall within a predicted footprint, we overlapped
the allele ratios for heterozygous SNPs (hSNPs) in DHS sites (DHS-hSNPs) with CENTIPEDE
footprint predictions in each sample. We then created a final set of annotated ASH-hSNPs by
aggregating the data across each sample and factor. For cases where an hSNP is within multiple
predicted binding sites, we selected the factor whose CENTIPEDE footprint model has the greatest
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log-likelihood ratio. This generated a set of 204,757 hSNPs across all samples. As the same hSNP
could affect multiple cell-types, this set of 204,757 hSNPs reflects 961,297 observations of ASH.
For hSNPs predicted to have an effect on binding (effect-hSNPs), we determined which ones were
predicted to have an effect in the same direction as the observed allele ratio (e.g., the allele with
a higher PWM score is observed more often in the DNase data). We then partitioned the data
into three non-overlapping categories: 1) hSNPs in predicted footprints whose binding effect is in
the direction predicted, 2) all other hSNPs in footprints, 3) all other DHS-hSNPs. Because each
annotation has a different prior expectation of being functional (Figure 2A), we readjusted for
multiple testing within each annotation separately by applying the Storey q-value method on the
p-values obtained from the QuASAR test to estimate the false discovery rate (FDR), following the
strategy of (44). The results of this analysis are summarized in the main text, Table 1.
Additionally, we examined the observed allele ratios (ρˆobs) across different CENTIPEDE an-
notations. Fig. A.12 shows that effect-hSNPs and switch-hSNPs tend to have a higher magnitude
of allelic imbalance. If we consider SNPs that are in the tail of the distribution |0.5− ρˆobs| > 0.15,
effect-hSNPs show a moderate but significant enrichment (1.29-fold, Fisher p = 1.1×10−229) com-
pared to DHS-hSNPs.
A.5.2 Comparison across different thresholds and using PWM score alone
In order to study the impact of the threshold in defining the effect-SNP category (Section A.3.2)
we experimented with different settings. The results (Figure A.14) show that the density of low
p-values compared to the uniform distribution increases with a higher threshold on the minimum
change in the prior probability of binding and vice versa. Here we opted to choose a hard-threshold
but it may be possible to develop downstream analytical methods that could take as input the
CENTIPEDE calculated probabilities directly.
It is also interesting to see what is the added benefit of only considering CENTIPEDE footprint
models compared to using the PWM score alone. To see how well the PWM score alone predicts
ASH, we compared our ASH results for DHS-hSNPs to the change in PWM score at those SNPs.
Here, we use the PWM score from the original seed motifs and we examined the degree of ASH
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for SNPs at various PWM score differences between the two alleles. As expected, we find that
the proportion of ASH increases among SNPs with a higher PWM score difference A.15. For a
very large PWM score difference threshold we start to approach an ASH enrichment similar to that
for effect-SNPs, but very few SNPs pass this threshold. These additional ASH enrichment results
further demonstrate that the best strategy is to integrate the sequence and footprint information in
defining which SNPs are more likely to be functional.
A.5.3 Comparison to existing functional annotations
To compare our functional predictions to existing annotations, we downloaded data from two
studies seeking to annotate functional non-coding variation, (12) (7,747 SNPs), (11) (5,654 SNPs).
These lists are not the full sets of non-coding variation from each study, but those that overlap
GWAS hits. For each set of SNPs, we overlapped our ASH data to determine the proportion of
SNPs showing allelic imbalance, leaving 3,838 and 2,187 SNPs, respectively. For both datasets, we
find that while there is an enrichment for ASH (Figure A.13), it is similar to the modest enrichment
seen for DHS- and footprint-SNPs, suggesting that a positional overlap with a DHS region or
binding site is not enough to support a claim of functional impact on binding.
We also examined ASH at variants with a large CADD score (23,027 SNPs with CADD score
≥20, (142)). Again we find only a modest enrichment for ASH within this set of SNPs (Figure
A.13). This is perhaps due to CADD being trained on very deleterious variants which may rely
more heavily on sequence conservation and other features compared to an explicit model that only
integrates sequence and functional information that is relevant for TF binding. The additional
information contained in the CADD score could provide important clues on the genetic variant
being functional at the organismal level, but it does not directly provide a mechanism of action or
a TF specific functional score for the genetic variant impact on disrupting binding.
Looking directly at conservation scores, we examined the primate phyloP scores of ASH-
hSNPs. SNPs with extreme conservation scores (|phyloP| >5) do show an enrichment for ASH
(Figure A.16, however few SNPs have such extreme conservation scores.
79
A.5.4 Individual motif analysis of binding predictions
In order to evaluate the extent to which the newly defined sequence models accurately predict
ASH, we compared CENTIPEDE predictions and ASH analysis for each motif individually. We
examined motifs containing at least 10 heterozygous SNPs in footprints for which we can estimate
the ASH allelic ratio ρˆ. ρˆ is calculated from the sequencing data as,
ρˆ =
# reads w/ reference allele
# reads w/ reference or alternate allele
(A.3)
For each motif, we compared the CENTIPEDE predictions to the ASH data by calculating the
Spearman’s correlation between the observed allelic imbalance (proportion of reference reads) and
the difference in binding predictions (∆Pr(binding)). Additionally, we fit a logistic model,
logit(ρˆ) ∼ β0 + β1 ∗∆logit(p) (A.4)
where ∆logit(p) is the change in log prior odds predicted by the sequence model in CENTIPEDE.
We fit the model on SNPs displaying some allelic imbalance (nominal ASH p-value < 0.1) to
focus on how well our predictions accurately capture allelic imbalance (note that this threshold is
not used for the Spearman correlation analysis where all instances are used). Figure A.11 shows the
correlation between our prediction and the observed ASH for the most predictive motif, belonging
to the factor AP-1. Table A.7 shows the correlation results for each motif.
A.6 EVALUATION OF RECALIBRATED SEQUENCE MODELS
A.6.1 Precision versus recall analysis with ChIP-seq
To compare the new sequence models to the originals, we first performed precision recall op-
erating characteristic (P-ROC) curve analysis using PWM scores of motif matches and ENCODE
ChIP-seq peaks from GM12878 samples. We annotated a list of all binding sites identified as a
PWM match or as having a ChIP-peak, using the PWM score as the predictions and the presence
or absence of a ChIP-seq signal as the labels. For sites with a ChIP-seq signal but no PWM match
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above the scan threshold a default PWM score of 0 was used (i.e., all ChIP-seq peaks are included
in the analysis). For each selected factor, we compared the precision-recall curve using the original
PWM models and the updated PWM models (Figure A.7). The curves show that in general, for
a given precision (precision = 1 - FDR, false discovery rate), the updated sequence models have
higher recall (sensitivity) than the original PWM in detecting ChIP-seq peaks.
A.6.2 Predicted binding strength correlation analysis with ChIP-seq
We also examined the correlation between the PWM scores (for the original seed and the recali-
brated motif models) and the number of ChIP-seq reads. For each PWM we identified all matching
sites genome-wide and extracted the ChIP-seq read coverage. Compared to the seed PWMs, we
find that the revised PWMs are better correlated with the ChIP-seq data. Data for the individual
comparisons can be seen in Figure A.8. The new recalibrated models, seem to better capture the
relationship between the prior probability of binding derived from the PWM score and TF occu-
pancy as measured by ChIP-seq reads. This indicates that we are also capturing a wide range of
binding events including weak binding sites.
A.6.3 PWM recalibration step impact on ASH
We also wanted to examined whether the recalibration process preferentially selected sites with
the strongest binding, and therefore most affected by variation. If so, this would potentially bias
our downstream ASH analysis, as we partition the SNPs based on their predicted impact on binding
(Section A.5.1). To see if this was the case, we compared ASH results within footprints predicted
by the two sets of sequence models. Using the original seed PWMs, we ran CENTIPEDE as in
Section A.3.2.
For each set of sequence models, we compared the proportion of SNPs within footprints pre-
dicted to have an effect. We find that the recalibrated sequence models discover more variation
within the footprints overall. However, the proportion of SNPs with low p-values (p < 0.05)
in footprints predicted to affect binding versus those that do not, remains extremely similar be-
tween the old models (OR 2.14, Fisher p = 1.6 × 10−289) and the new models (OR 2.08, Fisher
p = 1.5 × 10−263). Table A.4 shows the values used for this comparison. The new recalibrated
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models do not necessarily provide a much better discrimination on which genetic variants are
functional, but they seem to yield a higher number of regulatory sequences and genetic variants.
A.7 PRECISION VERSUS RECALL ANALYSIS USING DNASE-SEQ
AND CTCF QTLS
To facilitate the comparison with other methods we focused our analysis on the same DNase-
seq sensitivity QTL (dsQTL) signals as in (36). We downloaded the results from their Supple-
mentary Table 1 to reproduce their Figure 2e. Using the same definition for what is the known
underlying truth, we resampled the data so the genetic variants that are not dsQTLs have the aver-
age genomic background probability to be in a footprint. We then intersected the predictions from
the SVM approach with our effect-SNP annotation for LCLs using different cut-off thresholds on
the change of the prior log odds. The same procedure was then repeated for CATO scores (35)
in which we intersected their Supplementary data set 3 with Supplementary Table 1 from (36).
Then we proceeded to draw the precision versus recall operating curves (PROC) for each method
using R-package ROCR (version 1.0-7). In Figure 2B, we recapitulated the results from the SVM,
CADD and GERP methods, and we also show on the same graph the results from CATO and our
annotated effect-SNPs.
We would like to note that PROC are very useful for analyzing performance when there is no
uncertainty about the underlying truth (e.g. simulated data). However, QTL analysis as many other
statistical analyses using limited sample size and data will not give the perfect golden standard for
a yes/no answer necessary for the PROC analysis. On its own, QTL analysis may have false nega-
tives due to lack of power (e.g. for low allele frequency variants), or false positives due to linkage
disequilibrium to the true causal SNP. This could lead to discrepancies between different PROC
analyses, and for this reason we have not used our ASH results to do a PROC analysis, instead
we opted for checking the distribution of p-values in which we can better manage uncertainty. In
any case, with this caveat in mind to interpret the results from dsQTLs we demonstrate that our
annotation is highly accurate.
In addition to predict disruption of binding, CATO and our annotation also predicts which TF
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motif is the most likely to be affected. In order to assess how good is this prediction compared
to a non-specific sequence model we used a similar approach. Using the same type of PROC
analysis, we intersected the predictions for dsQTLs described before to CTCF QTLs identified
by (45). We focused on CTCF QTLs that are also dsQTLs, because this facilitates the comparison
with the results reported by Lee et al. Here true positives are defined as those dsQTLs that are
also CTCF QTLs, and the true negatives are both dsQTLs and non-dsQTLs for which we have
predictions from all methods but are not identified as CTCF QTLs. Again, we drew the precision
versus recall operating curves (PROC) for each method using R-package ROCR (Figure 2C). This
result demonstrates that our annotation has better performance in predicting the identity of the TF
at least for CTCF. This is presumably a consequence of the footprint information integrated in our
model which helps in improving TF specificity.
A.8 GENOMIC ANNOTATION AND SELECTION SIGNALS
A.8.1 Allele frequency
Allele frequency for each 1KG SNP was obtained as described in Section A.1. For each SNP,
we calculated the minor allele frequency by taking the absolute value of the difference between
the alleles frequencies and 0.5. Coding SNP annotations were also obtained from 1KG Project
(phase 1 release). We examined bi-allelic coding SNPs categorized as either ’synonymous’ or
’nonsynonymous’.
A.8.2 Distance to transcription start sites
For a given locus, distance to the nearest TSS was calculated as absolute value distances to
the nearest annotated TSS. Using Ensembl gene annotations (see Section A.1), we determined the
distance for each SNP in our set. For motif-wide analysis, we determined the median distance to
the nearest TSS across all binding sites genome-wide.
A.8.3 Identification of TF binding sites enriched for ASH
To identify which TF binding sites are enriched or depleted for ASH-hSNPs, we calculated, for
each factor, the proportion of binding sites containing ASH-hSNPs to all binding sites containing
a heterozygous SNP (ASH enrichment ratio). As the proportions can be skewed at lower total
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numbers, we included only factors with at least 100 heterozygous SNPs across all binding sites
genome-wide. For the 368 factors that met this criteria, we estimated the enrichment or depletion
of ASH by calculating the fold-change between the ASH enrichment ratio and the average ASH
enrichment ratio across all binding sites (with >100 hSNPs), using a binomial test to assess sig-
nificant difference between the ratios. Factors whose binding sites are enriched or depleted for
ASH-hSNPs (at a nominal p-value cutoff of p < 0.01) are displayed in Table A.9.
For this analysis we used ASH-hSNPs detected with an FDR=20%. Results are similar for
other FDR cut offs if we increase this threshold, but we cannot lower much the FDR threshold to
get enough SNPs for the downstream analyses.In general we observed that effect sizes increase
with lower FDR threshold as we include less false positives, but the confidence intervals get much
wider. The effect of using a higher FDR threshold in downstream analyses seems an appropriate
tradeoff between a more conservative estimate of the effect size (as those get shrunken to the
overall mean) and a more narrow confidence interval better suited to detect the differences across
TFs.
A.8.4 Selection on transcription factor binding sites
The McDonald-Kreitman test compares polymorphism (within species variation) and diver-
gence (between species variation) for non-synonymous and synonymous sites. The null hypothesis
being that under neutrality the ratio of non-synonymous to synonymous sites is the same within
and between species.To identify transcription factors with binding sites departing from neutrality,
here we defined non-synonymous and synonymous regulatory sites based on our effect-SNPs an-
notation. Using the footprint annotations from CENTIPEDE, we identified all footprints that do
not contain known human polymorphisms. We used the UCSC liftOver tool to obtain ortholo-
gous regions in the Chimpanzee genome (panTro3 assembly), using a minimum remap threshold
of 10%. At these loci in the chimp genome, we calculated PWM scores as in Section A.3.1. Next,
using the model obtained from CENTIPEDE on the human sites, we calculated the sequence-based
probabilities of binding for the chimpanzee sites. Sites where the prior probability of binding differ
from the human sites were classified as “divergent”, and were further categorized by the difference
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in binding affinity: “functional” (analogous to non-synonymous) for those that differ by ≥20-fold,
and “silent” for those that do not. For the polymorphic sites, we used binding sites with effect-
SNPs as “functional”, and those with footprint-SNPs that are not effect-SNPs as “silent”. For each
factor motif, we calculated the number of binding sites across the entire genome belonging to each
category to build a contingency table similar to the one built in the McDonald-Kreitman test:
Divergent Polymorphic
Functional Df Pf
Silent Ds Ps
Finally, we calculated a selection score using the following formula:
Selection score =
Df/Ds
Pf/Ps
(A.5)
To test for enrichment, we used a fisher exact test on the contingency table, and used the
Benjamini-Hochberg method to adjust for multiple testing. A full list of motif scores and the
data used to calculate them can be found in Table A.12. Using different thresholds (for example,
calling silent SNPs those with prior odds ratios < 10 and functional SNPs those with prior odds
ratio > 20) did not have any major impact on the analysis results.
A.8.5 Derived allele frequency of footprint SNPs
Orthologous alleles in chimpanzee were obtained via the UCSC Table Browser, using the
“snp142OrthoPt4Pa2Rm3” table from the hg19 genome assembly. For 1,371 motifs with >0 bind-
ing site SNPs with known chimpanzee alleles, the derived allele frequency was calculated using
the 1KG global allele frequencies (see Section A.1). Derived allele frequency was then categorized
into 8 bins: [0, 0.001), [0.001, 0.005), [0.005, 0.01), [0.01, 0.05), [0.05, 0.2), [0.2, 0.5), [0.5, 0.9),
and [0.9, 0.95]. Similarly, the selection scores were divided into 8 bins: [-6, -3), [-3, -1), [-1, -0.5),
[-0.5, -0.1), [-0.1, 0.1), [0.1, 0.5), [0.5, 1), and [1, 3]. We then calculated the enrichment for each
(DAF, Selection) bin pair, defined as the ratio between the observed number of SNPs in that bin
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and the expected number if each DAF/Selection pair is independent of the rest. A barplot of the
enrichment data, including on for singletons and doubletons, can be found in Figure A.19.
A.9 OVERLAP WITH GENOME-WIDE ASSOCIATION STUDIES
A.9.1 Analysis of SNPs in the GWAS catalog
We created an expanded GWAS catalog by adding SNPs in linkage disequilibrium (LD) with
each GWAS hit, using 1KG LD data for European populations r2 > 0.8. To identify overlap
between our annotations and those associated with a GWAS trait, we intersected our results with
this expanded catalog, but counting only one hit per GWAS locus. We used a Fisher exact test to
determine if the proportion of effect-SNPs for a given annotation were enriched in the catalog.
A.9.2 Adding annotations to SNPs associated with complex traits
We integrated our CENTIPEDE footprint annotations into the combined models learned in (42)
for GWAS meta-studies corresponding to 18 traits (Table A.13), using the fgwas command line
program. We assessed enrichment or depletion for footprint annotations using the log2(enrichment)
values, excluding any motifs whose 95% confidence interval (CI) spanned zero. For each TF motif
whose binding sites are either significantly enriched or depleted for trait-associated SNPs (Fig-
ure A.20), we examined the SNPs whose posterior probability of association (PPA) with a trait
had been increased by the addition of our annotation. Overall we found 88 unique SNPs whose
associations were strengthened by our footprint annotations (Table A.15).
A.9.3 Overlap with previous reporter gene assays
To compare our predictions to existing reporter gene assays results, we investigated the overlap
between our footprints and the regions described in (143). In the regions they tested, we identified
47 footprints in HepG2 cells and 70 footprints in K562 cells. If the mutated base (or bases, in the
case of the scrambled motifs) overlapped the footprint position, we calculated a new probability
of binding using the PWM match score and the model learned from the matched tissue, either
HepG2 or K562. In cases where multiple footprints overlapped, we selected the footprint model
with the greatest log-likelihood ratio (as in Section A.5.1). Additionally, we restricted our analysis
to only constructs in which the wild type is significantly expressed (mean normalized expression
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> 3.5), as in (36). Overall, we made predictions covering 22 construct pairs (8 in HepG2 and 14
in K562), corresponding to 9 scrambled motifs, and 13 single base mutations. Our predictions are
well correlated with the reporter gene assay results (Spearman’s ρ = 0.76, p-value = 4.37×10−05,
Figure A.22).
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Table A.1: DNase samples and sources. Listed for each sample is the source, the sample, and the number of reads.
Large table available at
http://genome.grid.wayne.edu/centisnps/supp/
Table A.2: Sources of additional data used in analyses. Download dates and, where applicable, specific cell-
types/tissues are also listed.
Type Data Source Cell-type/Tissue Date Downloaded
PWM matrices TRANSFAC – 11/1/11
PWM matrices JASPAR – 9/23/11
GWAS Catalog NIH – 7/16/13
LD data 1KG – 3/29/12
Gene annotations Ensembl – 10/21/12
ChIP-seq ENCODE GM12878 10/28/13
Genotypes 1KG GM12878 10/30/13
SNP Annotations https://github.com/ – 03/2014
joepickrell/1000-genomes
Table A.3: Active motifs in each sample. For each sample, motifs were determined active if the Z-score, obtained
from eq. A.2, was > 5, and if the motif instances showed correlation with DHS peaks (Section A.3.2).
Large table available at
http://genome.grid.wayne.edu/centisnps/supp/.
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Table A.4: Comparison of ASH within footprints between PWM models. Shown is the number of ASH-hSNPs
within footprints identified by the two sets of PWM sequence models. The counts are stratified by p-value from the
QuASAR test of ASH. Note that the old models, by default, only select sites with a PWM score > 12; for comparison,
the same constraint has been placed on the sequences used from the new models.
QuASAR ASH Test
p <0.05 P >0.05
Seed sequence
models
Effect-SNPs 4582 30834
Footprint-SNPs
(no effect) 6565 94325
Recalibrated
sequence
models
Effect-SNPs 4657 39675
Footprint-SNPs
(no effect) 5484 97272
Table A.5: Validation of genotype predictions. A comparison of 1KG genotypes and those called by QuASAR for
the 12,650 loci examined in the LCL GM12878.
1KG Hom 1KG Het
QuASAR Hom 11,271 7
QuASAR Het 0 1,372
Table A.6: Summary of post-processing filters. The first three rows show the threshold and number of samples
filtered for each parameter independently. After applying the three filters, the remaining samples were manually
examined and known cancer samples were removed.
Parameter Threshold # Removed
Avg. ρ <0.54 78
|cor(ρ, φ)| <0.15 31
1/Disp.=M >12 58
Cancer† – 13
†without evident chromosomal abnormalities
Table A.7: Motif-wide correlation between CENTIPEDE and ASH results. For each motif, CENTIPEDE pre-
dictions were compared to ASH data using 1) Spearman correlation and 2) a logistic model using the functional
predictions to predict the ASH.
Large table available at http://genome.grid.wayne.edu/centisnps/supp/
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Table A.8: Predictiveness of genomic characteristics on functional effects. We considered the following charac-
teristics in a regression analysis to determine their predictiveness as to whether a footprint-SNP is also an effect-SNP.
Effect Size p
Sequence Change† 1.051×10−4 < 10−16
TSS Distance (bp) -2.903×10−8 < 10−16
Number of Tissues -4.636×10−4 < 10−16
Minor Allele Frequency -5.169×10−2 < 10−16
Primate Conservation‡ -9.155×10−3 < 10−16
† units are log-fold change in factor affinity between alleles.
‡ based on phyloP scores from 46-way multiple alignment (Section A.1)
Table A.9: Enrichment of ASH-hSNPs within binding sites. Factors with at least 100 heterozygotes in a predicted
binding site are listed along with the counts, ratios, and enrichments of ASH-hSNPs, footprint-SNPs, and switch-SNPs
within them.
Large table available at
http://genome.grid.wayne.edu/centisnps/supp/
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Table A.10: Comparison of multiple motifs for a single factor. Motifs corresponding to the same transcription
factor are similarly enriched or depleted for ASH-hSNPs.
Factor ID hSNPs ASH-hSNPs ASH-hSNPs/hSNPs Fold-enrichment p-value
AP-1 M00517 461 10 0.021691974 1.036030117 0.869967821
M00188 296 16 0.054054054 2.581675041 0.000608884
M00199 111 22 0.198198198 9.466141817 1.81E-15
M00924 181 13 0.071823204 3.430347206 0.000131074
M00925 159 16 0.100628931 4.806137197 2.94E-07
M00926 210 24 0.114285714 5.45839865 2.60E-11
MA0099.2 1931 250 0.129466598 6.183452673 2.91E-114
CBF1 M01577 193 3 0.015544041 0.74239876 0.802620423
M01699 403 8 0.019851117 0.948108967 1
M01793 168 2 0.011904762 0.568583199 0.591560229
M01911 135 5 0.037037037 1.768925491 0.211980416
CREB M00113 451 14 0.031042129 1.48260276 0.136346848
M00178 136 4 0.029411765 1.404734964 0.374540498
M00916 950 32 0.033684211 1.608791208 0.011917593
M00917 188 4 0.021276596 1.016191253 0.800445788
M00801 675 59 0.087407407 4.174664144 1.08E-19
CTCF M01259 3500 49 0.014 0.668653836 0.00309612
MA0139.1 3426 43 0.01255108 0.599451985 0.000327385
M01196 479 35 0.073068894 3.489842592 3.37E-10
E2F/E2F-1 M00024 1001 11 0.010989011 0.524846026 0.026362164
M00425 949 16 0.016859852 0.805243194 0.49459686
M00427 508 7 0.013779528 0.658123876 0.349487781
M00918 1131 21 0.018567639 0.886808789 0.6773526
M00920 1117 13 0.011638317 0.555857522 0.02754515
M01114 577 5 0.008665511 0.41387337 0.039836283
M00426 2017 7 0.003470501 0.165754558 3.17E-11
M00516 1792 7 0.00390625 0.186566361 1.67E-09
M00428 3085 49 0.015883306 0.758602392 0.050945353
M00431 992 17 0.017137097 0.818484689 0.504382044
M00940 2007 32 0.015944195 0.761510511 0.137608155
M00939 1353 10 0.007390983 0.353000653 0.00012598
M01251 224 2 0.008928571 0.426437375 0.342585393
MA0024.1 158 2 0.012658228 0.60456948 0.77719828
Staf M00262 1132 2 0.001766784 0.08438335 3.07E-08
M00264 442 0 0 0 0.000167517
XBP1 M00251 257 5 0.019455253 0.929202111 1
M01770 452 13 0.028761062 1.373656746 0.246263429
M01970 674 6 0.008902077 0.425171996 0.029652731
M01513 985 5 0.005076142 0.242441559 7.90E-05
M01947 607 4 0.006589786 0.314734692 0.009734357
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Table A.11: ASH effects for several immune-related factors. For each factor listed, we calculated the aggregate
ASH enrichment ratio across all sequence models corresponding to that factor.
Factor Role in Immune
Response
Average
Number of
Samples
Hetero-
zygous
SNPs
ASH
SNPs
ASH/Het Ra-
tio
Fold-
enrichment
p-value
AP-1 Pro-inflammatory 39 3411 353 0.103 4.943 2.20E-16
c/EBP Pro-inflammatory 5 125 7 0.056 2.675 0.01657
CREB Anti-inflammatory 77 2947 127 0.043 2.058 1.53E-13
NF-kB Pro-inflammatory 6 147 7 0.048 2.274 0.03591
Table A.12: Selection score for individual motifs. For each factor motif, we used a modified MK test to calculated
a selection score. Shown for each motif is the number of binding sites belonging to each category used in the MK test
(divergent functional, divergent silent, polymorphic functional, and polymorphic silent) as well as the score.
Large table available at
http://genome.grid.wayne.edu/centisnps/supp/.
Table A.13: Summary of GWAS meta analysis traits examined. Shown for each trait is the trait abbreviation and
the citation for the meta analysis study.
Abbreviation Trait Study
BMI Body mass index Speliotes, E.K., et al. (2010). Nat. Genet. 42, 937-948
CD Chron disease Jostins, L., et al. (2012). Nature 491, 119-124
FG Fasting glucose levels Manning, A.K., et al. (2012). Nat. Genet. 44, 659-669
FNBMD Bone mineral density (femur) Estrada, K., et al. (2012). Nat. Genet. 44, 491-501
HB Hemoglobin levels van der Harst, P., et al. (2012). Nature 492, 369-375
HDL HDL cholesterol levels Teslovich, T.M., et al. (2010). Nature 466, 707-713
Height Height Lango Allen, H., et al. (2010). Nature 467, 832-838
LDL LDL cholesterol levels Teslovich, T.M., et al. (2010). Nature 466, 707-713
LSBMD Bone mineral density (lumbar spine) Estrada, K., et al. (2012). Nat. Genet. 44, 491-501
MCH Mean red blood cell hemoglobin van der Harst, P., et al. (2012). Nature 492, 369-375
MCHC Mean corpuscular hemoglobin concentration van der Harst, P., et al. (2012). Nature 492, 369-375
MCV Mean red blood cell volume van der Harst, P., et al. (2012). Nature 492, 369-375
MPV Mean platelet volume Gieger, C., et al. (2011). Nature 480, 201-208
PCV Packed red blood cell volume van der Harst, P., et al. (2012). Nature 492, 369-375
PLT Platelet counts Gieger, C., et al. (2011). Nature 480, 201-208
RBC Red blood cell count van der Harst, P., et al. (2012). Nature 492, 369-375
TC Total cholesterol levels Teslovich, T.M., et al. (2010). Nature 466, 707-713
TG Triglyceride levels Teslovich, T.M., et al. (2010). Nature 466, 707-713
Table A.14: Factor binding sites enriched for GWAS SNPs. For each trait, factors whose binding sites are enriched
for SNPs associated with the trait are listed. Shown also are the lower and upper limits of the 95% confidence interval.
Large table available at
http://genome.grid.wayne.edu/centisnps/supp/
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Table A.15: SNPs associated with GWAS traits that fall in CENTIPEDE-predicted TF binding sites. PPA,
Posterior probability of association estimated by fgwas for each SNP. “Before” indicates the PPA from the base model,
“after” indicates the PPA after adding footprint annotations to the model. The p-values listed are derived from the z-
scores that are used as input for fgwas.
Trait Motif Factor rsID PPA before PPA after p-value
BMI M00287 NF-Y rs12641981 0.2133 0.9486 3.67×10−17
BMI M00287 NF-Y rs13098327 0.3105 0.9709 5.70×10−08
BMI M01608 DAL82 rs4704230 0.2867 0.6469 8.95×10−08
CD M00197 ABF1 rs1052248 0.0518 0.2537 5.59×10−11
CD PBM0124 Elf4 rs2476601 0.7872 0.9985 2.18×10−09
CD M00433 Hmx3 (Nkx5-1) rs3810936 0.0681 0.9740 4.87×10−16
CD M00664 STE12 rs3828917 0.0297 0.7407 2.10×10−07
CD M02032 SWI4 rs7746082 0.1133 0.6320 2.25×10−08
FG M00698 HEB rs13266634 0.9479 0.9908 3.93×10−17
FG MA0019.1 Ddit3::Cebpa rs2191348 0.2111 0.4478 4.19×10−21
FNBMD M01644 EDS1 rs10205005 0.1831 0.3384 2.20×10−07
FNBMD M01550 Mbp1 rs383911 0.4307 0.8084 1.12×10−16
FNBMD M00357 bZIP910 rs6426749 0.2642 0.5711 1.03×10−23
FNBMD M00241 Nkx2-5 rs7466269 0.7019 0.9613 1.91×10−08
HB M01538 Aro80 rs13219787 0.8098 0.9741 5.23×10−09
HB M00986 Churchill rs198846 0.9989 0.9998 7.11×10−31
HDL M00332 Whn rs1044973 0.3681 0.7553 7.65×10−08
HDL M01641 RFX1 rs12740374 0.2660 0.6177 3.10×10−08
HDL M01946 LYS14 rs676210 0.2959 0.6569 1.33×10−30
HDL M01461 EMX2 rs6907508 0.2188 0.4655 3.65×10−10
Height MA0041.1 Foxd3 rs10171985 0.0359 0.2022 2.99×10−07
Height M01114 E2F rs11752007 0.7399 0.9523 4.84×10−08
Height M01264 TBX15 rs11752007 0.7399 0.9553 4.84×10−08
Height M01641 RFX1 rs12740374 0.0837 0.5101 3.81×10−05
Height MA0142.1 Pou5f1 rs17511102 0.9989 0.9999 6.32×10−13
Height M01641 RFX1 rs314263 0.2666 0.8066 4.16×10−18
Height M00792 SMAD rs34529769 0.3947 0.8177 1.13×10−10
Height M00776 SREBP rs3828559 0.1843 0.3429 2.74×10−06
Height M01641 RFX1 rs4073154 0.0628 0.4411 2.19×10−08
Height M01114 E2F rs4519508 0.1050 0.4438 8.12×10−06
Height M01641 RFX1 rs4725984 0.1155 0.6012 2.00×10−08
Height M00104 CDP CR1 rs4973431 0.1841 0.6903 8.51×10−07
Height M00241 Nkx2-5 rs7466269 0.4258 0.8376 5.86×10−15
Height M00104 CDP CR1 rs894344 0.0866 0.5023 7.79×10−11
Height MA0041.1 Foxd3 rs9849338 0.3562 0.7910 2.53×10−14
LDL M00359 bZIP911 rs2075375 0.2384 0.8109 1.64×10−07
LDL M01863 ATF-3 rs217381 0.2705 0.6777 7.41×10−11
Continued on next page
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Trait Motif Factor rsID PPA before PPA after p-value
LDL PBM0176 HLH-29 rs217386 0.2596 0.5864 2.13×10−11
LDL M01812 TGA2 rs2479409 0.9314 0.9979 9.70×10−29
LDL M01812 TGA2 rs267733 0.9777 0.9992 3.26×10−08
LDL M00513 ATF3 rs267733 0.9777 0.9983 3.26×10−08
LDL M00359 bZIP911 rs2954021 0.0748 0.5249 6.13×10−29
LDL M00187 USF/E-box rs532436 0.3971 0.7711 1.80×10−27
LDL M00513 ATF3 rs6920309 0.0595 0.4940 3.55×10−13
LDL MA0069.1 Pax6 rs9293637 0.1861 0.3661 2.62×10−11
LDL M00359 bZIP911 rs9438904 0.0327 0.3180 6.21×10−10
LSBMD M01733 MZF1 rs11898505 0.3838 0.8157 4.86×10−12
LSBMD M01525 Put3 rs1524068 0.2181 0.8539 2.41×10−15
LSBMD M01525 Put3 rs4869741 0.0866 0.6430 1.63×10−19
MCH M00235 AhR:Arnt rs11968166 0.9267 0.9923 4.67×10−34
MCH M01770 XBP1 rs12718598 0.7329 0.9667 9.29×10−09
MCH M00942 CPRF-1 rs1800562 0.4999 0.9280 1.73×10−66
MCH M01234 IPF1 rs2236496 0.9794 0.9795 1.17×10−16
MCH M00496 STAT1 rs3851296 0.0255 0.2805 1.39×10−08
MCH M01175 CKROX rs4729597 0.9522 0.9927 4.21×10−17
MCH M00942 CPRF-1 rs56050898 0.0773 0.5227 1.23×10−07
MCH M00513 ATF3 rs6568571 0.2151 0.4233 5.52×10−26
MCH M00235 AhR:Arnt rs7664687 0.0299 0.2360 1.42×10−06
MCH M00496 STAT1 rs869785 0.3464 0.8891 1.87×10−14
MCH MA0093.1 USF1 rs911910 0.1820 0.5454 6.42×10−07
MCH M01770 XBP1 rs9660992 0.0685 0.4665 3.54×10−10
MCHC M01641 RFX1 rs11240734 0.2396 0.5485 5.91×10−12
MCHC M01658 AML1 rs12733102 0.3623 0.8985 3.22×10−06
MCHC M00986 Churchill rs198846 0.9994 0.9999 3.73×10−21
MCHC M01030 Rim101p rs4737009 0.3690 0.8040 2.43×10−11
MCHC M00345 GAMYB rs4737010 0.4851 0.9013 2.14×10−11
MCHC M01658 AML1 rs9389268 0.2416 0.8496 9.60×10−15
MCV M01641 RFX1 rs10901252 0.1105 0.5953 4.06×10−08
MCV M01641 RFX1 rs11240734 0.5864 0.9445 2.22×10−09
MCV M00017 ATF rs12718597 0.0883 0.5035 2.38×10−13
MCV M01770 XBP1 rs12718598 0.5803 0.9573 3.35×10−14
MCV M00942 CPRF-1 rs1800562 0.8678 0.9841 7.75×10−47
MCV M00496 STAT1 rs3851296 0.0945 0.7763 1.59×10−08
MCV M01175 CKROX rs4729597 0.8192 0.9681 6.97×10−15
MCV M00942 CPRF-1 rs56050898 0.0558 0.3465 1.75×10−06
MCV M01863 ATF-3 rs6568571 0.5065 0.8577 8.07×10−23
MCV M01055 NAC69-1 rs6656196 0.4925 0.8656 1.46×10−08
MCV M01223 P50:P50 rs6730558 0.4072 0.8344 1.06×10−06
MCV M01197 ELF5 rs7022455 0.3546 0.8136 1.93×10−07
Continued on next page
94
Table A.15 – continued from previous page
Trait Motif Factor rsID PPA before PPA after p-value
MCV M00041 ATF2:c-Jun rs72667750 0.0494 0.2991 2.71×10−06
MCV M00496 STAT1 rs869785 0.3501 0.9456 4.83×10−15
MCV M01065 ABZ1 rs911910 0.2084 0.7617 1.07×10−08
MCV M01770 XBP1 rs9660992 0.2968 0.8784 5.18×10−10
PCV M00262 Staf rs1934661 0.2199 0.5262 3.95×10−07
PCV M00187 USF/E-box rs532436 0.4485 0.8706 7.48×10−18
PLT M00171 Adf-1 rs149290349 0.4414 0.8479 5.33×10−09
PLT M01814 AML2 rs17030845 0.2770 0.6496 6.34×10−11
PLT M00178 CREB rs2336384 0.1062 0.5901 6.24×10−09
PLT M01492 Ynr063w rs34592828 0.1358 0.2124 1.12×10−08
PLT M00739 E2F-4:DP-2 rs4731120 0.9853 0.9980 1.38×10−12
PLT M00178 CREB rs540909 0.2168 0.7814 3.99×10−07
PLT M01784 UPC2 rs6141 0.6676 0.9428 3.09×10−08
PLT M01653 HMGIY rs9399137 0.9999 1.0000 2.52×10−47
RBC M01797 SIRT6 rs10758656 0.7906 0.9607 3.79×10−10
RBC M00694 E4F1 rs12718598 0.4699 0.8635 3.04×10−09
RBC M01709 MAFA rs13027161 0.6889 0.9273 3.53×10−13
RBC M00261 Olf-1 rs1434282 0.7906 0.9632 7.39×10−09
RBC M00262 Staf rs1934661 0.4217 0.8423 4.51×10−07
RBC M00942 CPRF-1 rs532436 0.1135 0.2315 2.35×10−21
RBC M00694 E4F1 rs73019748 0.0875 0.4202 1.14×10−06
TC M01636 STB4 rs1556857 0.0666 0.4787 1.19×10−10
TC M00942 CPRF-1 rs1800562 0.9249 0.9946 1.24×10−08
TC M01636 STB4 rs2235215 0.6764 0.9655 2.79×10−10
TC M01812 TGA2 rs2479409 0.9696 0.9967 1.91×10−24
TC M00942 CPRF-1 rs532436 0.4694 0.9313 6.63×10−26
TC M00187 USF/E-box rs532436 0.4694 0.8359 6.63×10−26
TC M01636 STB4 rs553427 0.0320 0.3031 2.64×10−12
TG M01617 ZMS1 rs13173241 0.1691 0.2924 2.58×10−10
TG M00486 Pax-2 rs2270924 0.2590 0.5997 2.51×10−11
TG M01848 TCP15 rs7789194 0.2586 0.6452 1.38×10−07
TG M01204 SPI-B rs9686661 0.6413 0.9510 6.59×10−11
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Figure A.1: Flowchart detailing steps of the CENTIPEDE-based annotation of regulatory regions and vari-
ants. Numbers next to boxes refer to the corresponding section in Appendix A.
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Figure A.2: Flowchart detailing ASH analysis pipeline. Numbers next to boxes refer to the corresponding section
in Appendix A.
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Figure A.4: Binding profiles of AP-1 motif M00172. Footprint profiles are aggregated across all binding sites in
all 653 DNase-seq samples, and stratified by Z-score (color). The higher the Z-score, the more likely a factor is bound
as predicted by the CENTIPEDE model.
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Figure A.6: Comparison between seed and revised sequence model. For each factor motif, shown is the original
seed sequence model (left) and the revised model (right). x-axis: position within motif, y-axis: information content.
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Figure A.7: Precision-recall curves for seed (blue) and revised (black) sequence models. For each TF binding
motif, CENTIPEDE-predicted footprints in GM12878 cells were compared using ENCODE ChIP-seq data as a gold
standard. (A & B) CTCF (C & D) GABP (E & F) NRSF (G & H) PU.1
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Figure A.8: Comparison of prior Pr(binding) derived from PWM scores to ChIP-seq read data across all
motif matches using seed (blue) and revised (black) sequence models. Due to thresholds on the match score (see
Section A.3.2), few models have data Pr(binding) < 0.2. For ease of display data is binned in 10% increments.
Points represent the average number of ChIP-seq reads within that bin and vertical lines represent the 95% confidence
interval. Spearman correlation (legend) is calculated using the full data set without binning. (A & B) CTCF, (C & D)
NRSF, (E & F) PU.1
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A
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Figure A.9: Reference allele ratio ρ at 1KG variants. (A) Plot showing ρ allele ratios for SNPs interrogated
for CD34 primary cells (used for ASH analysis). Three peaks on the histogram (right) correspond to homozygous
reference (top), heterozygous (middle), and homozygous alternate (bottom) SNPs. (B) Plot showing ρ allele ratios for
SNPs interrogated for the cancer line K562 (discarded for ASH analysis). Signatures of chromosomal abnormalities
are evident from the scatterplot, such as copy number variation and loss of heterozygosity.
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Figure A.10: Distribution of values used for post-ASH analysis filter criteria. On all four panels y-axis represents
the parameter M that is reciprocally related to the dispersion of rho in the QuASAR model. Dotted lines represent
values used to filter samples. (A) Dispersion and correlation between ρ and φ (B) Dispersion and ρ estimation. Bottom
plots show zoomed view of samples with M < 100.
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Figure A.11: Correlation between CENTIPEDE predictions and observed ASH. SNPs identified in both the
CENTIPEDE and ASH analysis are shown, shaded by p-value of allelic imbalance from QuASAR. Points circled in
red display significant ASH at 20% FDR. The blue line is a logistic curve fit using points with a p < 0.1.
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Figure A.12: Magnitude of allelic imbalance within predicted functional annotations. Each line represents a
density plot of the magnitude of allelic imbalance |(allele ratio - 0.5)| for SNPs within each functional annotation.
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Figure A.13: ASH p-value densities for different SNP categories. Shown are three additional categories of SNPs
from recent studies of functional variation within TF binding sites.
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Figure A.14: Comparison of thresholds for functional annotation categories. ASH p-value densities for different
SNP categories. For effect-SNPs and switch-SNPs, shown are different thresholds used for defining the category (20x
is the threshold used throughout this analysis). The dotted blue line represents the null distribution.
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Figure A.15: Identification of ASH using only PWM score. ASH p-value densities for different SNP categories
and PWM (sequence match) match scores. Numbers in parentheses are the number of SNPs in those categories. The
dotted blue line represents the null distribution.
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Figure A.16: Identification of ASH using phyloP conservation score. ASH p-value densities for different SNP
categories and SNPs with indicated phyloP conservation scores. Numbers in parentheses are the number of SNPs in
those categories. The dotted blue line represents the null distribution.
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Figure A.17: Distribution of ASH enrichment ratios. For all motifs with >100 hSNPs, an ASH enrichment ratio
was calculated as # ASH-hSNPs (20% FDR) / # hSNPs across all binding sites genome-wide. The black line shows
the average ratio across all motifs. Several factors whose binding sites are highly enriched or depleted for ASH-hSNPs
are labeled.
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Figure A.18: Identifying selection signals in TF binding sites. (A) Density plot showing the distribution of
selection scores from the modified MK test. (B) Comparison of selection scores to the number of tissues each factor
is predicted to be active in. (C) Comparison of selection scores to the median distance to the TSS across all sites for a
given factor.
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Figure A.19: Derived allele frequency and selection score. Shown are the relative enrichments for each
DAF/selection score bin, for all variants (A) and for singletons and doubletons (B).
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Figure A.20: Enrichment of transcription factors motifs from fgwas. Shown are the log2(enrichment) values
with 95% confidence intervals for each factor whose binding sites are enriched for SNPs associated with the traits in
Table 14. x-axis is truncated at 10 for ease of display.
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Figure A.21: Association plots identifying SNPs in footprints. Log Bayes factor (top) and posterior probabilities
(bottom) of association to the indicated trait for all genetic variants in the regions containing rs4519508 and rs532436.
116
l
l
l
l
l
l
l
l
−4
−3
−2
−1
0
−100 −75 −50 −25 0
∆ Pr(binding), Mut − WT
∆ 
Ex
pr
es
sio
n,
 M
ut
 −
 W
T Mutation
l
l
Scramble
Single Base
cellType
l HepG2
K562
Figure A.22: Correlation of CENTIPEDE predictions and mutated enhancers in HepG2 and K562 cells. For
each point, plotted is the difference in the change in probability of binding (mutated prior log ratio - reference prior
log ratio, x-axis) versus the log2( fold change ) between mutated and wild type reporter constructs expression (y-axis).
The black line represents the best-fit line from a linear model fit on all 22 points.
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APPENDIX B: SUPPLEMENTAL MATERIAL FOR “A
HIGH-THROUGHPUT RNA-SEQ APPROACH TO PROFILE
TRANSCRIPTIONAL RESPONSES”
B.1 SELECTION OF SAMPLES FOR DEEP SEQUENCING
Selection of conditions to be carried over from step one to step two is a key step. Any picked
threshold will to some extent be arbitrary. One possibility we suggest is to consider the number of
DE genes (e.g. >100 at 10% FDR, note that for estrogen, here a negative control, we detect only
47 DE genes), an additional threshold could be placed on the log(FC) (e.g. at least 0.25 log(FC)).
A closer look at the number of DE genes in figure 3, however, shows two clearly separated groups:
treatments with<100 DE genes and treatment with>1000 DE genes. We decided to only consider
this second group and specifically we randomly selected i) a treatment with extreme number of DE
genes (iron, >10,000 DE genes), ii) the treatment with the lowest number of DE genes (copper,
2488 DE genes) and iii) 2 additional treatments (Vitamin A and selenium). As here our goal was
not to follow up on all conditions with a large number of DE genes, we could similarly have chosen
caffeine, dexamethasone and manganese for follow up.
B.2 FAILED BARCODES AND LIBRARY QUALITY ASSESSMENT
As reported in the Methods, sequencing failed for two barcodes corresponding to the iron
treatment for 18507 and the vitamin C treatment for 19239. In the kapa PCR quantification step,
these two samples had the lowest library concentration (0.5nM and 2.7nM, which were 1-2 order
of magnitude lower than most of the other samples). Therefore our QC step did already identify
these two samples as possible failed libraries. However we decided to sequence them anyway to
account for the possibility of a failed QC step. As to the reason why the library preparation may
have failed for these two samples: for the vitamin C sample we had extremely low mRNA starting
material 1.5ng, while for the iron sample the most likely explanation is a problem occurred during
library preparation.
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B.3 REPOOLING STRATEGY AND BATCH EFFECTS
For this study we did not merge the bam files from the shallow and the deep sequencing.
However, when pooling across sequencing runs (in step two), batch effects may potentially be
introduced. One possibility to account for them would be to add a “run” parameter in the DESeq2
model. In our case, the high correlation between shallow and deep sequencing data reassured us
that across deep sequencing runs that were pooled, no major batch effects were introduced that
could be detected on the normalized data.
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Table B.1: Library pooling proportions.
Treatment Cell line Pooling proportion
Ethanol Control GM19239 0.02
Ethanol Control GM18507 0.03
Ethanol Control GM18508 0.03
Ethanol Control GM19239 0.02
Ethanol Control GM18507 0.03
Ethanol Control GM18508 0.03
Ethanol Control GM19239 0.02
Ethanol Control GM18507 0.02
Ethanol Control GM18508 0.04
Media Control GM19239 0.02
Media Control GM18507 0.03
Media Control GM18508 0.04
Media Control GM19239 0.02
Media Control GM18507 0.03
Media Control GM18508 0.04
Media Control GM19239 0.02
Media Control GM18507 0.03
Media Control GM18508 0.03
Copper GM19239 0.03
Copper GM18507 0.05
Copper GM18508 0.06
Iron GM19239 0.04
Iron GM18508 0.04
Vitamin A GM19239 0.04
Vitamin A GM18507 0.05
Vitamin A GM18508 0.04
Selenium GM19239 0.05
Selenium GM18507 0.05
Selenium GM18508 0.06
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Table B.2: GO categories for genes upregulated by retinoic acid. Categories in bold are enriched in the deep
sequencing data only.
Biological Process Adj p value
immune response 1.20×10−09
translational elongation 6.00×10−05
cell activation 1.40×10−04
leukocyte activation 4.90×10−04
lymphocyte activation 8.10×10−04
defense response 5.70×10−03
T cell activation 7.70×10−03
positive regulation of biosynthetic process 8.40×10−03
response to oxygen levels 1.20×10−02
positive regulation of cellular biosynthetic process 1.60×10−02
translation 1.70×10−02
innate immune response 1.90×10−02
positive regulation of macromolecule biosynthetic process 2.10×10−02
regulation of programmed cell death 2.20×10−02
positive regulation of immune system process 2.20×10−02
response to nutrient 2.20×10−02
regulation of apoptosis 2.30×10−02
positive regulation of cytokine biosynthetic process 2.30×10−02
inflammatory response 2.30×10−02
regulation of cell death 2.40×10−02
response to hypoxia 2.50×10−02
negative regulation of transcription from RNA polymerase
II promoter
2.60×10−02
regulation of cytokine production 2.60×10−02
positive regulation of macromolecule metabolic process 3.00×10−02
positive regulation of RNA metabolic process 3.30×10−02
response to organic cyclic substance 3.50×10−02
response to wounding 3.60×10−02
positive regulation of transcription, DNA-dependent 3.70×10−02
response to vitamin 3.90×10−02
positive regulation of transcription 4.40×10−02
negative regulation of programmed cell death 4.60×10−02
response to extracellular stimulus 4.60×10−02
regulation of transcription from RNA polymerase II pro-
moter
4.70×10−02
positive regulation of gene expression 4.80×10−02
negative regulation of apoptosis 4.80×10−02
negative regulation of cell death 4.90×10−02
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Table B.3: GO categories for genes downregulated by retinoic acid. Categories in bold are enriched in the deep
sequencing data only.
Biological Process Adj p value
cell cycle phase 2.20×10−03
cell cycle 7.80×10−03
hemopoiesis 8.00×10−03
response to DNA damage stimulus 8.20×10−03
DNA metabolic process 8.90×10−03
M phase 8.90×10−03
intracellular signaling cascade 9.20×10−03
cell cycle process 9.70×10−03
immune system development 1.00×10−02
hemopoietic or lymphoid organ development 1.00×10−02
DNA repair 1.30×10−02
cellular response to stress 1.40×10−02
cell surface receptor linked signal transduction 1.70×10−02
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Table B.4: GO categories for genes upregulated by copper. Categories in bold are enriched in the deep sequencing
data only.
Biological Process Adj p value
negative regulation of protein ubiquitination 2.00×10−09
ubiquitin-dependent protein catabolic process 3.60×10−09
positive regulation of ubiquitin-protein ligase activity dur-
ing mitotic cell cycle
4.50×10−09
negative regulation of ubiquitin-protein ligase activity dur-
ing mitotic cell cycle
4.80×10−09
anaphase-promoting complex-dependent proteasomal
ubiquitin-dependent
protein catabolic process 4.80×10−09
positive regulation of ligase activity 4.90×10−09
positive regulation of ubiquitin-protein ligase activity 6.00×10−09
regulation of ubiquitin-protein ligase activity during mitotic
cell cycle
7.20×10−09
negative regulation of ligase activity 7.50×10−09
negative regulation of ubiquitin-protein ligase activity 7.50×10−09
cellular macromolecule catabolic process 1.50×10−08
macromolecule catabolic process 1.90×10−08
proteolysis involved in cellular protein catabolic process 2.30×10−08
cellular protein catabolic process 2.40×10−08
protein catabolic process 2.50×10−08
modification-dependent macromolecule catabolic process 3.00×10−08
modification-dependent protein catabolic process 3.00×10−08
regulation of ligase activity 5.00×10−08
proteolysis 6.20×10−08
regulation of ubiquitin-protein ligase activity 6.50×10−08
positive regulation of protein ubiquitination 6.50×10−08
proteasomal ubiquitin-dependent protein catabolic process 7.90×10−08
proteasomal protein catabolic process 7.90×10−08
regulation of protein ubiquitination 8.60×10−08
negative regulation of protein modification process 1.40×10−06
positive regulation of cellular protein metabolic process 2.20×10−06
positive regulation of protein metabolic process 1.30×10−05
negative regulation of cellular protein metabolic process 1.60×10−05
positive regulation of protein modification process 1.60×10−05
negative regulation of protein metabolic process 4.10×10−05
positive regulation of catalytic activity 2.80×10−04
positive regulation of molecular function 1.00×10−03
negative regulation of catalytic activity 1.50×10−03
negative regulation of molecular function 2.20×10−03
Continued on next page
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TableB.4 – continued from previous page
Biological Process Adj p value
mitotic cell cycle 3.80×10−03
regulation of protein modification process 5.70×10−03
regulation of cellular protein metabolic process 6.30×10−03
translational elongation 6.80×10−03
response to unfolded protein 1.10×10−02
protein folding 1.80×10−02
cell cycle process 3.10×10−02
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Table B.5: GO categories for genes downregulated by copper. Categories in bold are enriched in the deep se-
quencing data only.
Biological Process Adj p value
M phase of mitotic cell cycle 7.60×10−04
organelle fission 9.20×10−04
mitosis 1.20×10−03
nuclear division 1.20×10−03
M phase 3.30×10−03
cellular amino acid biosynthetic process 6.60×10−03
cell cycle phase 1.30×10−02
amine biosynthetic process 1.50×10−02
cell proliferation 4.30×10−02
nitrogen compound biosynthetic process 4.90×10−02
immune response 4.90×10−02
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Table B.6: GO categories for genes unregulated by iron. Categories in bold are enriched in the deep sequencing
data only.
Biological Process Adj p value
biological adhesion 8.70×10−27
cell adhesion 1.00×10−26
ion transport 1.10×10−17
neurological system process 1.10×10−14
metal ion transport 1.40×10−12
cell-cell adhesion 5.90×10−12
cell-cell signaling 9.50×10−12
cell surface receptor linked signal transduction 9.80×10−11
synaptic transmission 4.70×10−10
cell projection organization 1.10×10−09
cation transport 3.00×10−09
cell morphogenesis 3.50×10−09
cell morphogenesis involved in differentiation 7.90×10−09
transmission of nerve impulse 9.20×10−09
axonogenesis 1.50×10−08
cellular component morphogenesis 3.30×10−08
neuron differentiation 4.70×10−08
neuron projection morphogenesis 4.80×10−08
neuron projection development 4.80×10−08
cell morphogenesis involved in neuron differentiation 5.80×10−08
neuron development 6.20×10−08
extracellular structure organization 1.30×10−07
cell projection morphogenesis 1.40×10−07
enzyme linked receptor protein signaling pathway 1.60×10−07
regulation of system process 3.00×10−07
cognition 6.10×10−07
cell part morphogenesis 6.40×10−07
homophilic cell adhesion 4.40×10−06
cell motion 5.10×10−06
transmembrane receptor protein tyrosine kinase signaling
pathway
6.80×10−06
sodium ion transport 6.90×10−06
regulation of small GTPase mediated signal transduction 1.30×10−05
monovalent inorganic cation transport 1.40×10−05
behavior 3.60×10−05
potassium ion transport 3.80×10−05
learning or memory 5.20×10−05
localization of cell 5.70×10−05
cell motility 5.70×10−05
Continued on next page
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Biological Process Adj p value
protein amino acid phosphorylation 5.80×10−05
anion transport 7.60×10−05
calcium ion transport 8.20×10−05
extracellular matrix organization 1.30×10−04
excretion 1.90×10−04
chemical homeostasis 1.90×10−04
ion homeostasis 3.90×10−04
muscle contraction 4.20×10−04
transmembrane transport 4.50×10−04
di-, tri-valent inorganic cation transport 5.20×10−04
axon guidance 5.60×10−04
regulation of Ras protein signal transduction 6.40×10−04
muscle system process 6.40×10−04
G-protein coupled receptor protein signaling pathway 7.80×10−04
cell migration 1.30×10−03
organic acid transport 2.60×10−03
carboxylic acid transport 2.60×10−03
sensory perception 2.80×10−03
wound healing 2.80×10−03
integrin-mediated signaling pathway 2.90×10−03
memory 3.00×10−03
inorganic anion transport 3.10×10−03
regulation of Rho protein signal transduction 3.70×10−03
heart development 3.90×10−03
phosphate metabolic process 3.90×10−03
phosphorus metabolic process 3.90×10−03
regulation of synaptic transmission 5.40×10−03
regulation of transmission of nerve impulse 6.30×10−03
regulation of cell morphogenesis 6.30×10−03
cellular chemical homeostasis 7.40×10−03
multicellular organismal response to stress 8.60×10−03
cellular ion homeostasis 9.00×10−03
sensory perception of mechanical stimulus 9.40×10−03
regulation of neurological system process 9.50×10−03
cAMP-mediated signaling 1.10×10−02
cyclic-nucleotide-mediated signaling 1.10×10−02
positive regulation of lyase activity 1.10×10−02
limb morphogenesis 1.30×10−02
appendage morphogenesis 1.30×10−02
embryonic morphogenesis 1.40×10−02
cation homeostasis 1.40×10−02
regulation of lyase activity 1.60×10−02
Continued on next page
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Biological Process Adj p value
actin filament-based process 1.70×10−02
positive regulation of cyclase activity 1.70×10−02
embryonic appendage morphogenesis 1.70×10−02
embryonic limb morphogenesis 1.70×10−02
secretion 1.80×10−02
adult behavior 1.90×10−02
vasculature development 1.90×10−02
G-protein signaling, coupled to cyclic nucleotide second
messenger
1.90×10−02
sensory organ development 2.00×10−02
limb development 2.00×10−02
appendage development 2.00×10−02
response to wounding 2.00×10−02
regulation of cyclase activity 2.10×10−02
G-protein signaling, coupled to cAMP nucleotide second
messenger
2.10×10−02
gland development 2.20×10−02
sensory perception of light stimulus 2.30×10−02
visual perception 2.30×10−02
positive regulation of adenylate cyclase activity 2.30×10−02
muscle cell differentiation 2.30×10−02
ear development 2.60×10−02
inner ear development 2.70×10−02
actin cytoskeleton organization 2.70×10−02
sensory perception of sound 2.70×10−02
blood vessel development 2.70×10−02
synapse organization 2.90×10−02
startle response 3.10×10−02
cell-substrate adhesion 3.10×10−02
cell junction organization 3.20×10−02
activation of adenylate cyclase activity 3.30×10−02
regulation of locomotion 3.40×10−02
cell-matrix adhesion 3.40×10−02
striated muscle tissue development 3.50×10−02
tube development 3.50×10−02
urogenital system development 3.50×10−02
chloride transport 3.50×10−02
adult locomotory behavior 3.50×10−02
regulation of cell adhesion 3.80×10−02
regulation of heart contraction 4.00×10−02
second-messenger-mediated signaling 4.40×10−02
neuromuscular process 4.40×10−02
Continued on next page
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Biological Process Adj p value
regulation of cyclic nucleotide biosynthetic process 4.40×10−02
regulation of nucleotide biosynthetic process 4.40×10−02
regulation of cell migration 4.60×10−02
regulation of cyclic nucleotide metabolic process 4.60×10−02
regulation of adenylate cyclase activity 4.80×10−02
ectoderm development 4.80×10−02
sperm motility 4.80×10−02
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Table B.7: GO categories for genes downregulated by iron. Categories in bold are enriched in the deep sequencing
data only.
Biological Process Adj p value
RNA processing 7.70×10−13
RNA splicing 1.00×10−12
organelle fission 1.70×10−11
nuclear division 7.50×10−11
mitosis 7.50×10−11
M phase of mitotic cell cycle 9.90×10−11
mRNA processing 1.10×10−10
mRNA metabolic process 1.30×10−10
DNA metabolic process 1.40×10−10
cell cycle 3.60×10−10
M phase 1.30×10−09
cell cycle process 9.60×10−09
mitotic cell cycle 9.90×10−09
cell cycle phase 6.70×10−08
RNA splicing, via transesterification reactions with bulged
adenosine as nucleophile
1.10×10−07
RNA splicing, via transesterification reactions 1.10×10−07
nuclear mRNA splicing, via spliceosome 1.10×10−07
cell division 1.10×10−07
response to DNA damage stimulus 4.50×10−07
cellular response to stress 2.10×10−06
DNA repair 8.00×10−06
chromosome organization 8.20×10−06
chromosome segregation 2.90×10−05
cellular macromolecule catabolic process 6.60×10−05
protein modification by small protein conjugation or re-
moval
7.10×10−05
response to virus 1.50×10−04
protein targeting to membrane 2.30×10−04
macromolecule catabolic process 3.30×10−04
regulation of cell cycle 3.40×10−04
protein transport 6.00×10−04
establishment of protein localization 8.70×10−04
proteolysis involved in cellular protein catabolic process 1.00×10−03
protein catabolic process 1.30×10−03
modification-dependent macromolecule catabolic process 1.30×10−03
modification-dependent protein catabolic process 1.30×10−03
protein localization 1.40×10−03
cellular protein catabolic process 1.40×10−03
Continued on next page
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Biological Process Adj p value
generation of precursor metabolites and energy 3.10×10−03
apoptosis 3.70×10−03
programmed cell death 4.10×10−03
cofactor biosynthetic process 5.30×10−03
intracellular transport 5.70×10−03
DNA replication 7.40×10−03
protein modification by small protein conjugation 7.70×10−03
cellular respiration 8.80×10−03
energy derivation by oxidation of organic compounds 9.20×10−03
chromatin modification 1.30×10−02
chromosome condensation 1.30×10−02
histone modification 1.50×10−02
ubiquitin-dependent protein catabolic process 1.60×10−02
covalent chromatin modification 1.80×10−02
RNA elongation 2.00×10−02
proteasomal ubiquitin-dependent protein catabolic process 2.20×10−02
proteasomal protein catabolic process 2.20×10−02
cell death 2.20×10−02
cofactor metabolic process 2.30×10−02
DNA recombination 2.70×10−02
regulation of mitotic cell cycle 2.80×10−02
death 2.90×10−02
cellular protein localization 3.20×10−02
mitotic sister chromatid segregation 3.40×10−02
cotranslational protein targeting to membrane 4.10×10−02
chromatin organization 4.10×10−02
RNA elongation from RNA polymerase II promoter 4.20×10−02
cellular macromolecule localization 4.30×10−02
negative regulation of macromolecule metabolic process 4.80×10−02
microtubule organizing center organization 4.90×10−02
sister chromatid segregation 4.90×10−02
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Table B.8: GO categories for genes upregulated by selenium. Categories in bold are enriched in the deep sequenc-
ing data only.
Biological Process Adj p value
translation 7.40×10−43
translational elongation 4.90×10−32
RNA processing 8.20×10−18
RNA splicing 4.40×10−12
anaphase-promoting complex-dependent proteasomal
ubiquitin-dependent protein catabolic process 4.40×10−12
negative regulation of ubiquitin-protein ligase activity dur-
ing mitotic cell cycle
4.40×10−12
negative regulation of ligase activity 4.70×10−12
negative regulation of ubiquitin-protein ligase activity 4.70×10−12
positive regulation of ubiquitin-protein ligase activity 7.20×10−12
positive regulation of ubiquitin-protein ligase activity dur-
ing mitotic cell cycle
7.30×10−12
ribonucleoprotein complex biogenesis 9.30×10−12
negative regulation of protein ubiquitination 1.00×10−11
regulation of ubiquitin-protein ligase activity during mitotic
cell cycle
1.10×10−11
positive regulation of ligase activity 5.30×10−11
regulation of ubiquitin-protein ligase activity 6.80×10−11
proteasomal protein catabolic process 1.60×10−10
proteasomal ubiquitin-dependent protein catabolic process 1.60×10−10
mRNA processing 1.70×10−10
regulation of ligase activity 4.80×10−10
mRNA metabolic process 6.90×10−10
RNA splicing, via transesterification reactions with bulged
adenosine as nucleophile
7.10×10−10
RNA splicing, via transesterification reactions 7.10×10−10
nuclear mRNA splicing, via spliceosome 7.10×10−10
positive regulation of protein ubiquitination 7.90×10−10
ribosome biogenesis 2.90×10−09
generation of precursor metabolites and energy 1.50×10−08
regulation of protein ubiquitination 1.50×10−08
ncRNA metabolic process 2.90×10−08
cellular macromolecular complex subunit organization 3.10×10−08
cellular macromolecular complex assembly 5.30×10−08
rRNA metabolic process 2.00×10−07
rRNA processing 3.50×10−07
electron transport chain 1.10×10−06
oxidative phosphorylation 1.90×10−06
Continued on next page
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Biological Process Adj p value
ubiquitin-dependent protein catabolic process 3.80×10−06
ncRNA processing 8.30×10−06
macromolecular complex assembly 1.30×10−05
negative regulation of cellular protein metabolic process 1.40×10−05
macromolecular complex subunit organization 1.80×10−05
negative regulation of protein metabolic process 3.10×10−05
nucleosome assembly 3.20×10−05
chromatin assembly 3.60×10−05
translational initiation 3.70×10−05
nucleosome organization 7.00×10−05
protein-DNA complex assembly 7.00×10−05
negative regulation of protein modification process 8.10×10−05
DNA metabolic process 1.50×10−04
cellular respiration 3.30×10−04
DNA replication 6.90×10−04
ribosomal large subunit biogenesis 2.50×10−03
mitochondrial electron transport, NADH to ubiquinone 2.50×10−03
respiratory electron transport chain 2.80×10−03
response to DNA damage stimulus 2.90×10−03
mitochondrial ATP synthesis coupled electron transport 3.10×10−03
ATP synthesis coupled electron transport 3.10×10−03
nucleic acid transport 3.60×10−03
establishment of RNA localization 3.60×10−03
RNA transport 3.60×10−03
ribonucleoprotein complex assembly 4.00×10−03
chromatin assembly or disassembly 4.60×10−03
RNA elongation from RNA polymerase II promoter 6.70×10−03
energy derivation by oxidation of organic compounds 7.30×10−03
RNA elongation 7.30×10−03
RNA localization 7.70×10−03
DNA-dependent DNA replication 8.10×10−03
mitotic cell cycle 9.80×10−03
cellular macromolecule catabolic process 1.00×10−02
DNA packaging 1.30×10−02
protein folding 1.50×10−02
nucleobase, nucleoside, nucleotide and nucleic acid
transport
1.50×10−02
negative regulation of catalytic activity 1.80×10−02
DNA repair 1.80×10−02
modification-dependent macromolecule catabolic process 2.20×10−02
modification-dependent protein catabolic process 2.20×10−02
mitochondrial respiratory chain complex I assembly 2.40×10−02
Continued on next page
133
TableB.8 – continued from previous page
Biological Process Adj p value
NADH dehydrogenase complex assembly 2.40×10−02
mRNA transport 2.80×10−02
posttranscriptional regulation of gene expression 2.80×10−02
spliceosome assembly 3.00×10−02
proteolysis involved in cellular protein catabolic process 4.40×10−02
positive regulation of protein modification process 4.60×10−02
cellular protein catabolic process 4.70×10−02
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Table B.9: GO categories for genes downregulated by selenium. Categories in bold are enriched in the deep
sequencing data only.
Biological Process Adj p value
intracellular signaling cascade 5.10×10−04
actin cytoskeleton organization 5.20×10−03
leukocyte activation 6.50×10−03
chromatin modification 6.80×10−03
actin filament-based process 7.60×10−03
regulation of small GTPase mediated signal transduc-
tion
9.80×10−03
cell activation 1.00×10−02
protein transport 1.20×10−02
regulation of transcription 1.20×10−02
establishment of protein localization 1.30×10−02
lymphocyte activation 1.30×10−02
Ras protein signal transduction 1.70×10−02
glycoprotein biosynthetic process 1.80×10−02
protein kinase cascade 1.80×10−02
chromatin remodeling 1.80×10−02
chromosome organization 1.80×10−02
hemopoiesis 1.80×10−02
regulation of gene expression, epigenetic 1.90×10−02
protein localization 2.00×10−02
glycoprotein metabolic process 2.10×10−02
transcription 2.20×10−02
hemopoietic or lymphoid organ development 2.90×10−02
glycosylation 3.30×10−02
biopolymer glycosylation 3.30×10−02
protein amino acid glycosylation 3.30×10−02
actin filament organization 4.70×10−02
chromatin organization 4.70×10−02
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Table B.10: Correlation of downsampling analysis to deep sequencing data. Shown for each treatment is the
original correlation between shallow and deep sequencing (Ratio=1, based on transcript log fold change as in Figure
B.4), as well as the correlation between results calculated using downsampled shallow sequencing reads corresponding
to the indicated downsampling ratio.
Treatment DownsampleRatio
Spearman’s
ρ
95% CI # DEG(10% BH-FDR)
Vitamin A 1 0.734 0.731 - 0.737 3391
1/2 0.672 0.669 - 0.676 2373
1/4 0.584 0.580 - 0.588 1522
1/6 0.539 0.535 - 0.544 1082
1/8 0.525 0.520 - 0.530 846
1/10 0.470 0.465 - 0.474 677
1/12 0.514 0.509 - 0.520 587
Copper 1 0.746 0.742 - 0.749 1526
1/2 0.691 0.686 - 0.695 742
1/4 0.647 0.640 - 0.655 257
1/6 0.590 0.583 - 0.598 149
1/8 0.559 0.549 - 0.569 93
1/10 0.520 0.509 - 0.531 76
1/12 0.505 0.493 - 0.516 56
Iron 1 0.814 0.813 - 0.816 10677
1/2 0.734 0.732 - 0.737 6908
1/4 0.641 0.638 - 0.644 3780
1/6 0.582 0.578 - 0.585 2436
1/8 0.536 0.531 - 0.540 1788
1/10 0.505 0.500 - 0.509 1339
1/12 0.479 0.474 - 0.483 1014
Selenium 1 0.824 0.822 - 0.826 5521
1/2 0.798 0.795 - 0.801 3314
1/4 0.753 0.749 - 0.757 1668
1/6 0.738 0.733 - 0.743 1122
1/8 0.738 0.732 - 0.744 792
1/10 0.705 0.699 - 0.712 592
1/12 0.717 0.709 - 0.724 492
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Figure B.1: The 96-well plate design used for this study. LCLs from three individual samples were treated in
parallel on the same plate (sample 1, 2 and 3) to analyze 32 conditions (represented by different colors). The 32
conditions correspond to 23 treatments and 3 vehicle controls. For each LCL sample, each control treatment (in
different shades of grey) was performed in triplicates.
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Figure B.2: Comparison of gene expression differences between controls. Show are QQ-plots of the p-value
distribution from DESeq2 comparing media to ethanol from step one (A) and step two (B).
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Figure B.3: QQplot of the p-value distribution for DE genes for each step one treatment. Each treatment was
analyzed with respect to the appropriate control (see Table 1).
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Figure B.4: Correlation in the transcriptional response between shallow and deep sequencing. Plotted is the
log2(fold change) for each genetranscript calculated from shallow and deep sequencing data for the four treatments
analyzed in step two. Colored points represent transcripts differentially expressed at 1% BH-FDR. Vitamin A (A),
copper (B), iron (C), selenium (D).
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Figure B.5: Comparison of downsampled deep sequencing to shallow sequencing. Deep sequencing data for
the media controls was downsampled to the level of shallow sequencing, and gene expression (FPKM) values were
compared. Shallow and downsampled deep samples cluster closely within individual libraries.
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Figure B.6: Features of differentially expressed transcripts. Shown for each treatment are comparisons between
sets of differentially expressed transcripts (10% BH-FDR) for transcript length (in bp), GC content, and the standard
error of the log fold change from DESeq2. Transcript length was log10 transformed for display purposes.
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Figure B.7: Simulation of higher multiplexing through downsampling. Shallow sequencing data for selected
treatments were downsampled to reflect indicated multiplex level, then compared to the deep sequencing data. A table
of the correlation values can be found in Table S9.
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APPENDIX C: SUPPLEMENTAL MATERIAL FOR
“HIGH-THROUGHPUT ALLELE-SPECIFIC EXPRESSION
ACROSS 250 ENVRIONMENTAL CONDITIONS”
C.1 CELLS
Experiments were conducted using the following cell types: lymphoblastoid cell lines (LCLs),
peripheral blood mononuclear cells (PBMCs), human umbilical vein endothelial cells (HUVECs),
human smooth muscle cells (SMCs) and melanocytes. LCLs (GM18507, GM18508, and GM19239)
were purchased from Coriell Cell Repository, cultured and treated according to (103).
PBMCs were derived from whole human blood purchased from Research Blood Components.
Blood specimens were obtained from 3 individual donors. PBMCs were isolated by density gra-
dient centrifugation, using a Ficoll-Paque isolation protocol. For isolation, PBS-diluted blood was
gently layered over room temperature Histopaque-1077 (Life Technologies), centrifuged at 400 xg
and the mononuclear cell layer was collected using a transfer pipette. Following isolation, PBMCs
were resuspended in RPMI 1640, supplemented with 10% charcoal stripped FBS (CS-FBS) and
0.1% Gentamycin, at a 1×106 cells/mL and stored overnight at 4◦C, for use the following day.
Immediately before treatment, PBMCs were activated with PHA (2.5µg/mL).
Primary HUVECs and SMC were isolated from human umbilical cord tissue collected shortly
following birth. Umbilical cord tissue specimens were obtained from healthy full-term pregnant
women, admitted to DMC Hutzel Women’s Hospital (Detroit, Michigan). Two cord specimens,
between 10 and 30 cm in length, were first rinsed with warm PBS and a blunt-ended needle was
inserted into the umbilical vein at one end of the cord, and subsequently clamped in place. The
cord was then purged to remove any excess blood from the vein. The other end of the cord was then
sealed, in a manner identical to the first end, and pre-warmed 0.25% trypsin-EDTA (Gibco) was
then injected into the vein. Following a 20 minutes incubation, at 37◦C, detached HUVECs were
rinsed from the vein, collected by centrifugation, counted, and seeded into an appropriate vessel
at 10,000 cells/cm2, in EGM-2 growth medium (Lonza). Expanded cultures were cryopreserved
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prior to be used in the experiments. SMCs were collected from two additional cords. Briefly, fol-
lowing HUVECs isolation, the vein was purged with PBS and pre-warmed Collagenase A/Dispase
II solution was slowly injected in the vein until it becomes moderately distended. The filled cord
was then incubated in pre-warmed PBS for 60-120 min at 37◦C, in the water bath. Following in-
cubation, SMCs were collected from the vein with warm PBS, and resuspended in EGM-2 growth
medium. Cells were then collected by centrifugation, counted, and seeded into an appropriate ves-
sel at 3500 cells/cm2 in SmGM-2 medium (Lonza#: CC-4149) and cultured at 37◦C and 5% CO2
prior to cryopreservation. All specimens for this study were collected following guidelines ap-
proved by the institutional review board (#013213MP4E) of Wayne State University. Additionally,
cryopreserved HUVECs (CC-2517-0000315288) and SMCs (CC-2579-7F3794) were purchased
from Lonza.
Primary melanocytes (NHEM) isolated from neonatal foreskin were purchased from Lonza
(CC-2504 lot # 252410 and 5F0885J) and from Promocell (C-12400 lot # 3052103.1).
C.2 CELL CULTURING PRIOR TO THE TREATMENTS
LCLs were cultured prior to treatment as described in (103). PBMCs were seeded in phenol-
red free RPMI 1640, supplemented with 10% CS-FBS and 0.1% Gentamycin at 1x106 cells/mL
on a 96-well plate on the day of the treatment. For all HUVEC lines, cells were seeded onto 96-
well plates, at 5000 cells/cm2, in EGM-2. Following a 24 hour recovery period, the medium was
changed to a “starvation medium”, composed of phenol-red free EGM-2, without Hydrocortisone
and Vitamin C and supplemented with 2% CS-FBS. Cell starvation was continued for 48 hour
prior to treatment. HUASMCs and HUVSMCs (both referred as SMCs) were seeded at10,000
cells/cm2 in complete SmGM-2 medium on a 96-well plate. After 24hrs they were cultured in
SmGM-2-starvation medium, containing CS-FBS and without insulin for 2 days. NHEMs were
seeded at 10,000 cells/cm2 in complete MGM-4 (Lonza#: CC-4435) medium on a 96-well plate.
Following a recovery period of 24 hrs, the medium was changed to MGM-4 starvation medium
(with CS-FBS, without insulin and hydrocortisone) for 2 days.
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C.3 TREATMENTS
Table C.1 shows the concentrations used for the each treatment. These were derived from the
Clinical Guidelines Mayo Clinic Reference Levels (http://www.mayomedicallaboratories.
com) and the CDC National Biomonitoring Report Reference Levels (http://www.cdc.gov/
biomonitoring/). Vehicle controls were included to represent the solvent used to prepare the
different treatments. Treatments were subdivided into two panels, each containing the appropriate
controls. For each treatment panel and cell type, cells derived from three individuals were treated
at the same time on a 96-well plate. A schematic of the study design is provided in Figure C.1. On
each plate, the control treatments were performed in triplicate. For all cell types except PBMCs
(cells grown in triplicates), cells were treated in duplicate (two plates per treatment panel) and
the two duplicates for each treatment sample were pooled prior to RNA isolation, to ensure that
enough RNA could be obtained. Because we were interested in early changes in the transcriptome,
cells were treated for six hours (no cell doublings).
C.4 RNA-SEQ LIBRARY PREPARATION
Treated cells were collected by centrifugation at 2000 rpm and washed 2x using ice cold PBS.
Collected pellets were lysed on the plate, using Lysis/Binding Buffer (Ambion), and frozen at -80◦.
Poly-adenylated mRNAs were subsequently isolated from thawed lysates using the Dynabeads
mRNA Direct Kit (Ambion) and following the manufacturer instructions. RNA-seq libraries were
prepared using a protocol modified from the NEBNext Ultradirectional (NEB) library preparation
protocol to use 96 Barcodes from BIOOScientific added by ligation, as described in (103). The
individual libraries were quantified using the KAPA real-time PCR system, following the manu-
facturer instructions and using a custom-made series of standards obtained from serial dilutions of
the phi-X DNA (Illumina).
C.5 TWO STEP HIGH-THROUGHPUT SCREENING APPROACH
We used a two step approach to gene expression analysis that we recently developed (103).
Briefly, in the first step all samples were experimentally processed in parallel, from tissue culture
and treatments to library preparation, thus minimizing experimental variation from testing dozens
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of conditions at the same time (Figure C.1). Additionally, high multiplexing allows for the reduc-
tion of the number of controls that would need to be repeated across different treatment batches in
a less multiplexed experimental setup (here 32 treatments plus 3 controls for each of three individ-
uals represented on a plate, see Figure C.1). A 96-library pooling and shallow sequencing strategy
(<10M reads per library, Table C.2) was then used to minimize the amount of resources used in
the screening step. This allowed for a rapid screen of a large number of treatment conditions, while
sequencing resources could be strategically allocated to the in depth analysis of relevant cases.
For the second step, we repooled a selection of the initial libraries (Section C.8.1, Figure 1B),
without additional experimental costs. Furthermore, using a two-step approach allowed us to re-
pool the samples to achieve a more uniform allocation of sequencing reads across samples (130M
reads/sample on average, Table C.4).
C.6 SEQUENCING
A flowchart of the 2-step sequencing procedure can be found in Figure C.2. Pools of 96 samples
from Step 1 were sequenced on two lanes of an Illumina HiSeq2500 in fast mode to obtain 50bp PE
reads, at the University of Chicago and at the Michigan State University Genomics Cores; or on one
lane of the Illumina NextSeq500 for 75 cycles PE in HO mode in the Luca/Pique-Regi laboratory.
To prepare subpools for deep sequencing (Step 2), we used the re-pooling approach described
in (103) which allows for iterative adjustments of pooling proportions in order to reach the desired
total number of reads through multiple re-pooling and sequencing runs. Step 2 resequencing was
performed on the NextSeq500 in the Luca/Pique-Regi laboratory. The number of reads collected
for each sample in step 1 and step 2 is reported in Table C.2 and Table C.4, respectively. We
collected 6.6 billion reads in step 1 (averaging 8.2 million reads per sample) and 33.5 billion
reads of deep sequencing data in step 2 (averaging 113 million reads per sample). Note that reads
from shallow sequencing (obtained during the first step) were not combined to the ones from deep
sequencing (second step) because of differences in read length.
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C.7 PRE-PROCESSING OF RNA-SEQ DATA
C.7.1 Sequence alignment
RNA-seq data for step 1 was processed as described in (103). Briefly, raw sequencing reads
were aligned to the hg19 human reference genome using bwa mem (90)(http://bio-bwa.
sourceforge.net). Reads with quality<10 and duplicate reads were removed using samtools
rmdup (http://github.com/samtools/). Read counts per sample after filtering steps can
be found in Table C.2.
For step 2, reads were aligned to the hg19 human reference genome using STAR (104)(https:
//github.com/alexdobin/STAR/releases, version STAR_2.4.0h1), which is a highly
efficient aligner that can handle split reads, and the Ensembl reference transcriptome (version 75).
To index the genome using the reference transcriptome, we used the following command:
STAR --runThreadN 12 --runMode genomeGenerate --genomeDir ./ \
--genomeFastaFiles hg19.fa --sjdbGTFfile ensembl75.gtf \
--sjdbOverhang 150
Alignment of the fastq files was then carried out using the following options:
STAR --runThreadN 12 --genomeDir <genome> \
--readFilesIn <fastqs.gz> --readFilesCommand zcat \
--outFileNamePrefix <stem> --outSAMtype BAM Unsorted \
--genomeLoad LoadAndKeep
where <genome> represents the location of the genome and index files, <fastqs.gz> represents
that sample’s fastq files, and <stem> represents the filename stem of that sample. For each sample
(individual cell line and treatment), merging of sequencing replicates (lanes and runs on the same
sequencer) and quality filtering was performed using samtools (version 2.25.0), using a quality
score cutoff of “10”, which corresponds to uniquely mapping reads. Note that different individuals
are never merged, and that independent library preparations (i.e., controls on separate plates) are
never merged.
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C.7.2 Sequence filtering
To correct for potential alignment biases, we used the WASP suite of tools for allele-specific
read mapping (105)(https://github.com/bmvdgeijn/WASP, downloaded 09/15/15). Note
that we do not use the WASP combined haplotype test (CHT) as we tested each SNP separately
using QuASAR (40). The objective of the WASP pre-processing is to keep reads that are not am-
biguously mapping to multiple places while considering all the known allelic variants contained
in the corresponding genomic location. Briefly, after a first step of alignment and quality fil-
ter, we used find_intersecting_snps.py to identify reads overlapping SNPs of interest
(see Section C.9.1 for details on which SNPs are used). To do this, we used the paired-end flag
and the default search window of 100,000 base pairs. Output fastqs generated by WASP, which
were modified to include reads matching reference and alternate bases when overlapping SNPs,
were then re-aligned using STAR as detailed before (see Section C.7.1). To recover reads that
mapped correctly (e.g., reads with reference and alternate allele mapping to same position), we
used filter_remapped_reads.py with the paired-end flag. Finally, reads that did not over-
lap SNPs were merged with the retained reads after filtering, and duplicates were removed using
WASP’s rmdup.py. Importantly, when we identified duplicate paired reads with the reference
and alternate allele, we randomly retained only one copy. Retained read counts per sample after
filtering can be found in Table C.4.
C.8 GENE EXPRESSION ANALYSIS
C.8.1 Differential gene expression
To identify differentially expressed (DE) genes, we used the method implemented in the soft-
ware DESeq2 (91) (R version 3.2.1, DESeq2 version 1.8.1). DESeq2 estimates variance-mean
dependence in the read counts for each gene and tests for differential expression based on a model
using the negative binomial distribution. Transcripts with fewer than 20 reads total on a given plate
were discarded. To better estimate the dispersion parameters, the DESeq2 model was fit on all se-
quencing data from a single plate simultaneously (i.e., all treatment samples, and without merging
the technical replicates of the control samples, see Figure C.1):
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Kij ∼ NB(µij, αij) (C.1)
µij = sjqij (C.2)
log2(qij) = βi,0 + βi,Cl(j) + βi,Tr(j) (C.3)
where, for each transcript i and sample j, the read counts Kij are modeled using a negative
binomial distribution with fitted mean µij and a gene-specific dispersion parameter αi. The fitted
mean is composed of a sample-specific size factor sj and a parameter qij proportional to the ex-
pected true concentration of fragments for sample j. The coefficient β0 represents the mean effect
intercept, βCl(j) represents the cell line effect (in our case one parameter for each of the 3 cell lines
in each plate), and βTr(j) represents the specific treatment/control effect (one parameter for each
treatment and vehicle control used in that plate).
We then contrasted the treatment effect parameter βTr(j) to the appropriate matched control
(βCO1, βCO2 or βCO3) using the default DEseq Wald test for each transcript, and a Benjamini-
Hochberg (BH) adjusted p-value was calculated with automatic independent filtering (DEseq2 de-
fault setting). DE genes were determined as genes with at least one transcript having a Benjamini-
Hochberg controlled FDR (92) (BH-FDR) of 10% and an absolute log2 fold-change value > 0.25.
The same procedure was used for step 1 and step 2.
A summary of differential expression for both steps can be found in Tables C.3, and C.5, and a
full set of differential expression results from step 2 can be found in Table C.6.
C.8.2 Summary of 1st step DE analysis.
In step one, we used shallow RNA-seq (8.2 million reads/sample on average, Table C.2) to
coarsely characterize global changes in gene expression. To identify differentially expressed (DE)
genes we used the method implemented in the software DEseq2 (91) using gene annotations from
Ensembl version 69, described in Section C.8.1 (Figure C.3, Table C.3). This global characteri-
zation of transcriptional responses showed that certain treatments induce gene expression changes
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across all cell types (e.g. dexamethasone, retinoic acid), while others have a cell type specific ef-
fect (e.g. vitamin B6 in PBMCs) (Figure 1B). Of the 50 treatments considered, 16 do not induce
strong changes in gene expression (defined here as >80 DE genes, 10% FDR, |logFC| >0.25) in
any cell type, while 8 result in strong gene expression changes across all cell types (dexametha-
sone, caffeine, tunicamycin, iron and manganese, vitamin D, aspirin, retinoic acid). Some of the
more extreme responses, such as those corresponding to manganese, were determined to be a toxic
response and were removed from any subsequent analysis.
C.8.3 Summary of 2nd step DE analysis.
32 treatment conditions with at least 80 DE genes from step one (see Section C.8.2) were
selected for deep sequencing. In addition, 12 treatment conditions with fewer than 80 DE genes
were chosen to confirm that treatments with a small response from the shallow sequencing data
similarly have a small response when deep sequenced. Overall, 297 samples (32 treatments and
3 controls across up to 5 cell types) were selected for repooling (Figure 1B, Table C.4). Gene
annotations from Ensembl version 75 were used, consisting of 204,940 transcripts corresponding
to 60,234 unique ENSG gene identifiers. Sequencing reads covering transcripts were counted using
bedtools coverage, using the -s and -split options to account for strandedness and for
BED12 input, respectively.
C.8.4 Transcript and gene level FPKM summarization for each individual sample.
To perform Principal Component Analysis, we calculated FPKMs for each sample (defined as
the combination of a single individual and a single treatment, e.g., dexamethasone in GM19239)
from the number of reads covering each transcript. To control for potential confounders, we fit the
following linear model:
log10(FPKMi + 1× 10−6) ∼ Si + Li + Si ∗ Li (C.4)
where for each transcript i, Si is the transcript GC content proportion, Li is the transcript length,
and Si ∗ Li is an interaction term between GC content and transcript length. The residual of the
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linear model, the GC-corrected log10 FPKMs are then quantile normalized within each individual.
For analyses at the gene level, expression of a single transcript was chosen to represent each
gene for each different cell type. The most highly expressed transcript (based on average expres-
sion across the cell type before quantile normalization) was selected from each gene to represent
the overall expression of that gene.
After quantile normalization log10 FPKMs were further corrected within each individual by
subtracting that individual’s average value per transcript across all treatments. This was calculated
after removing the top and bottom 10%-iles of data, usually referred to as 10% trimmed mean or
Tukey’s mean. The procedure is implemented in R “mean” function using the “trim=0.1” option.
C.8.5 Hierarchical clustering and PCA
Principal component analysis and hierarchical clustering was performed on a Pearson corre-
lation matrix using transcript FPKM values for all samples on a plate (i.e., three individuals of a
cell type treated with a single treatment panel, see Figure C.1). Note that the input data is quantile
normalized which makes Pearson correlation more similar to rank correlation in terms of robust-
ness to outliers. Heatmaps were produced on the same correlation matrices, with dendrograms of
Euclidian distance calculated using the “hclust” function with linkage “method=complete”.
Samples corresponding to the same treatment tend to cluster together, and all controls (CO1,
CO2, CO3) also cluster together (Figures C.4 - C.5). We see similar results when performing
hierarchical clustering (Figures C.4 - C.5). Specifically, treatments that elicit strong responses
cluster distinctly from control samples, and are often separated from other samples along the first
or second PC (for example, selenium in HUVECs, dexamethasone and aldosterone in SMCs, tuni-
camycin in melanocytes – see Figures C.6 and C.4). In contrast, treatments that don’t have a strong
response cluster close with the controls (e.g., B vitamins in PBMCs, Figures C.4 and C.6). We also
see clustering of treatments in biologically relevant ways. For example, in LCLs (Figure C.4), PC1
separates the controls from the metal ions (selenium and copper), while PC2 separates the controls
from nuclear receptor ligands (dexamethasone and vitamin A) and from caffeine. Finally, we also
observe good concordance with the differential gene expression results. For example, vitamin D
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elicits a strong response in PBMCs, but less so in HUVECs (Figure 1B). This is reflected in the
fact that in PBMCs, vitamin D clusters apart from other treatments (and furthest from the controls),
while in HUVECs, vitamin D clusters with the controls (Figures C.4, C.6).
C.9 ALLELE SPECIFIC EXPRESSION ANALYSIS
C.9.1 Core set of SNPs for analysis
To create a core set of SNPs for ASE analysis, we started with the autosomal 1KG SNPs from
the phase 3 release (v5b.20130502, downloaded on 08/24/15), and first removed SNPs with low
minor allele frequency (MAF < 5%). We also removed SNPs within regions of annotated copy
number variation and ENCODE blacklisted regions (39), leaving a total of 7,085,180 SNPs in the
core set.
C.9.2 Joint genotyping
Counts of reads covering each allele at selected SNPs (Section C.9.1) were obtained by “piling
up” aligned reads for each sample over SNPs using samtools mpileup and the hg19 human
reference genome. Reads with a SNP at the beginning or at the end of the read were also removed
to avoid any potential bias, as well as those within a reference skip (i.e., within a splice junction,
meaning the read does not actually cover the SNP). All sample pileups for a given individual across
all treatment conditions and the two treatment plates were processed together (not merged) using
the QuASAR package (40) for joint genotyping. For each individual, SNPs with less than 15
reads across all conditions were removed as the genotype would not be reliable. Compared to the
DEseq2 analysis, technical replicate libraries for the same vehicle controls and plate are merged
together.
To verify that none of the samples had been contaminated with reads from another individual
during library preparation, we compared the allele ratio, ρˆ, across samples processed at the same
time (based on our study design these are samples from the same cell type, see Figure C.1). The
allele ratio is indicative of the genotype, as it follows a trimodal distribution with peaks for ho-
mozygous reference and alternate, and heterozygous (40). For each cell type, we examined the ρˆ
for SNPs covered in each of the three individuals across all samples. For each cell type,the ρˆ values
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were correlated across the three individuals, and the resulting correlation matrix used to perform
PCA (Figure C.8). We expect the three individuals to group into three distinct clusters on the PCA
plot, in the absence of sample contamination or mix-up. This clustering is what we observe for all
samples, confirming that there is no cross-individual contamination.
C.9.3 ASE Inference
ASE inference was performed for each sample separately. Using read count and genotyping
data from Section C.9.2, heterozygous SNPs were tested for ASE using QuASAR. Briefly, all
heterozygous SNPs with a posterior probability of being heterozygous higher than 0.99 and a read
coverage >40 reads were selected. To account for overdispersion, we calculated the Ms hyper
parameter of the Beta-binomial model separately within bins of read coverage for each sample.
SNPs were separated into the following eight bins: [40, 50), [50, 60), [60, 80), [80, 100), [100,
250), [250, 500), [500, 1000), [1000, 100000). We noted that the overdispersion decreases (i.e.
M increases) corresponding to bins with more depth of coverage (Figure C.9). The inference step
takes into account the appropriate dispersion estimate for a given SNP’s coverage, technical noise
of that sample, and the genotyping uncertainty estimate (calculated in C.9.2), and tests for the
possibility that the allele ratio (ρ, or the proportion of reference reads to total reads) is different
than 0.5. At the same time it also gives an estimate of ρ in log-odds form, βˆ = log(ρ/(1− ρ)) that
can be interpreted as log(reference reads / alternate reads) while taking into account overdispersion
and genotyping error. We also obtain an estimate of the standard error for βˆ, that we can use for
downstream analyses of cASE. A summary of the amount of ASE detected in each sample is in
Figure C.10 and Table C.9. A full list of SNPs tested can be found in Table C.10.
To calculate a SNP-based expression and fold change (rather than gene-based, as in the FPKM
(Section C.8.4) and DESeq2 (Section C.8.1) methods), we first calculated the read coverage at
each SNP, adjusted by the sequence depth of the sample:
TPMij = Rij ∗ 106/Dj (C.5)
where the transcripts per million (TPM) for SNP i in sample j is calculated as the read coverage
156
Rij times 106, divided by the sequence depth of the sample, Dj . The average expression level at a
SNP is then calculated as the average between treatment T and control C samples:
Avg. TPM =
log2(TPMT ) + log2(TPMC)
2
(C.6)
Similarly, the SNP-based fold change was calculated as:
log2(FC) = log2(TPMT/TPMC) (C.7)
C.10 CONDITIONAL ASE ANALYSIS
Most of the ASE signal is shared between treatment and control for a given SNP (dots along
the y = x line in Figure 3D). However, there is evidence for SNPs showing ASE only in the control
(along the x-axis) or ASE only in the treatment condition (along the y-axis). These SNPs represent
candidates for conditional ASE (cASE): SNPs that display ASE only in certain environmental con-
ditions. Additionally, there is a large number of SNPs falling in the space comprised between the
y = x line and the axes. These SNPs may represent cases of shared-ASE with large overdispersion
or cases of cASE with quantitative differences in the genetic effect across conditions. In general
testing for differences in genetic effects across two conditions is particularly challenging as it im-
plies comparing two noisy measurements to determine whether they are different while taking into
account heterogeneity of the underlying true genetic effects.
This problem has been previously faced in the context of condition-specific eQTL mapping
(e.g. reQTL mapping and tissue-specific eQTL mapping) (15–19, 98, 99, 107, 109, 110, 144–146)
and some of the approaches developed can be broadly translated to applications for cASE analysis.
With regard to condition-specific eQTL mapping, three major approaches have been used so far:
i) independent eQTL calling and comparing p-values, ii) comparing summary statistics using a
meta-analysis approach that takes into account heterogeneity of the sub-groups, and iii) directly
modeling the interaction term using ANOVA or QTL mapping of the fold-change.
In the first approach, independent eQTL are determined in the two conditions analyzed, and
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the p-values for each SNP compared across conditions. The SNP is defined then as an eQTL only
in the condition with the lowest p-value (98). A major limitation of this approach is that higher p-
values may result from incomplete power in any of the conditions analysed. Another modification
of this approach is based on setting different FDR thresholds across conditions so that a SNP is
assigned to condition 1 if it has a very low FDR in that condition (e.g.<1%) and a very high FDR
in condition 2 (FDR>90%) (19).
The second class of approaches directly compares different eQTL configurations in a Bayesian
framework (17, 106) and incorporates in the model heterogeneity in the effect sizes between the
groups contrasted. This class of models also defines the genetic effect of the response eQTL in a
strict on/off mode between the groups compared.
Finally the third class of approaches uses a linear model with an interaction term to directly
test for gene-by-environment interactions at a given gene and SNP (18), and has been also recently
applied to GxE analysis with ASE data (102). This class of approaches includes eQTL mapping
of gene expression log-fold change calculated across the two conditions tested (17, 19, 147). As
opposed to the Bayesian approaches they do not provide information on the specific eQTL config-
uration, they theoretically allow capturing any type of eQTL configuration, although they have the
greatest power for eQTLs with opposite genetic effects in the two conditions tested and may be
confounded with increased group heterogeneity.
To test for cASE, here we used two methods that belong to the classes of approaches described
in 2 and 3 above. The first one is MeSH (Meta-analysis of Subgroup Heterogeneity), which iden-
tifies qualitative GxE interactions. We also developed a test for cASE that compares the evidence
for ASE in the treatment to ASE in the control using the βˆ estimates from QuASAR directly, thus
identifying quantitative GxE interactions. We refer to this second method as ∆AST, Differential
Allele-Specific Test.
C.10.1 Meta-analysis of subgroup heterogeneity (MeSH)
When testing for genetic associations such as cASE, it is important to consider subgroup het-
erogeneity. Specifically, a joint analysis that allows for heterogeneity can yield stronger signals
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than analyzing each subgroup separately. Here, we used MeSH to model potentially heteroge-
neous cASE effects across multiple subgroups contained within the data. MeSH uses a Bayesian
approach to contrast 4 possible configurations: no ASE in either the treatment or the control, ASE
in both the treatment and the control (“shared ASE”), ASE in the treatment only, and ASE in the
control only, the latter two categories being cASE. To detect qualitative differences in the ASE sig-
nal between treatment and control samples, we used a modified version of MESH that quantifies
the amount of heterogeneity in the genetic effect across pairs of conditions. The input to MeSH is
a pair of ASE observations derived from QuASAR summarized by the the parameter β measuring
the allelic imbalance and a standard error of the parameter. In our case, for each heterozygous
SNP and individual, we pair the ASE observed in a treatment with the corresponding vehicle con-
trol on the same individual and plate. This results in 763,762 QuASAR ASE treatment/control
measurement pairs (31,214 unique heterozygous SNPs). MeSH then uses a hierarchical model to
characterize the ASE effects β and the heterogeneity across all observations. Then, a Bayes factor
is derived contrasting each of the configurations that assume ASE in at least one of the conditions
to the configuration with no ASE in either condition as baseline. Specifically, BFtreatment con-
trasts the evidence for βt 6= 0, βc = 0 to βt = 0, βc = 0; BFcontrol contrasts the evidence for
βt = 0, βc 6= 0 to βt = 0, βc = 0, and BFshared contrasts the evidence for βt 6= 0, βc 6= 0 to
βt = 0, βc = 0. To look specifically at conditional ASE, a Bayes factor for cASE is calculated
as BFtreatment −BFshared (treatment-only cASE) and BFcontrol −BFshared (control-only cASE).
SNPs with cASE are then identified as SNPs with BFcASE > 30.
C.10.2 ∆AST: A novel method to measure cASE
The cASE models tested in MESH assume extreme ASE differences between treatment and
control. However, extreme on/off cases of ASE may not be the only relevant ones as cASE may
also exist where the genetic effect (β) differs to a significant degree between treatment and control
(βT −βC 6= 0) but is non-zero in both conditions. To capture cASE genes that may not fit perfectly
to the models tested by MESH, we developed an alternative approach named ∆AST to identify
quantitative differences in the ASE ratios between treatment and control. Differential Z-scores
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(Z∆) were calculated from QuASAR betas using the following formula. For each SNP,
Z∆ =
βT − βC√
se2T + se
2
C
(C.8)
where βT and seT represent the beta and standard error estimates for the treatment condition,
and βC and seC represent the beta and standard error estimates for the control condition. The
Z∆ scores were then normalized by the standard deviation across Z∆ scores corresponding to
control vs control (CO1 vs. CO2). Finally p-values (p∆) are calculated from the Z∆ scores as
p∆ = 2×pnorm(−|z|). Under the null, Z∆ are asymptotically normally distributed and Figure 3E
shows that when contrasting the two sets of controls the p∆-values are almost uniformly distributed
as expected. To further correct for this small deviation we use the control vs. control p-values to
empirically estimate the FDR as detailed in the following section.
C.10.3 Empirical estimation of the cASE false discovery rate
For ∆AST analysis of cASE, we were also able to take advantage of our study design that
includes at least two pairs of vehicle controls per individual (CO1 and CO2) in each treatment
plate. This allowed us to apply our statistical methods to a subset of control data, contrasting
within each individual and plate the two controls (CO2 to CO1), and to empirically determine the
false discovery rate (FDR) or to recalibrate the p-values. This is very similar to a permutation
procedure to estimate the p-value in eQTL studies. Permuting read assignments in ASE studies
may not recapitulate the overdispersed nature of the allelic imbalances and there is a small number
of permutations possible across individuals. Nevertheless, in our experimental design, contrasting
the two control samples could be used to empirically reveal the underlying null distribution similar
to the permutation based approaches that are possible in QTL studies with big sample sizes.
To this end, we ran ∆AST analysis on 120,273 SNPs, contrasting the two controls (CO2 to
CO1) as we did for any of the treatments to its matched control (Tx to CO1 or Tx to CO2). To focus
on actual false positives, we removed 8,040 control SNPs with a SNP-based log2( fold change ) >
1 (see Section C.9.3) in the CO2 versus CO1) comparison (see Table C.12 for results of the CO2 vs
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CO1 analysis). For our test statistics for cASE (i.e., Z∆), we can observe the empirical distribution
obtained when contrasting the two sets of controls. This empirical distribution represents a sample
from the null distribution. Using this empirical distribution we can then derive a corrected p-value
based on the ranks observed in the control vs. control (this is exactly the same as in a permutation
based approach). After calculating the corrected p-values derived from Z∆, we applied multiple
test correction using the q-value method (41).
We identified 67 cASE SNPs using the ∆AST method, corresponding to an FDR of 10%. When
we relax the FDR threshold (25%), we find a total of 178 cASE SNPs (corresponding to 160 unique
genes), of which 68 SNPs are identified also with MeSH. The list of significant cASE SNPs is in
Table C.11 (also see Figure 4). Of the 31 genes with dexamethasone reQTLs previously identified
in 116 LCL and 88 PBMC samples (16, 17) and tested in our dataset, here we validated 21 genes
with cASE (p <0.05), 6 of which in response to dexamethasone, including the population-specific
reQTL gene NQO1 (p = 0.03).
When we considered all cASE SNPs, we observed a significant positive correlation between the
gene expression log2(fold change) after treatment and differences in the genetic effect in treatment
and control samples (Pearson’s r = 0.204, p-value = 0.038, Figure 5A) . However, we observed a
negative correlation between gene expression levels and the difference in the genetic effect in the
treatment and the control samples (Pearson’s r = -0.381, p-value = 6.7×10−5, Figure 5B).
C.10.4 Analysis of environmental displacement of genetic effects (EDGE)
In addition to characterizing significant differences in the allelic ratio parameters (β) between
treatment and control to determine cASE, we also characterized how correlated they are across all
heterozygous sites. This correlation measures the consistency of the genetic effect between the
treatment and control, and therefore a lower correlation indicates a higher perturbation or displace-
ment of the genetic effects, in our case the ASE β parameters estimated by QuASAR. Within each
treatment and cell line subgroup, we examined the Pearson’s correlation of the treatment standard-
ized effect size (ASE ZT=βT/seT ) to the matched control one (ASE ZC=βC/seC). To make the
measurement more comparable across environments, we normalized the treatment-control correla-
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tion to the correlation observed between the two controls (CO1 and CO2) as measured within the
same cell type (see Figure C.15A-B). Formally, we define this as the environmental displacement
of genetic effect (EDGE) index:
EDGEs,t =
Pearson(Zs,CO1, Zs,CO2)
Pearson(Zs,t, Zs,c)
(C.9)
where Pearson(Zs,t, Zs,c) is the sample Pearson correlation coefficient between treatment t and con-
trol c ASE Z-scores across all observed SNPs in cell type s. Equivalently, Pearson(Zs,CO1, Zs,CO2)
is the Pearson correlation coefficient between the two controls sets ASE Z-scores across all ob-
served SNPs in cell type s. These values can be found in Figure C.15C, Figure C.16, and Table
C.14.
We also asked whether the EDGE index was fully explained by the SNPs with significant
cASE. While the EDGE index and the proportion of tests with cASE are very well correlated
(see Figure C.15C), removing significant SNPs did not substantially alter the EDGE index (Figure
C.17) indicating that there may remain a similar fraction of cASE SNPs with a smaller effect size
that we are not able to detect and a higher coverage may be necessary.
C.10.5 Identification of induced ASE
Conditional ASE analyses require that for both treatment and control conditions the SNP has a
sufficiently high coverage (Section C.9.3), resulting in the somewhat implicit requirement that the
gene containing that SNP is expressed both in treatment and control conditions. However, many
genes may have very low expression levels for the control condition and very high expression
with ASE in the treatment. In other words, the expression of these genes would be induced by
a specific treatment. For these cases, ASE in the control condition is not well defined, as it is
exemplified in the extreme case where 0:0 reads are counted for both alleles. We denote this type
of phenomenon as induced ASE (iASE), which are cases when the ASE can only be observed
in genes that are induced by the treatment. Genes with iASE may be as interesting as genes
with cASE and would probably be missed by studies that only consider baseline eQTLs or ASE.
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Physiologically, the iASE allele with high expression may exceed the threshold for a downstream
effect on an observable cellular or organismal phenotype that may only manifest in a particular
environmental condition.
To identify genes with iASE, we selected SNPs that were well covered in the treatment (i.e.,
>40 reads) and had ASE (10% FDR) but had little to no expression in the matched control. We used
a coverage threshold in the control of 10× (DC/DT ), where DC and DT represent the sequencing
depth of the control and treatment libraries, respectively in TPM (see Section C.9.3). This equates
to a ratio of 40 reads to 10 (expression in the control is 4-fold lower than the minimum required for
a gene to be considered expressed in the ASE analysis), while accounting for sequencing depth dif-
ferences. Finally, we required the SNP-based log2( fold change) (Section C.9.3) to be greater than
log2( 5 ). This threshold represents a strong difference between treatment and control expression,
corresponding to the 0.13 percentile of fold change values for all SNPs tested for cASE. Using this
criteria, of 6,817 SNPs with ASE in 2,868 genes not expressed at baseline, we identified 75 iASE
SNPs (10% FDR) corresponding to 60 unique genes (Table C.15).
C.10.6 Analysis of SNPs in the GWAS catalog
We downloaded the GWAS catalog (117) (version 1.0.1) on January 5th, 2016. To identify
the overlap between our annotations and those associated with a GWAS trait, we intersected the
unique genes of interest from our data with the reported genes from the GWAS catalog. Of the
genes expressed in our dataset, 32,451 genes are differentially expressed in at least one treatment
condition while 7,734 genes are not. 22% of DE genes (7,010 genes) are identified in the GWAS
catalog while only 4% of non-differentially expressed genes (292 genes) are previously reported in
the GWAS catalog. Using a Fisher’s exact test on a 2x2 contingency table, we found an enrichment
of DE genes among the genes reported to be associated with a trait in the GWAS catalog (p <
2.2× 10−16, OR = 7.0).
We further studied whether we find an enrichment of genes containing cASE or iASE among
genes associated with organismal traits. Of the 215 genes that contain iASE or cASE, 105 genes
(49%) were found in the GWAS catalog. When compared to DE genes (after removing genes
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that contain either iASE or cASE, 6,906 were found in GWAS while 25,331 were not) using a
Fisher’s exact test, we found a significant enrichment of iASE/cASE genes among GWAS genes
(p < 2.2× 10−16, OR = 3.5). We also found that when compared to genes with ASE (not iASE or
cASE), genes containing iASE or cASE have 1.4 higher odds to be relevant for complex traits (p
= 0.025).
To assess our results relevant to other studies, we compared our iASE and cASE genes to
eGenes, genes associated with an eQTL, from the GTEx study (137). 194 iASE or cASE genes
were also found to be eGenes leaving 26,899 eGenes without evidence of GxE in our study. We
found, again, that iASE and cASE genes were enriched among genes associated with organis-
mal traits with 50% in the GWAS catalog (97 genes) as compared to 24% eGenes (6,419 genes)
(Fisher’s exact test, p = 4.3 × 10−15, OR = 3.2). We also repeated these enrichment analyses
excluding the iASE cases, but we essentially obtain the same odd ratios and with a significant
enrichment for cASE genes.
C.10.7 Examples of cASE/iASE in GWAS genes with a biological connection
One example of iASE that occurs following treatment with caffeine is in the gene GIPR asso-
ciated with obesity-related traits (124–131). Previous studies have shown that caffeine can help
prevent or treat obesity (121–123). This iASE links the effect of caffeine to obesity through GIPR.
The direction of the effect, with the low-BMI allele being in phase with the high expression allele,
is in agreement with a study showing that GIPR expression is lower in obese patients (148). An-
other example of iASE occurs at rs4619 in IGFBP1 following dexamethasone treatment. IGFBP1
is a gene that interacts with insulin-like growth factors and promotes cell migration. IGFBP1 has
also been associated with rheumatoid arthritis and major depressive disorder in genome wide as-
sociation studies (149, 150). These two disorders are seemingly unrelated until we consider that
dexamethasone is a drug often used to alleviate rheumatoid arthritis (151, 152) while glucocorti-
coids are often misregulated in depression (153–155). Here, our data suggests that IGFBP1 may be
associated with these very different phenotypes because it participates in one of the glucocorticoid
response pathways.
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We identified cASE following copper treatment at rs7587 in SAMM50, a gene associated with
liver enzyme levels and non-alcoholic fatty liver disease (156–160). Reduced copper levels is as-
sociated with non-alcoholic fatty liver disease and severe hepatic steatosis (161, 162). Our data
suggest that copper facilitates these liver responses through modulation of allele-specific expres-
sion in SAMM50. A missense SNP (rs17482078) in ERAP1 showed cASE in response to selenium
treatment. This SNP is associated with Behçet’s disease (163), an autoimmune disorder. Individu-
als with Behçet’s disease have lower selenium levels (164). Another example of cASE was identi-
fied at rs189899 in the gene, GOSR2, following treatment with mono-n-butyl phthalate. GOSR2 is
associated with blood pressure regulation (165,166). As phthalate exposure is also associated with
increased blood pressure (167), phthalate may influence blood pressure through ASE modulation
in GOSR2.
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Table C.1: Treatments used for analysis. The control shown for each treatment is the vehicle used to dilute it.
For example, dexamethasone was a powder resuspended in EtOH, so we used EtOH as control for the dexamethasone
treatment. Note that we also matched the concentration of the vehicle used. In the case of all the treatments with EtOH
as control, both the treatment and the control wells received 1ul of EtOH per 10,000µL of culturing media. “In range”
denotes whether the treatment concentration matches physiological levels in the blood (within 10x), as indicated by
Mayo Clinic or the Center for Disease Control. When this information was not available, we used literature reports
and we indicate the relevant PMID.
Treatment ID Common Name Control Treatment Concentration Physiological Concentration
T1C1 Vitamin C Media 1.00× 10−5M Yes
T2C1 Vitamin H Media 4.75× 10−10M Yes
T3C1 Vitamin B3 Media 1.50× 10−5M Yes
T4C1 Vitamin B5 Media 1.00× 10−7M 15539319
T5C1 Vitamin B6 Media 1.00× 10−5M Yes
T6C1 Vitamin A Ethanol 1.00× 10−8M 21307853
T7C1 Vitamin E Ethanol 5.00× 10−5M Yes
T8C1 Vitamin K3 Ethanol 1.00× 10−6M 21134493
T9C1 Aldosterone Ethanol 1.00× 10−5M No (2,000x higher)
T10C1 Progesterone Ethanol 1.00× 10−5M No (11x higher)
T10C2 Progesterone DMSO 1.00× 10−6M Yes
T11C1 Estrogen Ethanol 1.00× 10−5M No (1,000x higher)
T12C1 Dexamethasone Ethanol 1.00× 10−5M 21750684
T13C1 Caffeine Media 1.16× 10−3M No (15x higher)
T14C1 Nicotine Media 6.16× 10−4M 12194923
T15C1 Copper Media 6.00× 10−5M Yes
T16C1 Iron Media 5.00× 10−3M 18050301
T16C2 Iron Media 1.00× 10−5M Yes
T17C1 Manganese Media 3.00× 10−3M No (200,000x higher)
T17C2 Manganese Media 1.5× 10−8M Yes
T18C1 Molybdenum Media 5.00× 10−4M 18050301
T19C1 Selenium Media 1.00× 10−5M Yes
T20C1 Zinc Media 8.00× 10−5M Yes
T21C1 Tunicamycin DMSO 2 µg/mL 18704925
T22C1 PM 2.5 Media 5 µg/mL 23573366
T23C1 Vitamin D Ethanol 1.00× 10−7M Yes
T24C1 Acrylamide Media 2 ng/mL Yes
T25C1 BP-3 Ethanol 1000 ng/mL Yes
T26C1 BPA Media 20 ng/mL Yes
T27C1 Cadmium Media 2 ng/mL Yes
T28C1 CCl3 Media 0.100 ng/mL Yes
T29C1 PFOA Media 15 ng/mL Yes
T30C1 Triclosan Ethanol 1200 ng/mL Yes
T32C1 Vitamin B9 Media 250 ng/mL Yes
T33C1 Insulin Media 1004.6 ng/mL No (1000x higher)
T34C1 Glucagon Media 0.650 ng/mL Yes
T35C1 Oxytocin Media 10.07 ng/mL 16778082
T36C1 Vasopressin Media 0.0017 ng/mL Yes
T37C1 Acetylcholine Media 293.9 ng/mL 3801213
T38C1 Glucose Media 1800 ng/mL Yes
T39C1 MSG Media 93 µg/mL 10644540
T40C1 BHA Ethanol 0.2 µg/mL Yes
T41C1 Ibuprofen Ethanol 5 µg/mL Yes
T42C1 Acetaminophen Media 50 µg/mL Yes
T43C1 Aspirin Ethanol 10 µg/mL Yes
T44C1 Loratadine Ethanol 50 ng/mL 2965043
T45C1 Cetirizine Media 10 ng/mL 15025737
T46C1 Dextromethorphan Media 6 ng/mL Yes
T47C1 Phthalate Ethanol 100 ng/mL Yes
T48C1 Cholesterol Ethanol 2400 ng/mL Yes
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Table C.2: Summary of shallow sequencing. Plate ID, Cell Type, Cell Line, Barcode ID (see Section C.4),
Treatment ID (see Table C.1), Total reads (total number of reads sequenced), Aligned reads (number of reads
after initial alignment), Quality reads (number of reads passing quality filtering), Clean reads (number of
reads after duplicate removal).
See attached file, Supplemental_Table_S2.xlsx, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S2.xlsx
Table C.3: Number of differentially expressed genes identified by shallow sequencing. For each treat-
ment, shown is the number of differentially expressed genes for each cell type at 10% BH-FDR, with an
|logFC| > 0.25. Differentially expressed genes are determined by contrasting a treatment with its matched
control.
See attached file, Supplemental_Table_S3.xlsx, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S3.xlsx
Table C.4: Summary of deep sequencing. Total reads, total number of reads sequenced. Aligned reads,
number of reads after initial alignment. Quality reads, number of reads passing quality filtering. Clean
reads, number of reads after allele-specific read mapping and duplicate removal via WASP.
See attached file, Supplemental_Table_S4.xlsx, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S4.xlsx
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Table C.5: Number of differentially expressed genes identified by deep sequencing. For each treatment,
shown is the number of genes tested (“All”), the number of differentially expressed genes in each cell type
at 10% BH-FDR, with an |logFC| > 0.25, and the number of differentially expressed genes (DEG) both up-
and downregulated relative to the control. DEG are determined by contrasting a treatment with its matched
control. Included is also the number of DEG when contrasting Control 1 versus Control 2 in each plate
separately.
See attached file, Supplemental_Table_S5.xlsx, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S5.xlsx
Table C.6: Differentially expressed genes across treatments and cell lines. For each cell type/treatment
combination, given is the Ensembl transcript ID, DESeq2 p-value for differential expression, BH-adjusted
p-value for differential expression, log2 fold-change relative to the control, Ensembl gene ID, and Ensembl
gene name.
See attached files, Supplemental_Table_S6.tar.gz, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S6.tar.gz
Table C.7: Module assignments for network genes.
See attached file, Supplemental_Table_S7.xlsx, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S7.xlsx
Table C.8: Z-scores for module-treatment combinations. For each module, listed is the t-score for the
treatments in the cell type indicated. Also included for each module is the number of genes, the assigned
treatment (based on the highest average t-score across cell types), the number of heterozygous and ASE
SNPs in genes within the module, and the proportion of ASE to heterozygous SNPs in genes within the
module.
See attached file, Supplemental_Table_S8.xlsx, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S8.xlsx
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Table C.9: Summary of ASE in deep sequenced samples. For each treatment (row) and individual
(columns), listed is the number of ASE SNPs at 10% FDR, with the total number of heterozygous SNPs
tested in parentheses.
LCL HUVEC PBMC Mel SMC
Ind 1 Ind 2 Ind 3 Ind 1 Ind 2 Ind 3 Ind 1 Ind 2 Ind 3 Ind 1 Ind 2 Ind 3 Ind 1 Ind 2 Ind 3
Media 95
(10726)
94
(9355)
96
(9494)
95
(10536)
98
(10213)
115
(11330)
116
(10715)
128
(11943)
111
(10874)
90
(9325)
103
(10154)
112
(8520)
79
(7625)
85
(7725)
77
(7976)
Ethanol 107
(11874)
115
(12229)
118
(12474)
84
(10882)
89
(9667)
89
(10105)
125
(10145)
142
(12401)
108
(9785)
110
(9940)
113
(9884)
106
(8352)
90
(8369)
71
(8049)
66
(7805)
DMSO 31
(3364)
38
(3482)
39
(3120)
Dexamethasone 17
(3561)
24
(3908)
48
(4062)
25
(3822)
34
(4500)
44
(4561)
42
(3531)
42
(4308)
42
(3774)
32
(3239)
27
(2653)
31
(2980)
38
(3655)
33
(3666)
56
(5609)
Caffeine 13
(3265)
19
(4225)
33
(3600)
21
(4460)
29
(4539)
29
(4887)
43
(3736)
31
(4034)
34
(4080)
21
(2506)
23
(2702)
27
(2718)
42
(3683)
29
(3542)
32
(3797)
Nicotine 25
(3524)
22
(3330)
35
(3522)
Copper 32
(4153)
33
(3648)
21
(3807)
39
(3601)
28
(3954)
36
(3846)
Iron (C1) 29
(3489)
29
(3379)
24
(3213)
Molybdenum 36
(4440)
20
(2605)
28
(4407)
37
(3432)
30
(3316)
30
(3356)
40
(3937)
34
(3820)
73
(6650)
Selenium 12
(3154)
31
(3741)
26
(3273)
33
(5133)
38
(4580)
31
(4126)
11
(1872)
15
(2370)
39
(3313)
49
(3986)
34
(4229)
34
(3585)
Zinc 34
(3228)
34
(3950)
41
(4042)
Tunicamycin 15
(2336)
20
(2813)
39
(3792)
Vitamin D 31
(4196)
29
(4533)
32
(4610)
13
(2222)
21
(3170)
7
(1345)
20
(3120)
25
(3744)
49
(3572)
39
(3405)
31
(3659)
31
(4022)
Acrylamide 32
(4047)
57
(4781)
40
(3611)
63
(5681)
79
(6535)
68
(6829)
42
(4629)
44
(4410)
43
(4983)
BP-3 48
(4941)
54
(5030)
34
(4529)
54
(4769)
33
(4001)
33
(4107)
BPA 32
(3631)
37
(3584)
31
(3336)
45
(4592)
40
(4154)
37
(3627)
Cadmium 20
(2630)
26
(3524)
29
(4081)
32
(3746)
43
(4303)
44
(3988)
PFOA 23
(3752)
28
(3663)
31
(3670)
50
(4989)
21
(3015)
35
(4305)
Vitamin H 40
(3390)
32
(3786)
37
(3560)
Triclosan 38
(4430)
64
(6267)
35
(4224)
38
(4756)
37
(4411)
38
(3726)
37
(3882)
51
(4251)
44
(4820)
Insulin 38
(4257)
32
(4097)
33
(4063)
34
(4582)
40
(4369)
50
(4866)
48
(4681)
40
(4113)
41
(4745)
Acetyl Choline 31
(4337)
24
(3175)
37
(3583)
Vitamin B3 41
(3361)
23
(2603)
38
(3840)
BHA 34
(4278)
65
(6326)
35
(4605)
27
(2605)
31
(3221)
24
(2648)
31
(3903)
50
(4627)
41
(4393)
Ibuprofen 40
(4566)
46
(4716)
43
(4293)
Acetaminophen 27
(3793)
29
(3418)
40
(3793)
30
(3689)
31
(4389)
55
(4651)
59
(5735)
38
(4252)
37
(4240)
Aspirin 28
(3484)
26
(2855)
38
(3627)
41
(4064)
54
(4853)
42
(4967)
27
(3224)
38
(3778)
33
(3254)
32
(4142)
60
(5924)
35
(2585)
37
(4486)
43
(4222)
41
(3996)
Loratadine 30
(3739)
41
(3404)
50
(4981)
39
(4357)
33
(4610)
41
(3858)
Cetirizine 24
(3826)
20
(2151)
32
(3548)
Phthalate 27
(3698)
28
(3432)
31
(3695)
30
(4118)
52
(4872)
36
(4485)
24
(3248)
26
(3184)
42
(4117)
23
(3474)
38
(4756)
53
(4754)
Vitamin B5 41
(3513)
28
(3767)
33
(3402)
28
(2510)
32
(3628)
33
(4025)
Vitamin B6 47
(3386)
31
(4153)
27
(3297)
25
(2960)
35
(3597)
40
(4021)
Vitamin A 27
(3885)
28
(4636)
34
(4458)
11
(2420)
38
(4649)
34
(4591)
50
(3980)
26
(3531)
29
(3590)
28
(2820)
16
(2454)
41
(3500)
35
(3589)
37
(3343)
44
(4565)
Vitamin E 45
(3691)
35
(3565)
24
(2818)
28
(3124)
25
(3336)
33
(3147)
Aldosterone 45
(4517)
36
(3403)
38
(4005)
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Table C.10: ASE results for all SNPs tested. All heterozygous SNPs covered by at least 40 reads are
listed, along with the cell type and treatment condition. Also listed are the number of reads covering the
reference and alternate alleles, the ASE βˆ, standard error, p-value from QuASAR, and the q-value.
See attached file, Supplemental_Table_S10.txt.gz, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S10.txt.gz
Table C.11: SNPs displaying conditional ASE. For each cASE SNP, listed is the SNP rsID, cell type, gene,
treatment, the ∆AST Z-score, empirical p-value, and q-value, the MeSH control-only BF, and the MeSH
treatment-only BF. Significant cASE is defined as having q-value < 0.24 (24% FDR) from at least one of
the tests.
rsID Cell
Type
Gene Treatment Z∆ Z∆ correctedp-
value
Z∆ q-value MeSH CBF MeSH TBF
rs9069 LCL RAB4A Selenium 5.547 2.91E-08 0.091 -5.931 -2.961
rs16926021 LCL KIAA1279 Copper -4.405 1.06E-05 0.249 -0.286 3.500
rs4980895 LCL CCDC77 Dexamethasone -4.653 3.27E-06 0.224 3.286 0.264
rs17521586 LCL AKAP11 Caffeine -5.120 3.06E-07 0.091 0.492 4.635
rs11699 LCL TMCO3 Selenium -5.260 1.44E-07 0.091 -0.426 2.063
rs17103743 LCL KHNYN Vitamin A -5.142 2.72E-07 0.091 2.829 -5.724
rs11620816 LCL HECTD1 Caffeine -4.553 5.28E-06 0.224 -0.325 4.071
rs7167612 LCL TRIP4 Selenium 5.478 4.30E-08 0.091 0.366 4.345
rs12929100 LCL SMG1 Selenium -4.637 3.53E-06 0.224 2.144 2.188
rs1801635 LCL PITPNA Caffeine 5.265 1.40E-07 0.091 0.297 3.806
rs77903511 LCL AC087645.1 Caffeine -5.182 2.19E-07 0.091 -3.889 -11.855
rs9303891 LCL USP14 Selenium -5.351 8.75E-08 0.091 -0.619 2.195
rs1055002 LCL VPS4B Selenium -4.377 1.20E-05 0.249 -0.568 2.680
rs17072146 LCL SERPINB10 Selenium 4.417 1.00E-05 0.249 0.644 3.081
rs7247504 LCL STAP2 Caffeine 4.915 8.89E-07 0.091 1.447 2.959
rs17028275 LCL VPS54 Caffeine -6.113 9.77E-10 0.091 -0.616 3.111
rs77388906 LCL C1D Vitamin A -4.403 1.07E-05 0.249 -7.380 -27.925
rs1878583 LCL SLC25A12 Copper 4.435 9.21E-06 0.244 1.981 2.114
rs7587 LCL SAMM50 Copper -4.705 2.54E-06 0.208 -0.486 4.110
rs3773713 LCL SSR3 Caffeine 5.934 2.96E-09 0.091 -18.250 -9.325
rs16833703 LCL LAMP3 Selenium 4.411 1.03E-05 0.249 1.505 1.909
rs693758 LCL PHACTR1 Dexamethasone -4.498 6.87E-06 0.224 1.240 2.609
rs2269978 LCL SCRN1 Caffeine -4.414 1.02E-05 0.249 0.117 3.810
rs1043615 LCL DNAJB9 Vitamin A -4.612 3.98E-06 0.224 2.365 2.066
rs16904746 LCL PHF20L1 Copper -4.956 7.19E-07 0.091 -0.083 3.917
rs10964471 LCL SMARCA2 Copper 5.560 2.69E-08 0.091 0.292 4.658
rs1053959 LCL PTGR1 Selenium 5.073 3.92E-07 0.091 -11.511 3.055
rs1053959 LCL PTGR1 Caffeine 4.970 6.71E-07 0.091 -8.299 2.507
rs1065675 SMC NUP133 Triclosan -4.599 4.25E-06 0.224 2.441 2.080
rs1829556 SMC WNT5A PFOA 4.428 9.53E-06 0.249 1.070 3.003
rs2274136 SMC NUP153 BPA 4.495 6.94E-06 0.224 2.860 1.576
rs945508 Mel ARHGEF11 Tunicamycin -4.696 2.65E-06 0.208 1.599 3.019
rs2277300 Mel OSBPL5 Vitamin D -4.466 7.99E-06 0.224 1.442 2.584
rs3742722 Mel CEP128 Selenium -5.471 4.49E-08 0.091 2.506 3.707
rs3815820 Mel BANP Tunicamycin -4.440 8.99E-06 0.244 1.969 2.349
rs3088016 Mel CCDC137 Dexamethasone -4.397 1.10E-05 0.249 -0.644 3.293
rs112976362 Mel ADNP2 Vitamin D 4.483 7.35E-06 0.224 1.640 2.505
rs2229259 Mel ECH1 Tunicamycin -4.901 9.53E-07 0.091 1.624 3.654
rs2304802 Mel TMA16 Tunicamycin -5.045 4.53E-07 0.091 -0.357 4.635
rs17482078 Mel ERAP1 Selenium -4.402 1.07E-05 0.249 1.739 2.347
rs221790 Mel GIGYF1 Vitamin E 4.704 2.55E-06 0.208 -2.867 3.750
rs1127635 Mel STXBP3 BHA 4.405 1.06E-05 0.249 -0.221 3.242
rs823137 Mel RAB7L1 Acetaminophen 4.462 8.13E-06 0.244 1.239 -6.282
rs8946 Mel BAG3 Phthalate 4.997 5.83E-07 0.091 -8.535 -8.497
rs11025310 Mel NAV2 Loratadine 5.947 2.73E-09 0.091 0.877 5.392
rs35216474 Mel PAMR1 Aspirin -5.298 1.17E-07 0.091 0.711 -10.708
rs4752904 Mel PTPRJ Acetaminophen -5.490 4.02E-08 0.091 0.469 4.987
rs4414223 Mel SNX19 Acetaminophen 5.014 5.34E-07 0.091 1.417 3.583
rs10844253 Mel FGD4 Acetaminophen 4.391 1.13E-05 0.249 2.708 1.553
rs1298463 Mel ZFC3H1 Acetaminophen 4.775 1.80E-06 0.208 3.790 -0.088
rs177393 Mel PAPLN Ibuprofen -4.454 8.44E-06 0.244 3.397 -0.870
rs903160 Mel SMG6 Aspirin 4.700 2.61E-06 0.208 3.350 0.695
rs1071705 Mel NUP88 Ibuprofen -4.636 3.56E-06 0.224 4.073 -0.987
rs2279103 Mel CTDP1 Loratadine -5.204 1.95E-07 0.091 1.590 3.739
rs56076827 Mel IFT172 Phthalate 4.435 9.22E-06 0.244 -1.399 3.427
rs2285365 Mel PLXND1 Loratadine 4.507 6.58E-06 0.224 2.852 -3.341
rs1048145 Mel NCK1 Phthalate 4.409 1.04E-05 0.249 0.096 3.288
rs79940815 Mel AC024560.3 Phthalate 4.679 2.88E-06 0.224 -3.378 3.628
rs11762014 Mel TECPR1 BHA 5.211 1.88E-07 0.091 0.267 4.214
rs13277646 Mel UBXN2B BHA -4.614 3.96E-06 0.224 2.073 2.706
rs8507 Mel ZER1 Aspirin -4.497 6.89E-06 0.224 0.892 3.090
rs6661946 HUVEC HEATR1 Vitamin A 4.501 6.78E-06 0.224 -0.012 3.166
rs3209896 HUVEC AKR1C3 Selenium -5.405 6.49E-08 0.091 2.526 -9.749
rs11552445 HUVEC COMMD3-
BMI1
Caffeine -4.508 6.53E-06 0.224 -1.210 4.013
rs11556066 HUVEC TWF1 Caffeine -4.800 1.59E-06 0.177 -2.950 4.085
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rs6580942 HUVEC ESPL1 Dexamethasone 5.179 2.23E-07 0.091 0.632 3.903
rs61730727 HUVEC PWP1 Caffeine 4.094 4.24E-05 0.445 -0.115 3.431
rs1168666 HUVEC SETD1B Dexamethasone 5.503 3.73E-08 0.091 3.709 1.691
rs1168666 HUVEC SETD1B Vitamin A 5.398 6.74E-08 0.091 3.576 1.447
rs6488868 HUVEC SBNO1 Molybdenum -4.332 1.48E-05 0.281 -0.267 3.479
rs15587 HUVEC DDX55 Selenium -5.255 1.48E-07 0.091 1.944 3.490
rs872224 HUVEC NCOR2 Dexamethasone -4.413 1.02E-05 0.249 1.389 2.630
rs1372085 HUVEC PARP4 Vitamin A -4.456 8.33E-06 0.244 -0.136 3.608
rs1822135 HUVEC PARP4 Vitamin A -5.584 2.35E-08 0.091 3.272 2.641
rs14193 HUVEC RABGGTA Selenium -4.918 8.75E-07 0.091 2.234 2.632
rs14193 HUVEC RABGGTA Caffeine -4.654 3.25E-06 0.224 2.190 2.126
rs9904043 HUVEC SUPT6H Selenium 4.739 2.14E-06 0.208 2.262 3.068
rs1046045 HUVEC YPEL2 Dexamethasone -4.390 1.13E-05 0.249 1.953 1.903
rs4298 HUVEC ACE Selenium 4.704 2.55E-06 0.208 3.815 -8.462
rs7503278 HUVEC ACTG1 Dexamethasone 5.424 5.83E-08 0.091 -11.665 5.528
rs6102 HUVEC SERPINB10 Dexamethasone -6.171 6.80E-10 0.091 -9.610 -1.867
rs2043449 HUVEC CYP20A1 Vitamin D 4.797 1.61E-06 0.177 1.463 3.039
rs2255341 HUVEC ATP9A Dexamethasone -4.511 6.44E-06 0.224 0.860 2.966
rs1135618 HUVEC MRPL39 Molybdenum 4.712 2.45E-06 0.208 3.155 1.214
rs2272007 HUVEC ULK4 Caffeine 4.419 9.93E-06 0.249 -5.232 -0.387
rs17052357 HUVEC PBRM1 Selenium 4.481 7.43E-06 0.224 0.943 3.500
rs13080329 HUVEC COL8A1 Caffeine 5.452 4.99E-08 0.091 -5.673 -1.557
rs2270226 HUVEC RBPJ Vitamin D -4.482 7.38E-06 0.224 1.449 2.678
rs190450 HUVEC FBN2 Vitamin A 4.455 8.41E-06 0.244 0.975 3.210
rs2502599 HUVEC SYNJ2 Vitamin A 5.852 4.87E-09 0.091 -12.583 -7.599
rs2502598 HUVEC SYNJ2 Vitamin A 5.780 7.47E-09 0.091 -8.376 -4.665
rs13272579 HUVEC PREX2 Molybdenum -4.484 7.33E-06 0.224 0.264 3.203
rs896849 HUVEC TP53INP1 Vitamin D 4.446 8.76E-06 0.244 -0.431 3.818
rs8218 HUVEC HRSP12 Vitamin D 4.646 3.38E-06 0.224 2.998 0.787
rs1129768 HUVEC EHMT1 Selenium -4.989 6.08E-07 0.091 -0.311 4.257
rs2296377 PBMC TOR3A Acetylcholine -4.408 1.04E-05 0.249 -2.439 3.114
rs12084264 PBMC C1orf27 BHA 4.580 4.65E-06 0.224 1.509 2.872
rs7899928 PBMC WDR11 Phthalate -4.686 2.79E-06 0.224 -3.065 4.014
rs1145207 PBMC SIK3 Cadmium 4.552 5.31E-06 0.224 3.177 0.600
rs17125548 PBMC SORL1 Acetylcholine -4.503 6.70E-06 0.224 -0.488 2.832
rs3168600 PBMC COPS7A Phthalate 5.342 9.19E-08 0.091 1.215 4.022
rs15993 PBMC ACTN1 Acetaminophen -4.381 1.18E-05 0.249 0.202 3.472
rs2526882 PBMC PCNX Aspirin 4.864 1.15E-06 0.091 3.686 0.722
rs11160859 PBMC IGHG2 Acetylcholine 4.528 5.94E-06 0.224 -10.775 -2.669
rs11651270 PBMC NLRP1 Phthalate -4.491 7.08E-06 0.224 1.896 1.992
rs3826709 PBMC KRI1 Acetylcholine -4.413 1.02E-05 0.249 0.212 3.479
rs11555053 PBMC SUGP1 Aspirin 5.113 3.18E-07 0.091 -1.542 4.131
rs1130426 PBMC ETFB Aspirin -4.876 1.08E-06 0.091 -0.667 3.979
rs1138484 PBMC ST3GAL5 Phthalate 5.294 1.20E-07 0.091 0.729 3.877
rs62154801 PBMC ANKRD36 Acetylcholine 4.761 1.93E-06 0.208 1.934 -7.373
rs3951216 PBMC LY75-CD302 BHA -4.435 9.22E-06 0.244 2.713 1.615
rs463312 PBMC TUBB1 Acetaminophen -4.645 3.40E-06 0.224 -3.572 2.631
rs415064 PBMC TUBB1 Acetaminophen -4.645 3.40E-06 0.224 -3.572 2.631
rs394321 PBMC IGLV3-1 Cadmium 7.423 1.15E-13 0.091 4.393 6.018
rs2034244 PBMC MIER3 Acetylcholine 6.542 6.09E-11 0.091 3.350 5.263
rs3097146 PBMC TMEM161B BHA -4.702 2.58E-06 0.208 4.057 -0.886
rs1131769 PBMC TMEM173 Acetylcholine 4.482 7.39E-06 0.224 0.030 3.709
rs78233829 PBMC TMEM173 Acetylcholine 4.531 5.86E-06 0.224 0.092 3.776
rs1801265 PBMC DPYD Nicotine 4.686 2.79E-06 0.224 1.769 2.680
rs200319336 PBMC NBPF9 Vitamin H -5.600 2.15E-08 0.091 -13.145 -10.942
rs200319336 PBMC NBPF9 Molybdenum -5.984 2.18E-09 0.091 -9.305 -9.975
rs200319336 PBMC NBPF9 Caffeine -5.621 1.90E-08 0.091 -10.205 -10.707
rs200319336 PBMC NBPF9 Copper -5.579 2.42E-08 0.091 -9.740 -10.744
rs1778112 PBMC PDE4DIP Vitamin D -5.642 1.68E-08 0.091 6.248 -8.641
rs6029 PBMC F5 Copper -4.879 1.06E-06 0.091 -1.174 4.244
rs7998427 PBMC SETDB2 Vitamin A -5.443 5.25E-08 0.091 3.535 2.027
rs17103743 PBMC KHNYN Vitamin B5 -4.934 8.06E-07 0.091 1.727 -9.641
rs976272 PBMC SLC38A6 Zinc 4.724 2.32E-06 0.208 1.642 2.627
rs12971834 PBMC CTD-
2521M24.9
Vitamin B6 4.537 5.70E-06 0.224 -1.040 3.829
rs12979773 PBMC CTD-
2521M24.9
Vitamin B6 4.332 1.48E-05 0.281 -0.856 3.675
rs2627765 PBMC PNPT1 Vitamin B5 4.565 5.00E-06 0.224 -2.171 4.608
rs1107065 PBMC DIP2A Caffeine 5.232 1.68E-07 0.091 -0.594 4.504
rs1051169 PBMC S100B Caffeine 6.039 1.55E-09 0.091 6.739 -9.889
rs1051169 PBMC S100B Vitamin D 9.170 4.74E-20 0.091 13.692 -1.973
rs9610729 PBMC TOP3B Vitamin H 5.366 8.04E-08 0.091 1.196 4.206
rs2280083 PBMC CHST2 Dexamethasone 4.199 2.68E-05 0.314 -1.052 3.675
rs6768054 PBMC RNF13 Vitamin A 5.040 4.67E-07 0.091 1.532 3.809
rs1042994 PBMC PLK2 Vitamin D -4.929 8.27E-07 0.091 4.180 -2.589
rs7735338 PBMC CWC27 Molybdenum 4.457 8.32E-06 0.244 1.801 2.558
rs34741656 PBMC STEAP4 Vitamin B5 -5.237 1.63E-07 0.091 -10.625 -1.276
rs3118863 PBMC DAPK1 Nicotine 4.628 3.69E-06 0.224 3.755 -7.202
rs270502 LCL TARBP1 Cadmium 4.570 4.88E-06 0.224 4.127 -4.000
rs8018720 LCL SEC23A Cadmium 4.179 2.92E-05 0.323 -0.083 3.495
rs1107413 LCL SRPRB PFOA 4.229 2.35E-05 0.294 -2.725 3.671
rs34558821 LCL FRYL Cetirizine -4.439 9.05E-06 0.244 -1.760 3.376
rs200499 LCL HIST1H4J Phthalate -6.368 1.91E-10 0.091 -6.961 1.004
rs73581683 LCL HDDC2 Cadmium 4.793 1.65E-06 0.208 -10.409 -3.196
rs4310250 LCL PRRC2B Cadmium -4.467 7.95E-06 0.224 0.757 3.413
rs7868455 LCL EHMT1 Cetirizine 4.925 8.42E-07 0.091 -11.233 1.298
rs1126972 HUVEC PPT1 Phthalate -4.518 6.24E-06 0.224 -2.275 -16.018
rs2794751 HUVEC HEATR1 BHA -4.795 1.63E-06 0.208 3.104 2.032
rs35363135 HUVEC RPS6KB2 Triclosan -4.751 2.03E-06 0.208 2.565 2.308
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rs13508 HUVEC MRPS31 Insulin -4.677 2.91E-06 0.224 3.086 1.426
rs61620792 HUVEC RP11-
632K20.7
Insulin -4.753 2.00E-06 0.208 -6.399 0.725
rs4777755 HUVEC CHD2 Phthalate -4.397 1.10E-05 0.249 2.340 2.001
rs189899 HUVEC GOSR2 Phthalate 4.505 6.63E-06 0.224 -2.741 3.651
rs17853713 HUVEC RNF213 Insulin 4.852 1.22E-06 0.091 1.889 3.422
rs7238987 HUVEC CYB5A Aspirin -4.576 4.75E-06 0.224 1.047 -6.300
rs1135618 HUVEC MRPL39 Aspirin -4.781 1.74E-06 0.208 -0.658 4.449
rs2470548 HUVEC ANKRD28 Triclosan -5.902 3.60E-09 0.091 4.837 2.460
rs9503797 HUVEC RP1-140K8.5 Phthalate -4.478 7.55E-06 0.224 -10.770 -1.455
rs12540098 HUVEC MICALL2 Triclosan 4.463 8.09E-06 0.244 1.631 2.531
rs16836943 SMC RPRD2 Dexamethasone 5.434 5.51E-08 0.091 3.870 2.379
rs1045247 SMC CDC42BPA Vitamin D 4.578 4.68E-06 0.224 0.692 3.369
rs6989 SMC LGALS8 Vitamin B5 4.901 9.56E-07 0.091 2.584 2.697
rs2025258 SMC IPO4 Aldosterone 4.728 2.26E-06 0.208 3.005 1.841
rs13225 SMC AKAP13 Caffeine 4.392 1.13E-05 0.249 2.347 1.843
rs11640454 SMC KNOP1 Dexamethasone 4.283 1.85E-05 0.294 -0.580 3.503
rs2251219 SMC SMIM4 Dexamethasone -4.954 7.26E-07 0.091 3.228 1.675
rs13146 SMC UMPS Vitamin B5 4.580 4.66E-06 0.224 0.998 3.346
rs6778479 SMC WWTR1 Molybdenum 4.705 2.54E-06 0.208 1.650 3.251
rs1042094 SMC PPP3CA Vitamin B5 4.416 1.01E-05 0.249 2.793 1.339
rs1042094 SMC PPP3CA Caffeine 4.691 2.72E-06 0.208 2.770 1.787
rs698912 SMC COL4A3BP Vitamin B5 -4.662 3.13E-06 0.224 1.348 3.094
rs2278221 SMC ADAMTS2 Selenium -4.593 4.36E-06 0.224 -1.613 3.841
rs3747807 SMC DMTF1 Caffeine 4.457 8.32E-06 0.244 2.008 2.464
rs1061195 SMC SLC25A32 Selenium 4.455 8.39E-06 0.244 2.653 1.486
rs3206852 SMC FOCAD Vitamin D -4.658 3.19E-06 0.224 -2.092 3.745
Table C.12: cASE results for all SNPs tested. For each SNP tested for cASE, listed is the same information
in C.11, as well as ASE data (similar to Table C.10) for treatment and control SNPs, and two additional
columns: the SNP-based expression and SNP-based log( fold change ), described in Section C.9.3.
See attached file, Supplemental_Table_S12.txt.gz, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S12.txt.gz
Table C.13: cASE genes with a reQTL signal. Out of 83 genes reported to have GxE in previous reQTL
and ASE studies and able to be tested for cASE in our data, 63 genes are listed in this table that also have
cASE in our data (p-value <0.05). The table denotes the genes, the environment in which the reQTL was
identified, the citation of the paper establishing the reQTL, and the cell types and treatments for which we
find cASE
Gene with reQTL Environment for reQTL /ASE Citation Cell Type(s) for cASE (p-value <0.05) Treatment(s) for cASE
ADCY3 Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, LCL, Mel, PBMC
BHA, Caffeine, Ibuprofen, Loratadine,
Mono-n-butyl Phthalate, Retinoic Acid,
Vitamin B6
AGTRAP Rhinovirus Caliskan M et al., 2015(25874939) HUVEC Insulin
ARL5B Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, LCL, PBMC, SMC
Acetylcholine, Acrylamide, BHA, Bisphenol
A, Caffeine, Copper, Dexamethasone, Iron,
Molybdenum, Panthothenic acid, Retinoic
Acid, Selenium, Vitamin B6, Vitamin D,
Vitamin H
CALM1 Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, LCL, Mel Aspirin, Cadmium, Caffeine
CCDC146 Rhinovirus Caliskan M et al., 2015(25874939) PBMC Acetaminophen
DNTTIP1 Rhinovirus Caliskan M et al., 2015(25874939) Mel, PBMC
Acetaminophen, Caffeine, Insulin,
Tunicamycin, Vitamin E, Zinc
EXOSC9 Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, LCL, SMC
Dexamethasone, Molybdenum, Retinoic
Acid
FBN2 Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, SMC
Benzophenone-3, Bisphenol A, Caffeine,
Retinoic Acid, Selenium, Vitamin B6,
Vitamin D
GJA3 Rhinovirus Caliskan M et al., 2015(25874939) Mel Loratadine
INPP1 Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, LCL, Mel, PBMC, SMC
Acetaminophen, Acrylamide, Aspirin,
Benzophenone-3, BHA, Bisphenol A,
Copper, Insulin, Mono-n-butyl Phthalate,
Retinoic Acid, Selenium, Vitamin D
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IRF5 Rhinovirus Caliskan M et al., 2015(25874939) PBMC Mono-n-butyl Phthalate, Panthothenic acid
ITGA2 Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, Mel, SMC
Aspirin, Benzophenone-3, Caffeine,
Dexamethasone, Ibuprofen, Insulin,
Loratadine, Molybdenum, Mono-n-butyl
Phthalate, Panthothenic acid, Retinoic Acid,
Selenium, Triclosan, Vitamin D
MASTL Rhinovirus Caliskan M et al., 2015(25874939) LCL, Mel, PBMC
Aspirin, BHA, Caffeine, Cetirizine, Copper,
Mono-n-butyl Phthalate, Retinoic Acid
MYO1D Rhinovirus Caliskan M et al., 2015(25874939) Mel Caffeine
RAB31 Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, Mel, SMC
Acetaminophen, Aspirin, Dexamethasone,
Ibuprofen, Insulin, Selenium, Vitamin D
SLFN5 Rhinovirus Caliskan M et al., 2015(25874939) LCL, Mel, PBMC
Acetaminophen, Cadmium, Caffeine,
Copper, Dexamethasone, Loratadine,
Mono-n-butyl Phthalate, Panthothenic acid,
Retinoic Acid, Tunicamycin, Vitamin D,
Vitamin E
SPTLC2 Rhinovirus Caliskan M et al., 2015(25874939) HUVEC, LCL, Mel, PBMC, SMC
Acetylcholine, Acrylamide, Aspirin,
Benzophenone-3, Caffeine, Copper,
Dexamethasone, Ibuprofen, Iron, Loratadine,
Molybdenum, Mono-n-butyl Phthalate,
Retinoic Acid, Selenium, Vitamin B6,
Vitamin D
TMTC1 Rhinovirus Caliskan M et al., 2015(25874939) Mel Aspirin, Mono-n-butyl Phthalate
C1orf85 Flu Vaccine Franco LM et al., 2013(23878721) HUVEC, LCL, Mel, SMC
Acrylamide, Caffeine, Insulin, Molybdenum,
Panthothenic acid, Perfluorooctanoic Acid,
Tunicamycin
DIP2A Flu Vaccine Franco LM et al., 2013(23878721) LCL, Mel, PBMC
Caffeine, Insulin, Loratadine, Nicotine,
Panthothenic acid, Retinoic Acid, Selenium,
Triclosan, Tunicamycin, Vitamin B3,
Vitamin D, Vitamin E, Vitamin H, Zinc
DYNLT1 Flu Vaccine Franco LM et al., 2013(23878721) HUVEC, Mel
Retinoic Acid, Triclosan, Vitamin D,
Vitamin E
FGD2 Flu Vaccine Franco LM et al., 2013(23878721) LCL, PBMC
Acetaminophen, Aspirin, Caffeine, Copper,
Mono-n-butyl Phthalate, Retinoic Acid,
Vitamin E
GM2A Flu Vaccine Franco LM et al., 2013(23878721) HUVEC, LCL, Mel, PBMC, SMC
Acrylamide, Aspirin, Benzophenone-3,
BHA, Caffeine, Copper, Dexamethasone,
Loratadine, Molybdenum, Nicotine,
Panthothenic acid, Retinoic Acid, Selenium,
Triclosan, Tunicamycin, Vitamin B3,
Vitamin B6, Vitamin D, Zinc
HERC2 Flu Vaccine Franco LM et al., 2013(23878721) LCL, Mel, SMC
Acetaminophen, Caffeine, Dexamethasone,
Perfluorooctanoic Acid, Retinoic Acid,
Tunicamycin
JUP Flu Vaccine Franco LM et al., 2013(23878721) SMC Acrylamide
RPL14 Flu Vaccine Franco LM et al., 2013(23878721) SMC Aspirin, Triclosan, Vitamin D
TAP2 Flu Vaccine Franco LM et al., 2013(23878721) HUVEC, LCL, Mel
Acetaminophen, Acrylamide, Aspirin, BHA,
Bisphenol A, Caffeine, Copper, Ibuprofen,
Loratadine
PRUNE2 Malaria Idaghdour Y et al., 2012(22949651) Mel
Aspirin, Dexamethasone, Insulin,
Tunicamycin, Vitamin E
SLC39A8 Malaria Idaghdour Y et al., 2012(22949651) LCL, PBMC
Acrylamide, Copper, Dexamethasone,
Perfluorooctanoic Acid, Selenium
UNC119B Malaria Idaghdour Y et al., 2012(22949651) HUVEC, LCL, PBMC, SMC
Acrylamide, Caffeine, Cetirizine,
Loratadine, Nicotine, Panthothenic acid,
Retinoic Acid, Triclosan, Vitamin D
ARHGEF18 Opiates Knowles DA et al., 2015(13/025874) HUVEC, LCL, Mel, PBMC
Acrylamide, Dexamethasone, Ibuprofen,
Mono-n-butyl Phthalate, Retinoic Acid
CPT1B Blood PressureMedication
Knowles DA et al., 2015
(13/025874) LCL, Mel, PBMC
Acetaminophen, Cadmium, Caffeine,
Ibuprofen, Mono-n-butyl Phthalate
DYSF Exercise Knowles DA et al., 2015(13/025874) HUVEC
Benzophenone-3, Dexamethasone,
Molybdenum, Retinoic Acid
GSTO1 BMI Knowles DA et al., 2015(13/025874) HUVEC, LCL, PBMC
Aspirin, Caffeine, Mono-n-butyl Phthalate,
Vitamin D
IFI44L Exercise Knowles DA et al., 2015(13/025874) LCL, PBMC
Aspirin, Cadmium, Iron, Molybdenum,
Vitamin B6, Vitamin D
IL10RA Num. of Cigarettes/day Knowles DA et al., 2015(13/025874) LCL, PBMC Aspirin, Copper
NKG7 Antidepressants Knowles DA et al., 2015(13/025874) PBMC Vitamin B6
SSNA1 NSAIDs Knowles DA et al., 2015(13/025874) SMC Vitamin D
ZFAT Opiates Knowles DA et al., 2015(13/025874) LCL, PBMC Aspirin, Loratadine
ZMAT2 Decongestant Medication Knowles DA et al., 2015(13/025874) Mel Triclosan
ATP5SL Simvastatin Mangravite LM et al., 2013(23995691) Mel, SMC Retinoic Acid, Tunicamycin, Vitamin B6
ITFG2 Simvastatin Mangravite LM et al., 2013(23995691) HUVEC Mono-n-butyl Phthalate
C12orf45 Dexamethasone Maranville JC et al., 2011(21750684) LCL, PBMC
Caffeine, Dexamethasone, Molybdenum,
Vitamin B6, Zinc
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CST7 Dexamethasone Maranville JC et al., 2011(21750684) PBMC Dexamethasone
LSG1 Dexamethasone Maranville JC et al., 2011(21750684) HUVEC, LCL, Mel, PBMC, SMC
Benzophenone-3, Caffeine, Copper,
Dexamethasone, Loratadine, Molybdenum,
Mono-n-butyl Phthalate, Panthothenic acid,
Selenium, Triclosan, Vitamin D
MCFD2 Dexamethasone Maranville JC et al., 2011(21750684) LCL, PBMC Bisphenol A, Vitamin E
MFGE8 Dexamethasone Maranville JC et al., 2011(21750684) HUVEC, LCL
Bisphenol A, Caffeine, Insulin,
Molybdenum, Mono-n-butyl Phthalate,
Perfluorooctanoic Acid, Selenium, Triclosan,
Vitamin D
NQO1 Dexamethasone Maranville JC et al., 2011(21750684) Mel Dexamethasone, Vitamin D
PANK3 Dexamethasone Maranville JC et al., 2011(21750684) LCL, Mel, PBMC
Cadmium, Caffeine, Tunicamycin, Vitamin
E
PDGFRL Dexamethasone Maranville JC et al., 2011(21750684) HUVEC, SMC Dexamethasone, Vitamin D
SGK1 Dexamethasone Maranville JC et al., 2011(21750684) HUVEC Caffeine
TNIP1 Dexamethasone Maranville JC et al., 2011(21750684) Mel, SMC
Aldosterone, Insulin, Loratadine,
Molybdenum
ACAT1 Dexamethasone Maranville JC et al., 2013(24055111) HUVEC, Mel
Acetaminophen, Insulin, Loratadine,
Selenium, Tunicamycin
ATF7IP Dexamethasone Maranville JC et al., 2013(24055111) HUVEC, LCL, Mel, PBMC, SMC
Acetaminophen, Caffeine, Mono-n-butyl
Phthalate, Perfluorooctanoic Acid, Retinoic
Acid, Selenium, Vitamin D, Zinc
FAM117A Dexamethasone Maranville JC et al., 2013(24055111) LCL Caffeine
GORAB Dexamethasone Maranville JC et al., 2013(24055111) LCL, Mel, PBMC, SMC
Aspirin, Benzophenone-3, Cadmium,
Caffeine, Insulin, Mono-n-butyl Phthalate,
Retinoic Acid, Triclosan, Zinc
MGAT1 Dexamethasone Maranville JC et al., 2013(24055111) LCL Cadmium, Caffeine, Loratadine
MTA1 Dexamethasone Maranville JC et al., 2013(24055111) LCL, PBMC, SMC
Acetylcholine, Acrylamide,
Benzophenone-3, Caffeine, Cetirizine,
Copper, Perfluorooctanoic Acid, Vitamin B3
PLEKHG3 Dexamethasone Maranville JC et al., 2013(24055111) Mel Acetaminophen, Triclosan
RAB23 Dexamethasone Maranville JC et al., 2013(24055111) HUVEC Selenium
RCAN3 Dexamethasone Maranville JC et al., 2013(24055111) Mel, PBMC Acetaminophen, Cadmium, Insulin
SULT1C4 Dexamethasone Maranville JC et al., 2013(24055111) HUVEC
Aspirin, Benzophenone-3, Mono-n-butyl
Phthalate, Triclosan
UGGT2 Dexamethasone Maranville JC et al., 2013(24055111) HUVEC, Mel, SMC
Aspirin, BHA, Dexamethasone, Insulin,
Retinoic Acid, Triclosan, Vitamin D
Table C.14: EDGE index values for each cell type/treatment subgroup. EDGE index and confidence
intervals are calculated as described in Section C.10.4. Also shown for each subgroup is the number of
significant ASE and cASE SNPs.
Cell Type Treatment EDGE index Lower 95% CI Upper 95% CI ASE(10% FDR)
cASE
(24% FDR)
HUVEC Dexamethasone 1.215 1.240 1.192 103 7
HUVEC Caffeine 1.247 1.274 1.223 79 6
HUVEC Molybdenum 1.209 1.236 1.184 84 3
HUVEC Selenium 1.239 1.266 1.215 102 7
HUVEC Vitamin D 1.289 1.318 1.261 92 4
HUVEC Acrylamide 0.874 0.878 0.871 210 0
HUVEC BP-3 0.964 0.972 0.955 136 0
HUVEC Triclosan 1.020 1.033 1.008 137 3
HUVEC Insulin 0.982 0.991 0.974 103 3
HUVEC BHA 0.953 0.962 0.944 134 1
HUVEC Aspirin 0.956 0.965 0.948 137 2
HUVEC Phthalate 1.028 1.041 1.016 118 4
HUVEC Vitamin A 1.232 1.260 1.206 83 7
LCL Dexamethasone 1.274 1.303 1.248 89 2
Continued on next page...
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Table C.14 – continued from previous page
Cell Type Treatment EDGE index Lower 95% CI Upper 95% CI ASE SNPs cASE SNPs
LCL Caffeine 1.528 1.588 1.475 65 9
LCL Copper 1.371 1.413 1.333 86 5
LCL Selenium 1.509 1.571 1.455 69 9
LCL Acrylamide 0.898 0.903 0.894 129 0
LCL BPA 0.925 0.932 0.918 100 0
LCL Cadmium 1.019 1.032 1.006 75 4
LCL PFOA 0.991 1.001 0.981 82 1
LCL Aspirin 0.942 0.950 0.934 92 0
LCL Loratadine 0.939 0.945 0.932 121 0
LCL Cetirizine 1.021 1.035 1.008 76 2
LCL Phthalate 1.053 1.067 1.040 86 1
LCL Vitamin A 1.242 1.267 1.220 89 3
Mel Dexamethasone 1.071 1.093 1.051 90 1
Mel Caffeine 1.093 1.119 1.070 71 0
Mel Selenium 1.105 1.134 1.079 65 2
Mel Tunicamycin 1.208 1.245 1.175 74 4
Mel Vitamin D 1.095 1.118 1.073 94 2
Mel Triclosan 1.053 1.066 1.041 113 0
Mel Insulin 1.100 1.115 1.086 124 0
Mel BHA 1.046 1.059 1.035 122 3
Mel Ibuprofen 1.072 1.085 1.059 129 2
Mel Acetaminophen 1.055 1.068 1.043 116 5
Mel Aspirin 1.010 1.021 1.000 127 3
Mel Loratadine 1.059 1.073 1.047 113 3
Mel Phthalate 1.071 1.085 1.058 114 4
Mel Vitamin A 1.094 1.119 1.071 85 0
Mel Vitamin E 1.106 1.131 1.083 86 1
PBMC Dexamethasone 1.136 1.155 1.119 126 1
PBMC Caffeine 1.189 1.211 1.168 108 3
PBMC Nicotine 1.139 1.159 1.121 82 2
PBMC Copper 1.066 1.080 1.054 103 2
PBMC Iron (C1) 1.146 1.167 1.127 82 0
PBMC Molybdenum 1.076 1.091 1.061 97 2
PBMC Zinc 1.079 1.094 1.066 109 1
PBMC Vitamin D 1.389 1.447 1.338 41 3
PBMC Cadmium 1.144 1.162 1.126 119 2
PBMC Vitamin H 1.033 1.045 1.022 109 2
PBMC Acetylcholine 1.178 1.201 1.157 92 8
PBMC Vitamin B3 1.051 1.065 1.037 102 0
PBMC BHA 1.121 1.143 1.101 82 3
PBMC Acetaminophen 1.198 1.222 1.176 96 3
PBMC Aspirin 1.145 1.166 1.126 98 3
PBMC Phthalate 1.198 1.222 1.175 92 4
PBMC Vitamin B5 1.064 1.078 1.051 102 3
PBMC Vitamin B6 1.060 1.073 1.047 105 2
PBMC Vitamin A 1.080 1.096 1.066 105 2
PBMC Vitamin E 1.026 1.039 1.014 104 0
SMC Dexamethasone 1.060 1.072 1.048 127 3
SMC Caffeine 1.082 1.095 1.069 103 3
SMC Molybdenum 1.028 1.039 1.018 147 1
SMC Selenium 1.072 1.085 1.061 117 2
Continued on next page...
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Table C.14 – continued from previous page
Cell Type Treatment EDGE index Lower 95% CI Upper 95% CI ASE SNPs cASE SNPs
SMC Vitamin D 1.053 1.065 1.042 101 2
SMC Acrylamide 0.979 0.988 0.971 129 0
SMC BP-3 1.008 1.018 1.000 120 0
SMC BPA 1.011 1.021 1.002 122 1
SMC PFOA 1.007 1.017 0.997 106 1
SMC Triclosan 0.997 1.006 0.989 132 1
SMC Insulin 0.994 1.003 0.985 129 0
SMC Acetaminophen 0.984 0.993 0.975 134 0
SMC Aspirin 1.024 1.034 1.014 121 0
SMC Vitamin B5 1.104 1.120 1.089 93 4
SMC Vitamin B6 1.078 1.091 1.065 100 0
SMC Vitamin A 1.052 1.063 1.041 116 0
SMC Aldosterone 1.049 1.061 1.039 119 1
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Table C.15: SNPs displaying induced ASE. Each iASE SNP is listed with the inducing treatment and
matched control, cell type, and gene. Also given is the adjusted read coverages (see Section C.10.5) for the
reference and alternate allele in both treatment and control conditions.
rsID Treatment ID Control ID Cell Type Gene Adjusted TreatmentCoverage (Reference)
Adjusted Control
Coverage (Reference)
Adjusted Treatment
Coverage (Alternate)
Adjusted Control
Coverage (Alternate)
rs5390 T13C1 CO1 LCL GIPR 0.416 0.010 0.055 0.010
rs77388906 T19C1 CO1 LCL C1D 3.034 0.010 0.727 0.010
rs28485150 T6C1 CO2 LCL LRRFIP1 0.415 0.010 0.026 0.010
rs932501 T19C1 CO1 LCL MACROD2 0.597 0.056 0.140 0.056
rs17238053 T13C1 CO1 LCL SEMA5A 0.353 0.071 0.010 0.010
rs1061837 T6C1 CO2 LCL CCDC69 0.609 0.010 1.817 0.010
rs200499 T19C1 CO1 LCL HIST1H4J 0.010 0.010 0.569 0.010
rs61741379 T42C1 CO1 SMC PLEKHG5 0.228 0.041 0.054 0.012
rs650616 T26C1 CO1 SMC PINK1-AS 0.263 0.044 0.051 0.010
rs2244262 T42C1 CO1 SMC RAB3B 0.182 0.021 0.046 0.017
rs192449674 T42C1 CO1 SMC NBPF15 0.323 0.058 0.083 0.012
rs2834218 T30C1 CO2 SMC TMEM50B 0.351 0.010 0.045 0.010
rs226202 T26C1 CO1 SMC ATG10 0.063 0.024 0.376 0.047
rs8191993 T42C1 CO1 SMC hsa-mir-490 0.186 0.033 0.041 0.012
rs3735943 T42C1 CO1 SMC TRPA1 0.021 0.010 0.149 0.025
rs6866 T26C1 CO1 SMC SNHG7 0.321 0.066 0.073 0.010
rs12857 T13C1 CO1 Mel DYNLL1 0.454 0.010 2.945 0.010
rs12615308 T13C1 CO1 Mel UBE2F 1.081 0.010 0.219 0.010
rs3172404 T21C1 CO3 Mel CLDN1 0.041 0.010 0.529 0.010
rs1051122 T41C1 CO2 Mel CRYZ 2.477 0.010 0.974 0.010
rs1883 T30C1 CO2 Mel EIF5 0.742 0.010 0.232 0.010
rs2110964 T47C1 CO2 Mel PRKD3 0.910 0.010 0.186 0.010
rs57381261 T43C1 CO2 Mel AC007246.3 0.266 0.053 0.035 0.010
rs2305222 T33C1 CO1 Mel ANKRD28 0.590 0.010 0.042 0.010
rs200813578 T44C1 CO2 Mel EGR1 0.548 0.010 0.100 0.010
rs7326277 T12C1 CO2 HUVEC FLT1 0.944 0.010 0.098 0.010
rs7326277 T23C1 CO2 HUVEC FLT1 1.055 0.010 0.306 0.010
rs155053 T23C1 CO2 HUVEC CAST 0.366 0.010 0.037 0.010
rs2296198 T13C1 CO1 HUVEC RNF144B 1.161 0.010 0.329 0.010
rs4619 T12C1 CO2 HUVEC IGFBP1 0.024 0.010 0.312 0.010
rs12530729 T19C1 CO1 HUVEC ZNF117 0.111 0.010 0.613 0.010
rs3807069 T19C1 CO1 HUVEC ZNF117 0.102 0.010 0.669 0.010
rs73672486 T18C1 CO1 HUVEC SWI5 1.060 0.010 0.239 0.010
rs12784633 T23C1 CO2 PBMC RP11-445P17.8 0.303 0.021 0.010 0.021
rs11235851 T2C1 CO1 PBMC RAB6A 0.630 0.010 0.079 0.010
rs11235851 T5C1 CO1 PBMC RAB6A 0.840 0.010 0.156 0.010
rs11235851 T20C1 CO1 PBMC RAB6A 0.454 0.010 0.023 0.010
rs11235851 T13C1 CO1 PBMC RAB6A 0.565 0.010 0.040 0.010
rs217086 T13C1 CO1 PBMC CTSC 0.783 0.010 2.357 0.010
rs2239008 T16C1 CO1 PBMC MMP1 0.164 0.010 1.254 0.010
rs470215 T16C1 CO1 PBMC MMP1 0.059 0.010 0.478 0.010
rs10488 T16C1 CO1 PBMC MMP1 1.357 0.010 0.251 0.010
rs28675952 T12C1 CO2 PBMC RP11-324E6.6 0.073 0.010 0.429 0.010
rs11160859 T4C1 CO1 PBMC IGHG2 0.502 0.039 0.029 0.019
rs11160859 T14C1 CO1 PBMC IGHG2 0.346 0.037 0.037 0.019
rs2591050 T14C1 CO1 PBMC LINC00926 0.039 0.010 0.525 0.010
rs121565 T6C1 CO2 PBMC CCL22 2.494 0.010 0.674 0.010
rs121565 T7C1 CO2 PBMC CCL22 2.304 0.010 0.780 0.010
rs3027955 T2C1 CO1 PBMC SLC1A5 1.016 0.010 0.088 0.010
rs3027955 T4C1 CO1 PBMC SLC1A5 0.925 0.010 0.088 0.010
rs3027955 T13C1 CO1 PBMC SLC1A5 0.371 0.010 0.024 0.010
rs1130094 T5C1 CO1 PBMC ADAM17 1.186 0.010 0.312 0.010
rs7583955 T4C1 CO1 PBMC AC009950.2 0.531 0.010 0.068 0.010
rs1106639 T16C1 CO1 PBMC D2HGDH 0.338 0.010 1.263 0.010
rs1106639 T14C1 CO1 PBMC D2HGDH 0.131 0.010 0.663 0.010
rs8139993 T15C1 CO1 PBMC DESI1 0.119 0.010 0.698 0.010
rs111462360 T20C1 CO1 PBMC LINC00847 0.419 0.051 0.051 0.010
rs17295741 T2C1 CO1 PBMC NCF1 0.123 0.010 0.622 0.010
rs17295741 T13C1 CO1 PBMC NCF1 0.040 0.010 0.476 0.010
rs10264853 T13C1 CO1 PBMC UPK3B 0.066 0.010 0.554 0.010
rs202105684 T7C1 CO2 PBMC UPK3B 0.315 0.010 0.053 0.010
ss1388100066 T40C1 CO2 HUVEC RP11-22B23.1 0.066 0.010 0.376 0.080
rs2834218 T24C1 CO1 HUVEC TMEM50B 0.313 0.021 0.053 0.010
rs7289170 T24C1 CO1 HUVEC CECR1 0.015 0.010 0.155 0.030
rs7726384 T24C1 CO1 HUVEC SREK1IP1 0.011 0.010 0.234 0.034
rs1047494 T24C1 CO1 HUVEC IQGAP2 0.136 0.019 0.019 0.010
rs4656992 T18C1 CO1 SMC ADAMTS4 0.076 0.014 0.241 0.036
rs76197396 T18C1 CO1 SMC HERC2P3 0.403 0.064 0.045 0.011
rs3743104 T9C1 CO2 SMC GREM1 0.475 0.010 4.186 0.010
rs2303262 T4C1 CO1 SMC MPHOSPH6 0.052 0.030 0.322 0.037
rs2292843 T18C1 CO1 SMC PRDM8 0.011 0.010 0.118 0.010
rs3932940 T18C1 CO1 SMC CCDC127 0.011 0.010 0.104 0.010
rs1012899 T12C1 CO2 SMC LRRC16A 0.427 0.010 0.119 0.010
rs2502598 T18C1 CO1 SMC SYNJ2 0.216 0.028 0.017 0.010
rs1134170 T4C1 CO1 SMC COL5A1 5.536 0.010 1.519 0.010
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Table C.16: Overlap of GWAS-identified genes and genes containing cASE or iASE SNPs. The table
shows genes that have previously been associated with a phenotype through GWAS and contain evidence of
cASE (79 genes with 87 SNPs) or iASE (28 genes with 35 SNPs). Also denoted are the treatment and cell
type for which we identified cASE.
See attached file, Supplemental_Table_S18.xlsx, also available at http://genome.grid.
wayne.edu/gxebrowser/Tables/Supplemental_Table_S18.xlsx
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Figure C.1: Study design for one cell type (A) and all cell types (B). (A) Each cell type is represented by three
individuals, each treated with treatments belonging to two treatment panels. For each treatment panel, the three
individuals were treated in parallel on the same plate to analyze 32 samples (corresponding to sequencing libraries
with unique barcode IDs, and represented by the different colors on the plate design). The 32 conditions correspond
to 23 treatments and 3 vehicle controls for panel one, and to 26 treatments and 2 vehicle controls for panel two. For
each control sample (colored in shades of grey), three technical replicates were performed (i.e., triplicates of the same
sample/library). (B) The study design described in (A) is repeated for each cell type in the study.
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Figure C.2: Workflow of the two-step approach, modified from (103).
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Figure C.3: Heatmap of differential gene expression from Step 1. Shown for each cell type (columns) and treat-
ment (rows) combination are the number of differentially expressed genes (10% FDR and |logFC|> 0.25). Number of
differentially expressed genes is indicated by the number in the cell as well as the shade of red. Colors next to treatment
names represent treatments chosen for deep sequencing. Grey indicates treatments that were not deep sequenced.
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Figure C.4: Principal component analysis of gene expression levels across all deep sequenced samples, for
Panel 1 treatments. Gene expression levels (FPKMs) were obtained for each sample (individual and treatment combi-
nation) as a vector indexed by gene. Those vectors were correlated and PCA was performed on the resulting correlation
matrix.
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Figure C.5: Principal component analysis of gene expression levels across all deep sequenced samples, for
Panel 2 treatments. Gene expression levels (FPKMs) were obtained for each sample (individual and treatment combi-
nation) as a vector indexed by gene. Those vectors were correlated and PCA was performed on the resulting correlation
matrix.
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Figure C.6: Heatmap and hierarchical clustering of gene expression levels across all deep sequenced samples,
for Panel 1 treatments. Gene expression levels (FPKMs) were obtained for each sample (individual and treatment
combination) as a vector indexed by gene. Those vectors were clustered using hierarchical clustering and the den-
drogram is displayed at the top of a heatmap visualizing the Pearson correlation between each sample. The sample
identity is detailed by a two-way coloring indexing the individual and treatment (see legend).
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Figure C.7: Heatmap and hierarchical clustering of gene expression levels across all deep sequenced samples,
for Panel 2 treatments. Gene expression levels (FPKMs) were obtained for each sample (individual and treatment
combination) as a vector indexed by gene. Those vectors were clustered using hierarchical clustering and the den-
drogram is displayed at the top of a heatmap visualizing the Pearson correlation between each sample. The sample
identity is detailed by a two-way coloring indexing the individual and treatment (see legend).
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Figure C.8: Principal component analysis of the genotype data. For each cell type, the allele ratio (ρˆ) was corre-
lated using all samples for each of the three individuals. PCA was performed on the correlation matrix, showing three
distinct clusters representing each of the three individuals, confirming that there is no cross-individual contamination.
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Figure C.9: Average M estimates from the QuASAR model. For each bin of coverage (total number of
reads covering a SNP), plotted is the average M estimate (1 / Dispersion) for all samples.
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Figure C.10: QQ-plot of p-values from the QuASAR test for ASE.
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Figure C.11: Example diagrams and plots describing cASE and iASE SNPs. Left, gene expression in treatment
(T) and control (C) samples for both reference (R) and alternate (A) alleles. Middle, barplot of example expression
levels. The dotted line represents a threshold for the detection of transcript expression. Inset is a forest plot of βˆ values
calculated from the reads covering each alleles, using the provided formulas. Note that in the control sample, the βˆ
is undefined for iASE. Right, scatter plot contrasting expression levels (normalized to library coverage) of the two
alleles for both treatment (black point) and control (grey point). The line represents the magnitude of the fold-change
between treatment and control. The dotted line represents equal expression of the two alleles (i.e., no ASE).
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Figure C.12: Scatterplot of βˆs for SNPs with cASE. For each cASE SNP, plotted is the βˆ from QuASAR for the
control (y-axis) and treatment (x-axis) conditions. The size of the point indicates the degree of differential expres-
sion for the gene containing the SNP, while the color indicates whether the treatment causes the gene to be up- or
downregulated.
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Figure C.13: Density of ASE βˆ values across SNPs. All, all SNPs tested for ASE; ASE, SNPs with ASE (10%
FDR); iASE, SNPs with induced ASE (10% FDR).
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Figure C.14: Percent of cASE SNPs identified in each cell type. For each cell type, plotted is the percent of cASE
SNPs identified, relative to the number of SNPs tested for that group. The dotted black line represents the average
percent of cASE SNPs across all categories or cell type. Groups with a “*” are significantly enriched or depleted
(Binomial p-value < 0.05) relative to the average.
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Figure C.15: Environmental displacement of genetic effect (EDGE) index. (A & B) Example of EDGE. The low
correlation of ASE Z-scores in (B) relative to the control in (A) highlights how the genetic effect is modulated by the
treatment. In this example, the EDGE index would be calculated (using Equation 4.2) as 1 / (0.401 / 0.557) = 1.389.
(C) For each treatment (indicated by color and label), plotted is the average EDGE Index across cell types versus the
% cASE. The number of heterozygous SNPs tested for cASE in each treatment is indicated by the size of the point.
The black line represents a linear model fit on the points, indicating the two are highly correlated (Spearman’s ρ =
0.717, p = 3.8× 10−6).
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Figure C.16: Barplot of EDGE index values for each cell type and treatment. Values are normalized within each
cell type based on the controls (see Equation 4.2). Error bars indicate the 95 % confidence interval.
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Figure C.17: Comparison of EDGE index values with and without including cASE SNPs. For each sample, the
EDGE index was calculated as described in Section C.10.4, using either all SNPs in that subgroup (y-axis) or only
SNPs that do not display significant cASE (x-axis). Note that for this analysis, we only included SNPs passing the
default coverage filter (40 reads).
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Advances in next-generation sequencing technologies and functional genomics strategies have
allowed researchers to identify both common and rare genetic variation, to deeply profile gene
expression, and even to determine regions of active gene transcription. While these technologies
and strategies have contributed greatly to our understanding of complex traits and diseases, there
are many biological questions and analytical issues to be addressed.
Genome-wide association studies (GWAS) have successfully identified large numbers of ge-
netic variants associated with complex traits and diseases. However, in many cases the mechanistic
link between the phenotype and associated variant remains unclear. This may be because most
variants identified by GWAS lie outside coding regions, and likely affect regulatory regions that
are not well characterized. Chapter 2 describes a computational approach to integrate functional
genomics data with DNA sequence models to predict which variants in a DNase I footprint affect
transcription factor binding. These predictions prove useful in assessing which variants in GWAS
association regions are the likely causal variants.
While a mismatch between genotype and environment can lead to an increased disease risk, it
can be difficult to study the role of the environment directly. This is because environmental co-
variates are complex and difficult to control at the organismal level. We can alternatively study the
cellular environment using in vitro treatments as proxy for the organismal environment. Chapters 3
and 4 describe a high-throughput system for the characterization of gene expression response using
a panel of cell types and treatment conditions. Chapter 4 identifies genes with GxE, and follow-
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up studies have shown that they are also associated with a phenotype through GWAS, providing
putative molecular mechanisms through which the environment influences the trait.
Together, these chapters present novel approaches and analyses of next-generation sequencing
data to identify functional variation and gene-environment interactions.
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